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Metabolic  disturbances  associated  with  central  obesity  and  insulin  resistance  might  underlie 
the  higher  rates  of  diabetes  and  coronary  heart  disease  in  South  Asians  compared  with 
Europeans.  A  cross  sectional  study  of  135  healthy  South  Asians  and  Europeans,  aged  40- 
55  years,  was  performed  to  test  whether  lower  insulin  sensitivity  in  South  Asians  is  explained 
by  ethnic  differences  in  body  fat  pattern  and  to  establish  if  there  are  ethnic  differences  in 
postprandial  triglyceride  and  intramyocellular  lipid  (IMCL)  content  that  are  associated  with 
insulin  sensitivity. 
Visceral  fat  area  (VFA),  measured  by  CT  scan,  was  higher  in  South  Asians  than  in 
Europeans  in  analyses  adjusted  for  age,  sex  and  body  mass  index  (p=0.001).  VFA  was 
strongly  associated  with  insulin  sensitivity  index  (ISI),  measured  by  the  short  insulin 
tolerance  test,  in  both  groups  independently  of  total  %  body  fat  (measured  by  DEXA  scan). 
In  age  and  sex  adjusted  analyses  ISI  was  0.71  %  min-'  lower  in  South  Asians  (95%  CI  -1.18 
to  -0.25,  p=0.003).  Adjustment  for  body  fat  pattern  and  triglyceride  (fasting  and  8  hour 
postprandial)  reduced  the  ethnic  difference  in  ISI  to  -  0.41  %  min-'  (95%  Cl  -0.86  to  0.03, 
p=0.066).  In  both  groups  8  hour  postprandial  triglyceride  was  highly  correlated  with  ISI  and 
VFA  and  the  relationship  of  ISI  to  VFA  was  eliminated  by  adjusting  for  triglyceride.  In  a  sub- 
study,  mean  IMCL  content  (measured  by  magnetic  resonance  spectroscopy)  was  higher  in 
South  Asians  (p=0.046).  In  Europeans  IMCL  was  correlated  positively  with  %  body  fat, 
waist/hip  ratio,  VFA  and  negatively  with  ISI.  In  South  Asians  IMCL  was  not  significantly 
related  to  ISI  or  obesity. 
We  conclude  that  body  fat  pattern  and  IMCL  cannot  account  for  ethnic  difference  in  insulin 
sensitivity.  Alterations  of  lipid  metabolism,  possibly  in  the  postprandial  period,  are  likely  to 
underlie  the  association  of  central  obesity  with  insulin  resistance. 
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The  rates  of  insulin  resistance,  diabetes  mellitus  and  coronary  heart  disease  are  known  to  be 
higher  in  people  originating  from  India,  Pakistan  and  Bangladesh  (South  Asians)  than  in 
people  of  European  descent.  This  project  was  designed  to  test  a  set  of  related  hypotheses 
about  the  mechanisms  relating  obesity  (generalised  obesity  and  central  obesity)  to  insulin 
resistance  and  increased  coronary  heart  disease  (CHD)  risk  in  South  Asians.  It  is  hoped 
that  the  results  will  guide  further  research  on  the  aetiology  and  control  of  both  diabetes  and 
CHD. 
This  thesis  is  arranged  in  four  parts.  The  first  part  deals  with  the  background  and  rationale 
to  this  area  of  research  and  is  presented  in  chapters  1,2,3  and  4.  These  deal  specifically 
with  the  epidemiology  of  coronary  heart  disease  in  South  Asians  and  prevalence  of  the 
insulin  resistance  syndrome  in  this  group  in  chapter  one;  with  the  proposed  role  for 
postprandial  lipids  in  chapter  two;  and  with  the  potential  role  for  skeletal  muscle  cell 
triglyceride  stores  in  insulin  resistance  in  chapter  three.  The  aims  of  the  study  are  described 
in  chapter  four. 
The  second  part  describes  the  methods  employed  to  achieve  the  aims  and  objectives  of  this 
study  (chapter  5).  In  the  third  part  the  results  are  presented  along  with  relevant  discussion 
(chapters  6  to  9).  The  final  part  of  the  thesis  is  dedicated  to  overall  discussion,  conclusions 
and  suggestions  for  future  research  (chapters  10  and  11). 
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PM,  and  Bell  JD.  Relation  of  triglyceride  stores  in  skeletal  muscle  cells  to  central  obesity 
and  insulin  sensitivity  in  European  and  South  Asian  men.  Diabetologia  1999;  42:  932- 
935. 
2.  Forouhi  NG,  Mullick  S,  Eathorne  P,  Kooner  JS  and  McKeigue  PM.  Elevated 
postprandial  triglyceride:  ethnic  and  sex  differences,  and  relation  to  the  insulin  resistance 
syndrome.  To  be  submitted  to  Atherosclerosis  1999. 
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Arteriosclerosis,  Thrombosis  and  Vascular  Biology  1999. 
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South  Asians  Overseas 
1.1.  Use  of  the  term  "South  Asian" 
Different  terms  have  been  used  to  describe  the  people  originating  from  the  Indian 
subcontinent,  which  includes  the  countries  of  India,  Pakistan,  Bangladesh  and  Sri  Lanka. 
Some  of  these  have  included  "Asian",  as  is  in  common  use  in  the  U.  K.,  but  which  in  the 
United  States  has  been  used  more  commonly  for  people  originating  from  the  Far  East;  and 
"Indian  Asians"  or  "Asian  Indians"  as  has  been  used  in  the  published  literature  in  the  past 
on  both  sides  of  the  Atlantic  to  distinguish  these  people  from  Pacific  Indians  and  Native 
American  Indians.  Throughout  this  dissertation  the  term  "South  Asian"  is  used  to  denote 
origin  from  any  part  of  the  Indian  subcontinent. 
However,  the  people  originating  from  countries  as  diverse  as  those  that  form  part  of  the 
subcontinent  are  not  homogeneous,  and  it  is  fair  to  ask  the  question  whether  they  can  all  be 
studied  together  when  considering  their  risk  for  coronary  heart  disease  or  diabetes. 
1.1.1.  Heterogeneity  of  the  people  constituting  "South  Asians" 
Within  India  it  has  been  claimed  that  there  might  be  genetic  differences  in  the  people  of 
north  India  (Aryan  descent)  and  south  India  (Dravidian  descent).  However  this  has  not 
been  supported  by  genetic  studies'.  Within  each  of  the  parts  of  the  Indian  subcontinent 
there  is  great  heterogeneity  in  the  population:  there  are  people  of  diverse  cultural,  religious 
and  linguistic  backgrounds  such  as  Hindu  Gujaratis,  Punjabi  Sikhs,  Muslim  Bangladeshis 
and  Muslim  Pakistanis,  Tamil  South  Indians  and  Sri  Lankans,  many  of  whom  are  Hindu, 
but  many  converted  to  Christianity,  and  to  Buddhism,  with  widely  differing  dietary  and 
lifestyle  habits.  Moreover,  South  Asians  have  historically  emigrated  since  1834  to  various 
parts  of  the  world  as  indentured  labourers2'3,  forming  sizeable  communities  in  Mauritius, 
the  West  Indies,  Natal,  the  Straits  Settlements,  Fiji  and  East  Africa.  The  indentured  labour 
system  was  banned  in  1917  but  a  steady  migration  of  professionals,  traders,  agricultural 
Epidemiology  of  CHD  in  S.  Asians  1-16 and  manual  workers  and  their  families  has  continued  ever  since.  Migration,  on  peoples' 
own  initiative,  to  the  U.  K.  from  the  Indian  subcontinent  increased  after  1960  and  reached  a 
peak  around  1966-674.  There  has  also  been  a  steady  stream  of  migration  to  North 
America.  It  is  estimated  that  there  are  some  11  million  South  Asians  living  outside  of  the 
subcontinent. 
1.2.  High  risk  for  coronary  heart  disease  among  South  Asians 
It  has  long  been  observed  in  several  parts  of  the  world  that  mortality  and  morbidity  from 
coronary  heart  disease  (CHD)  are  higher  in  people  of  South  Asian  descents.  This  is 
reflected  in  the  higher  relative  risks  for  CHD  among  South  Asians  when  compared  with 
other  ethnic  groups.  For  example,  when  compared  with  populations  known  to  be  at  low 
risk  for  CHD,  such  as  the  Chinese6,  Melanesians'  and  Africans',  the  age  standardised 
CHD  death  rates  calculated  from  national  mortality  data  have  ranged  between  3  to  4  times 
higher  among  immigrant  South  Asian  men  than  in  other  groups  settled  in  the  same  country. 
Even  when  compared  with  populations  known  to  be  at  high  risk  for  CHD,  such  as 
Europeans9  and  South  Africans10,  the  relative  risk  for  CHD  mortality  in  South  Asians  was 
higher  by  a  magnitude  of  around  50%. 
The  high  coronary  mortality  is  seen  in  the  heterogeneous  subgroups  of  people  within  the 
South  Asian  population  -  thus  Gujarati  Hindus,  Punjabi  Sikhs  and  Muslims  from  Pakistan 
and  Bangladesh  all  share  the  high  CHD  mortality"'12  Although  minor  variations  in  heart 
disease  risk  factor  profiles  between  Indian  sub-communities  have  been  demonstrated13,  the 
overwhelming  evidence  points  to  all  cultural  groups  in  the  Indian  subcontinent  sharing  an 
increased  risk  of  CHD  morbidity  and  mortality.  Thus  it  is  reasonable  when  investigating 
CHD  risk  to  consider  individuals  from  different  parts  of  the  Indian  subcontinent 
collectively,  even  though  they  may  originate  from  a  wide  range  of  cultural  backgrounds. 
There  are  two  important  observations  about  the  high  rates  of  CHD  in  South  Asians. 
Firstly,  the  high  rates  of  CHD  are  common  to  South  Asian  populations  residing  around  the 
world.  This  raises  the  point  that  any  environmental  factor  that  might  explain  the  high  rates 
of  CHD  in  South  Asians  must  be  common  to  all  the  main  ethnic  groups  of  the  Indian 
subcontinent,  to  both  sexes,  and  persist  several  generations  after  migration.  Secondly,  the 
higher  relative  risk  for  CHD  and  type  2  diabetes  in  South  Asians  does  not  wear  off  with 
Epidemiology  of  CHD  in  S.  Asians  1-17 increasing  generations  since  migration,  i.  e.,  it  continues  to  diverge  from  the  rates  in  other 
ethnic  groups  in  the  same  country.  For  example,  in  Singapore,  a  rapid  transition  to 
affluence  has  been  shared  by  all  three  of  the  main  ethnic  groups  residing  there  (Chinese, 
Malays  and  Indians),  but  the  prevalence  of  diabetes  is  much  higher  in  Indians  than  in 
Chinese".  From  studies  of  CHD  in  other  migrant  populations  (such  as  the  Japanese  in  the 
U.  S.  A.  )  it  has  emerged  that  CHD  rates  in  those  settled  overseas  the  longest  and  in  their 
descendants  converge  to  those  in  the  host  population15.  This  has  formed  the  basis  of  the 
view  that  between-population  differences  in  CHD  rates  are  environmentally  rather  than 
genetically  determined.  However  given  the  contrasting  situation  in  South  Asians  where 
higher  risk  persists  several  (five  or  six)  generations  post-migrations,  a  genetic  explanation 
is  more  likely  to  apply  than  an  environmental  one. 
The  relative  risk  of  coronary  disease  in  South  Asian  men  is  highest  at  early  ages:  between 
1979  and  1983,  CHD  mortality  in  men  aged  less  than  40  years  born  in  South  Asia  was 
more  than  twice  the  U.  K.  national  average16.  In  patients  undergoing  coronary  angiography 
the  anatomical  distribution  of  disease  does  not  differ  between  South  Asians  and  Europeans, 
but  the  extent  and  severity  of  lesions  are  greater  in  South  Asians",  'g.  Case  fatality  six 
months  after  acute  myocardial  infarction  was  reported  to  be  twice  as  high  in  South  Asians 
compared  with  Europeans',  but  a  large  part  of  this  excess  hazard  was  attributable  to  non- 
insulin  dependent  diabetes  (NIDDM):  adjustment  for  NIDDM  reduced  the  hazard  ratio 
from  2.02  to  1.26'9. 
Despite  a  reduction  in  CHD  mortality  in  all  Western  European  countries  between  1970  and 
1985,  over  the  same  period  there  was  a6%  and  13  %  increase  in  CHD  mortality  for  South 
Asian  men  and  women  respectively'  1,16°2o  By  1991,  however,  there  was  a  decline  in  CHD 
mortality  compared  with  1970-72,  among  those  born  in  the  Indian  sub-continent  (20%  for 
men  and  7%  for  women)9.  However,  this  decline  was  of  a  smaller  magnitude  than  those 
born  in  England  and  Wales  (29%  for  men  and  17%  for  women)9. 
The  consistency  of  the  high  risk  of  CHD  among  South  Asian  people  in  several  studies  from 
around  the  world,  affecting  both  sexes  and  with  early  onset,  particularly  in  men,  has 
driven  research  to  try  to  identify  the  risk  factors  that  contribute  to  this  excess  risk.  The 
speculation  has  been  that  there  might  be  a  common  underlying  explanation  for  the  high 
CHD  risk. 
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There  are  no  current  population  based  national  data  on  CHD  incidence,  prevalence  or 
mortality  in  the  Indian  subcontinent,  although  studies  from  some  towns  in  India  exist.  The 
largest  of  these  was  a  population  study  in  Delhi  in  1985-86,  of  13,723  men  and  women21. 
Prevalence  of  ECG  changes  was  7%  in  men  and  4.3%  in  women  aged  45-64  years. 
However  the  overall  prevalence  of  Minnesota-coded  major  Q  waves  was  3.6  %22.  A  survey 
of  725  adults  aged  over  30  years  in  the  city  of  Varanasi  showed  a  6.5  %  prevalence  of 
CHD  (based  on  WHO  chest  pain  questionnaire  and  ECG  changes)23.  The  prevalence  of 
CHD  in  urban  settings  in  India  is  reported  to  be  higher  than  that  among  inhabitants  of  rural 
areas  and  is  approximately  equivalent  to  that  among  South  Asians  who  have  settled  outside 
the  subcontinent22'24-26 
1.2.2.  Coronary  risk  factors  in  South  Asians 
A  thorough  description  of  the  prevalence  of  conventional  risk  factors  such  as  levels  of 
smoking,  blood  pressure  and  serum  cholesterol  in  South  Asians  has  been  given  before  by 
McKeigue  and  colleagues',  ".  A  brief  summary  is  given  here.  Compared  to  the  U.  K. 
national  average  of  about  30%,  the  prevalence  of  smoking  in  men  of  Gujarati  Hindu  and 
Indian  or  Pakistani  Muslim  origin  is  generally  comparable,  higher  among  Bangladeshi 
Muslims,  and  much  lower  (about  4%)  in  Punjabi  Sikhs,  whose  religion  prohibits  them 
from  smoking.  Smoking  rates  are  very  low  in  all  groups  of  South  Asian  women  except 
Bangladeshis.  No  South  Asian  community  studied  in  the  U.  K.  has  higher  average  plasma 
cholesterol  levels  in  middle  age  than  the  national  average  of  about  6.0  mmol/l.  It  has  been 
found  that  compared  with  Europeans,  average  blood  pressure  levels  are  higher  in  Punjabi 
Hindus  and  Sikhs,  similar  in  Gujarati  Hindus  and  Pakistani  Muslims,  and  lower  in 
Bangladeshis.  However,  although  conventional  risk  factors  such  as  smoking,  hypertension 
and  hypercholesterolaemia  remain  highly  important  risk  factors  for  CHD  within  each 
ethnic  group  of  Europeans  as  well  as  South  Asians,  they  fail  to  account  for  the  excess  of 
CHD  rates  in  South  Asians  when  compared  to  Europeans22,28,29. 
Non  insulin  dependent  diabetes  mellitus  is  present  in  about  20  %  of  South  Asian  men  and 
women  aged  over  40  years  in  the  U.  K.,  compared  with  about  5%  of  Europeans29.  In  a 
case  control  study  the  proportion  of  all  myocardial  infarctions  which  were  attributable  to 
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Europeans30.  However,  most  South  Asian  patients  with  CHD  are  not  diabetic3'  and 
glucose  intolerance  cannot  alone  explain  more  than  a  small  proportion  of  the  coronary  risk 
in  South  Asians32.  Levels  of  haemostatic  factors  such  as  fibrinogen  were  similar  to  or 
lower  in  South  Asians  than  those  in  Europeans33,3a  and  factor  VIIc  was  lower  in 
Bangladeshi  than  European  men28.  Thus  haemostatic  factors  also  do  not  account  for  the 
excess  CHD  risk  in  South  Asians. 
An  adverse  diet  among  South  Asians  has  been  implicated  in  promoting  CHD.  However  in 
studies  that  assessed  diet  similar  proportion  of  total  energy  intake  was  derived  from  fat  in 
both  European  and  South  Asian  groups,  and  the  polyunsaturated/saturated  fat  ratio  was 
higher  in  South  Asians33°35.36  Psychosocial  factors  possibly  contributing  to  CHD  were 
investigated  in  a  cross  sectional  study  of  Punjabi  origin  South  Asians  with  the  general 
population  in  Glasgow37.  A  much  larger  proportion  of  South  Asians  reported  worse  socio- 
economic  circumstances  as  well  as  stress  factors  such  as  longer  working  hours,  low 
income,  crowded  housing,  liability  to  attack  and  perceived  lack  of  social  support.  The 
authors  of  the  study  proposed  that  stress  and  socio-economic  deprivation,  along  with  the 
high  prevalence  of  diabetes  was  likely  to  explain  the  excess  risk  of  CHD  in  South  Asians. 
However  the  study  was  based  on  a  small  number  of  173  South  Asians,  and  no  attempt  was 
made  at  studying  specifically  the  relationship  between  coronary  risk  factors  and  socio- 
economic  status  or  CHD  and  socio-economic  status.  Additionally  the  participants 
expressed  little  dissatisfaction  about  these  conditions.  No  clear-cut  role  of  these  stresses  in 
promoting  CHD  has  been  found  in  South  Asians,  but  it  is  plausible  that  they  play  some 
contributory  role. 
Based  on  the  failure  of  the  above  risk  factors  to  account  for  the  excess  CHD  in  South 
Asians,  and  on  the  results  of  cross-sectional  surveys  in  east  London28  and  Southall,  west 
London29,  McKeigue  et  al  have  suggested  that  a  pattern  of  physiological  disturbances 
related  to  central  obesity  and  insulin  resistance  underlies  the  high  coronary  risk  and 
diabetes  prevalence  in  South  Asians. 
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1.3.1.  Background 
In  1975  in  their  seminal  paper  Miller  and  Miller38  proposed  that  a  reduction  in  plasma 
HDL-cholesterol  concentration  may  accelerate  the  development  of  atherosclerosis  and 
hence  CHD,  by  impairing  the  clearance  of  cholesterol  from  the  arterial  wall.  This  was 
later  also  confirmed  by  findings  from  the  Framingham  study  in  197739.  Around  the  same 
time  a  predictive  role  for  triglycerides  was  also  shown  in  prospective  studies40.  High 
levels  of  fasting  triglyceride  and  low  levels  of  plasma  HDL-cholesterol  have  been  found 
fairly  consistently  in  South  Asians  overseas  compared  with  other  groups.  This  was 
specifically  reported  in  South  Asians  in  Trinidad  compared  with  people  of  African  origin" 
and  in  the  U.  S.  A.  compared  with  European  descent  Americans42.  In  Fiji  higher  plasma 
triglyceride  levels  were  shown  compared  to  Melanesians43,  and  in  East  London  mean 
HDL-cholesterol  was  0.3  mmol/1  lower  and  plasma  triglycerides  after  a  glucose  load  were 
50%  higher  among  Bangladeshis  than  in  Europeans28.  In  fact  in  the  latter  study  McKeigue 
et  al  identified  a  pattern  of  interrelated  metabolic  disturbances  among  South  Asians  of 
Bangladeshi  descent:  glucose  intolerance,  low  plasma  HDL-cholesterol,  and  high 
concentrations  of  insulin  and  triglyceride  after  a  glucose  load.  In  other  populations  these 
aa  disturbances  are  associated  with  insulin  resistance,  as 
1.3.2.  Definition  of  the  insulin  resistance  syndrome 
The  insulin  resistance  syndrome  (also  known  as  the  `metabolic  syndrome'  or  `Syndrome  X' 
first  defined  by  Reaven)  has  been  defined  as  a  cluster  of  related  factors  that  include 
resistance  to  insulin-stimulated  glucose  uptake,  glucose  intolerance,  hyperinsulinaemia, 
increased  levels  of  VLDL  triglycerides,  decreased  levels  of  HDL-cholesterol  and 
hypertension".  Insulin  resistance  is  also  associated  with  central  obesity  -a  pattern  of 
obesity  in  which  a  high  proportion  of  body  fat  is  deposited  intra-abdominally. 
The  mechanisms  underlying  the  associations  of  features  of  the  insulin  resistance  syndrome 
are  poorly  understood.  Resistance  to  insulin-stimulated  glucose  uptake  is  probably 
responsible  for  the  glucose  intolerance,  hyperinsulinaemia,  and  hypertension.  Failure  of 
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(particularly  increased  intra-abdominal  adipose  tissue  of  central  obesity)  may  cause 
hypertriglyceridaemia46,  low  plasma  concentrations  of  HDL-cholesterol,  and  changes  in  the 
composition  and  size  of  particles  in  the  LDL  fraction47. 
1.3.3.  The  relation  of  coronary  risk  to  insulin  resistance  in  South  Asians 
McKeigue  and  colleagues  proposed  in  1988  that  a  tendency  for  this  insulin  resistance 
syndrome  to  develop  was  generally  present  in  South  Asians  overseas,  and  that  this 
tendency  might  underlie  the  high  rates  of  CHD  and  type  2  diabetes5'28.  They  later 
confirmed  these  findings  in  further  studies  of  South  Asians  living  in  north-west  London, 
where  they  also  found  a  tendency  towards  central  obesity  associated  with  all  the  above 
features22°29.  Waist-hip  ratio  (as  an  index  of  central  obesity)  was  higher  in  South  Asian 
than  European  men  although  the  average  body  mass  index  was  no  higher  in  South  Asian 
men  than  in  European  men29.  In  the  Southall  study22  adjusting  for  central  obesity,  glucose 
intolerance  and  hyperinsulinaemia  reduced  the  odds  ratio  for  major  Q  waves  on  ECG  from 
2.4  (when  adjusted  for  age,  smoking  and  cholesterol)  to  1.5,  explaining  two  thirds  of  the 
excess  CHD  morbidity  in  South  Asian  men. 
1.3.3.1.  Support  for  the  insulin  resistance  hypothesis  in  South  Asians 
Several  lines  of  evidence  support  the  insulin  resistance  hypothesis  as  the  explanation  for 
the  high  CHD  risk  in  South  Asians.  Socio-economic  status,  smoking,  plasma  cholesterol, 
blood  pressure,  haemostatic  factors  and  fatty  acid  composition  of  plasma  lipids  differ 
markedly  between  the  various  South  Asian  groups  who  share  the  high  CHD  risk28,29,33,35It 
is  also  important  to  highlight  that  in  some  South  Asian  groups  who  share  high  CHD  risk, 
some  of  the  risk  factors  associated  with  insulin  resistance  are  not  more  unfavourably 
distributed  than  in  Europeans.  For  instance,  in  comparison  with  Europeans,  South  Asian 
Muslims  do  not  have  higher  systolic  and  diastolic  blood  pressures,  Sikhs  do  not  have  lower 
HDL  cholesterol,  and  Gujarati  Hindus  do  not  have  higher  fasting  triglyceride  levels.  As 
high  CHD  risk  is  common  to  all  these  groups,  it  follows  that  the  increased  CHD  risk  in 
South  Asians  cannot  be  mediated  mainly  through  raised  blood  pressure,  low  HDL- 
cholesterol  or  raised  fasting  triglyceride.  However,  common  to  all  South  Asian  groups  at 
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raised  triglyceride  level  after  a  glucose  load'29 
The  narrowing  of  the  sex  difference  in  CHD  mortality  that  occurs  in  South  Asians  after  the 
age  of  40  years  parallels  the  changes  in  body  fat  pattern  and  lipoprotein  pattern  that  occur 
in  women  around  the  time  of  the  menopause.  The  attenuation  of  the  sex  difference  in 
coronary  risk  in  older  South  Asians  is  also  explained  by  the  insulin  resistance  syndrome, 
since  the  insulin  resistance  syndrome  is  associated  with  several  risk  factors  which  are 
normally  less  prevalent  in  women  than  in  men.  These  include  central  obesity,  raised 
plasma  triglyceride,  and  lower  HDL-cholesterol.  A  similar  loss  of  women's  immunity  to 
CHD  occurs  in  NIDDM48. 
Several  other  groups  have  also  confirmed  these  findings  of  higher  WHR,  higher  levels  of 
fasting  triglyceride  and  lower  levels  of  HDL-cholesterol  combined  with  higher  prevalence 
of  glucose  intolerance  among  South  Asians.  These  cross  sectionala9,  so  and  case  control 
studies31°s'  have  supported  the  hypothesis  that  features  of  the  insulin  resistance  syndrome 
promote  CHD  risk  in  South  Asians. 
Studies  among  young  South  Asian  adults  also  suggest  early  onset  of  features  of  insulin 
resistance.  Young  (mean  age  21  years)  male  offspring  of  South  Asian  patients  with 
coronary  disease  were  found  to  have  significantly  higher  fasting  insulin  levels  and  waist- 
hip  ratios  than  age  matched  male  offspring  of  European  patients52.  Additionally,  young 
relatives  of  South  Asian  patients  with  NIDDM  compared  with  age  matched  subjects 
without  such  a  family  history  were  demonstrated  to  have  significantly  higher  fasting  insulin 
levels  and  poorer  insulin  sensitivity  measured  by  the  short  insulin  tolerance  test53.  It  thus 
appears  that  South  Asian  people  have  a  tendency  to  features  of  the  insulin  resistance 
syndrome  from  an  early  age.  The  insulin  resistance  hypothesis  provides  a  unifying 
explanation  for  the  high  rates  of  both  diabetes  and  CHD  in  South  Asians. 
1.3.4.  Origins  of  insulin  resistance:  genes  or  environment? 
1.3.4.1.  Genetic  hypothesis 
The  pathophysiology  and  aetiology  of  insulin  resistance  and  development  of  type  2  diabetes 
is  not  clearly  understood.  Neel  first  proposed  a  "thrifty  genotype"  hypothesis  in  196254  to 
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observed  this  century.  He  proposed  that  during  the  early  stages  of  human  evolution  a 
series  of  genes  were  selected  that  gave  a  survival  advantage  to  individuals  who  underwent 
cyclic  changes  in  food  availability,  as  would  be  associated  with  the  hunter-gatherer  or  early 
agriculturist  lifestyle.  Expression  of  these  genes  would  result  in  a  "quick  insulin  trigger" 
(large  bursts  in  insulin  secretion)  in  response  to  hyperglycaemia,  thus  leading  to  reduced 
urinary  caloric  loss  and  the  efficient  storage  of  dietary  calories  as  fat.  This  would  provide 
an  energy  store  (from  breakdown  of  fat  in  adipocytes  to  release  NEFA)  to  be  used  in  times 
when  food  was  more  scarce  and  hence  would  be  beneficial  when  there  was  a  cyclical 
availability  of  food.  He  also  proposed  that  such  a  setting  would  become  detrimental  to 
health  in  conditions  of  more  plentiful  food  supply,  as  the  quick  insulin  trigger  would 
become  over-stimulated,  leading  to  beta-cell  decompensation  and  diabetes. 
This  hypothesis  came  under  question  when  it  was  reported  that  the  high  rates  of  diabetes 
(and  glucose  intolerance)  previously  recorded  in  the  Pacific  island  of  Nauru  were 
decreasing,  despite  the  recent  transition  from  undernutrition  to  relative  affluence" 
1.3.4.2.  Environmental  hypothesis 
Exactly  30  years  after  Neel's  hypothesis,  Hales  and  Barker  suggested  a  "thrifty  phenotype" 
hypothesis56  as  an  alternative  to  the  thrifty  genotype  hypothesis.  Their  hypothesis  proposes 
that  the  high  rates  of  diabetes  result  from  undernutrition  in  fetal  and  infant  life,  followed 
by  relative  over  nutrition  later,  suggesting  an  environmental  rather  than  genetic  basis  for 
the  disease.  They  postulated  that  this  hypothesis  better  explains  the  changes  seen  in 
Nauru.  Based  on  the  associations  seen  between  low  birth  weight  and  subsequent 
development  of  CHD,  hypertension  and  type  2  diabetes  (or  glucose  intolerance),  they  have 
proposed  that  the  peri-conception  and  pregnancy  period  has  influences  on  foetal  growth 
(such  as  foetal  undernutrition)  which  "programme"  the  susceptibility  to  development  of 
these  disorders  in  later  life57-59.  They  showed  in  particular  that  factors  associated  with  low 
birth  weight  and  with  high  adult  BMI  contribute  independently  to  an  individual's  glucose 
tolerance. 
There  has  been  support  for  this  hypothesis  from  other  groups.  Recent  evidence  suggests 
particularly  increased  risk  among  small  babies  of  women  with  high  body  mass  index60.  A 
study  of  twins  in  Denmark"  found  that  in  both  monozygotic  and  dizygotic  twins  discordant 
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those  of  the  non-diabetic  twins.  This  supported  the  role  of  a  non-genetic  (environmental) 
intrauterine  component,  such  as  intrauterine  environment,  for  the  development  of  diabetes 
later  in  life.  One  study  has  found  results  conflicting  with  this  hypothesis.  This  study62 
compared  174  Russian  adults exposed  in  utero  to  malnutrition  during  the  1941-42  siege  of 
Leningrad,  with  controls  born  before  the  siege  or  outside  Leningrad.  Fasting  and  2h 
glucose  were  not  significantly  higher  in  the  group  exposed  to  malnutrition  in  utero  than  in 
controls.  However,  it  is  uncertain  whether  malnutrition  in  this  population  was  restricted  to 
those  classified  as  exposed.  The  Dutch  famine  study63,  in  contrast,  reports  a  higher  mean 
2h  glucose  in  those  exposed  to  famine  during  mid  gestation  or  late  gestation  than  in  those 
not  exposed,  and  this  effect  was  independent  of  BMI.  This  famine  of  1944-45  was  sharply 
delimited  and  provides  a  good  setting  for  testing  the  hypothesis  that  impaired  nutrition  in 
foetal  life  may  cause  increased  risk  of  diabetes  in  adult  life. 
The  "Barker"  hypothesis  has  been  extended  to  other  populations  at  high  risk  for  diabetes, 
including  South  Asians,  Native  Americans  and  Mexican-Americans.  In  a  study  of  1179 
Pima  Indians  there  was  a  U-shaped  relationship  between  birth  weight  and  prevalence  of 
diabetes64.  Prevalence  of  diabetes  was  raised  only  in  those  with  birth  weight  less  than  2.5 
kg  or  more  than  4.5  kg.  In  a  study  in  the  south  Indian  city  of  Mysore  the  prevalence  of 
diabetes  was  positively  related  to  ponderal  index  (weight/  length')  at  birth65  (in  contrast  to 
the  inverse  associations  seen  in  European  populations).  The  authors  suggested  that  the 
effects  of  gestational  diabetes  on  size  at  birth  and  beta-cell  function  in  adult  life  might 
account  for  this  association.  In  a  study  of  4  year  old  children  in  India  there  was  an  inverse 
association  between  low  birthweight  (weight  less  than  2.4kg)  and  30  minute  post-load 
glucose  and  insulin  levels  in  201  routine  deliveries66.  However  no  association  was  seen  in 
low  birthweight  children  looked  after  in  a  special  care  baby  unit.  Whincup  and 
colleagues67  have  studied  these  relationships  in  children  aged  10-11  years  from  10  towns  in 
the  U.  K.,  including  children  of  South  Asian  origin.  They  found  that  in  all  children 
childhood  obesity  was  a  stronger  determinant  of  insulin  level  and  insulin  resistance  than 
size  at  birth  (either  ponderal  index  or  birthweight).  It  appears  that  in  populations  at  high 
risk  for  diabetes  the  inverse  relationship  between  glucose  intolerance  and  size  at  birth  is 
less  clear,  and  the  relationship  may  be  U  shaped  or  reversed.  This  could  be  attributable  to 
the  effects  of  glucose  intolerance  during  pregnancy. 
Epidemiology  of  CHD  in  S.  Asians  1-25 1.3.4.3.  Which  hypothesis  explains  the  ethnic  differences  in  prevalence  of  insulin 
resistance  and  diabetes? 
There  arises  a  question  as  to  whether  impaired  foetal  growth  can  account  for  ethnic 
differences  in  prevalence  of  diabetes.  In  other  words  is  the  thrifty  phenotype  hypothesis 
important  only  in  explaining  the  high  prevalence  of  diabetes  within  populations  or  does  it 
explain  variation  between  populations  as  well?  Although  reduced  foetal  growth  may  be 
part  of  the  explanation  for  high  prevalence  of  diabetes  in  the  high  risk  populations,  the 
evidence  that  genetic  factors  underlie  the  ethnic  differences  in  diabetes  risk  remains 
compelling.  Evidence  from  migrant  (see  sections  1.1.1  and  1.2)  and  admixture  studies 
suggests  that  differences  in  diabetes  risk  between  high  risk  ethnic  groups  such  as  Pacific 
islanders  and  low-risk  ethnic  groups  such  as  Europeans  are  attributable  to  genetic  factors. 
In  Nauruans  inverse  associations  of  diabetes  with  genetic  markers  of  European  admixture 
have  been  reported68.  Admixture  in  Nauru  resulted  mainly  from  unions  between  Nauruan 
women  and  European  men;  thus  the  effect  was  to  introduce  European  genes  but  not 
European  maternal  environment.  It  is  possible  that  ethnic  differences  in  the  risk  of 
diabetes  could  be  a  consequence  of  ethnic  differences  in  foetal  growth  which  have  a  genetic 
basis. 
There  is  yet  another  hypothesis  called  the  "foetal  insulin  hypothesis"  as  an  alternative 
explanation  of  the  association  of  low  birth  weight  with  diabetes  and  vascular  disease" 
This  hypothesis  has  been  proposed  in  1999  by  Hattersley  and  Tooke,  and  it  proposes  that 
the  association  between  low  birthweight  and  adult  insulin  resistance  is  principally 
genetically  determined.  Central  to  this  hypothesis  is  the  concept  that  insulin-mediated 
foetal  growth  will  be  affected  by  foetal  genetic  factors  that  regulate  either  foetal  insulin 
secretion  or  the  sensitivity  of  foetal  tissues  to  the  effects  of  insulin.  However  this 
hypothesis  is  not  entirely  consistent  with  the  findings  of  the  Danish  twins  study61  or  the 
Dutch  famine  study63.  Of  practical  importance  is  the  point  that  if  ethnic  differences  in 
disease  risk  have  a  genetic  basis  it  is  possible  to  map  the  genes  underlying  these  differences 
by  studying  populations  where  there  has  been  recent  admixture70. 
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Although  insulin  resistance  is  strongly  associated  with  central  obesity  in  South  Asians  as  in 
other  ethnic  groups,  it  is  not  known  whether  the  primary  defect  is  central  obesity, 
resistance  to  insulin  action,  or  some  other  defect.  Many  studies  have  demonstrated  that 
excessive  accumulation  of  fat  in  the  abdominal  region  is  strongly  associated  with  metabolic 
alterations  such  as  disturbed  plasma  lipoprotein  profile  7-71,  hyperinsulinaemia,  insulin 
resistance  and  glucose  intolerance  74-76.  In  the  cross-sectional  study  in  Southall,  adjusting 
for  waist-hip  ratio  (WHR)  explained  only  about  half  of  the  ethnic  difference  in  insulin 
levels29.  However,  WHR  is  not  an  accurate  measure  of  the  proportion  of  body  fat  sited 
intra-abdominally:  the  correlation  with  CT  scan  measures  is  only  about  0.55".  To 
establish  whether  the  ethnic  difference  in  insulin  resistance  can  be  explained  by  central 
adiposity,  we  need  to  measure  visceral  fat  distribution  directly  by  CT  scan. 
If  adiposity  is  important  then  there  should  not  be  a  difference  in  insulin  resistance  between 
lean  people  of  South  Asian  and  European  origin.  In  other  conditions  associated  with 
insulin  resistance,  susceptibility  to  insulin  resistance  depends  on  the  levels  of  adiposity. 
Thus  overweight  women  with  polycystic  ovary  syndrome  (PCOS)  are  more  insulin 
resistant  than  weight-matched  controls,  but  when  lean  women  with  PCOS  are  compared 
with  lean  controls  there  is  no  difference  in  insulin  sensitivity's.  In  a  study  in  Swedish  men, 
the  association  between  thinness  at  birth  and  raised  post-load  insulin  levels  was  present 
only  in  men  who  were  overweight79.  South  Asian  infants  born  in  the  U.  K.  are  thinner  at 
birth  than  native  British  infants,  and  it  is  possible  that  the  tendency  to  insulin  resistance  in 
South  Asian  adults  is  similarly  dependent  on  the  degree  of  obesity.  It  is  important  to  test 
whether  in  South  Asians  the  slope  of  the  regression  line  for  the  relation  between  central 
obesity  and  insulin  resistance  is  parallel  to  that  for  Europeans,  or  the  lines  cross  over  with 
varying  adiposity. 
1.4.  Mediation  of  increased  coronary  risk 
It  is  not  established  which  component  of  insulin  resistance  promotes  CHD.  It  is  possible 
that  hyperinsulinaemia  and  insulin  resistance  increase  the  risk  for  CHD  indirectly  through 
their  effects  on  cardiovascular  risk  factors,  such  as  raised  triglyceride  and  lowered 
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have  direct  effects  on  the  coronary  artery  wall  and  thereby  promote  atherosclerosis80 
As  discussed  earlier  (section  1.3.3.1)  the  effect  of  insulin  resistance  on  the  excess  CHD 
risk  in  South  Asians  cannot  be  mediated  mainly  through  blood  pressure  or  HDL  cholesterol 
since  these  risk  factors  are  not  unfavourably  distributed  in  all  the  groups  of  South  Asian 
settlers  in  the  U.  K.  who  share  high  CHD  risk28,29.  Other  disturbances  associated  with 
central  obesity  and  insulin  resistance  include  elevated  plasminogen  activator  inhibitor 
(PAI-1)81,  elevated  IDL  and  predominance  of  small  dense  LDL82'83,  the  last  of  which  has 
been  particularly  speculated  to  be  associated  with  the  increased  atherogenic  risk  in  South 
Asians.  However,  one  study84  concluded  that  compared  to  European-descent  men,  South 
Asian  men  in  Texas  had  larger  LDL  particles  and  a  lower  prevalence  of  small  dense  LDL 
in  the  presence  of  normolipidaemia.  In  contrast  a  recent  study  of  92  men  in  London  has 
found  a  preponderance  of  lower  LDL  size  among  South  Asians  compared  to  Europeans 
and  Afro-CaribbeansS5 
. 
Raised  triglyceride  levels  are  seen  both  in  obesity  and  insulin  resistance.  Coronary  heart 
disease  in  South  Asians  is  more  strongly  associated  with  raised  plasma  triglyceride  levels 
than  with  any  other  metabolic  measurement,  but  ethnic  differences  in  fasting  triglyceride 
levels  are  too  small  to  account  statistically  for  the  excess  prevalence  of  CHD  in  South 
Asian  compared  with  European  men22.  It  is  possible  that  postprandial  rather  than  fasting 
triglyceride  levels  could  account  for  the  excess  risk  of  CHD  in  South  Asians.  There  are  no 
published  studies  that  have  measured  postprandial  lipid  metabolism  in  South  Asians.  The 
potential  role  of  postprandial  lipids  in  insulin  resistance  and  coronary  heart  disease  is 
explored  in  chapter  2. 
The  mechanism  of  how  insulin  resistance  comes  about  is  also  not  known.  One  possibility 
is  that  it  comes  about  as  a  result  of  increased  stores  of  triglyceride  in  skeletal  muscle  cells. 
The  evidence  for  this  is  presented  in  chapter  3. 
1.4.1.  The  controversy  about  the  role  of  insulin  and  insulin  resistance  in 
CHD 
The  hypothesis  that  insulin  resistance  or  hyperinsulinaemia  is  causally  related  to  the  risk  of 
CHD  is  still  controversial.  An  extensive  review  of  the  evidence  from  prospective  studies 
Epidemiology  of  CHD  in  S.  Asians  1-28 for  and  against  the  association  between  baseline  insulin  level  and  future  risk  of  CHD  has 
been  presented  by  Laakso86.  Many  reject  the  insulin  hypothesis87-89.  Jarrett87  has  noted  that 
raised  fasting  and  post-load  insulin  levels  not  only  fail  to  predict  CHD  consistently  when 
other  risk  factors  are  taken  into  account,  but  sometimes  fail  to  predict  even  in  univariate 
analyses.  However,  even  if  insulin  fails  to  be  a  risk  factor  in  univariate  analysis,  it  does 
not  necessarily  imply  that  hyperinsulinaemia  cannot  contribute  to  accelerated  atherogenesis 
or  thrombogenesis.  It  is  still  possible  that  the  effects  of  insulin  are  mediated  through  its 
impact  on  other  cardiovascular  risk  factors.  The  insulin  resistance  hypothesis  does  not 
assume  that  insulin  only  directly  promotes  atherogenesis.  Thus  it  is  possible  that  the 
associations  between  hyperinsulinaemia  and  CHD  are  mediated  through  disturbances  of 
lipoprotein  metabolism  such  as  raised  plasma  triglycerides,  low  HDL-cholesterol  and  small 
dense  LDL. 
Nevertheless  it  has  been  observed  that  raised  fasting  or  post-load  insulin  levels  are  far  less 
consistently  predictive  of  cardiovascular  disease  than  would  be  expected  if  the  insulin 
resistance  hypothesis  is  correct.  To  explain  this  McKeigue  and  Davey9°  have  argued  that 
this  is  largely  attributable  to  failure  to  control  for  the  effects  of  undernutrition  and weight 
loss  resulting  from  poor  health.  Poor  nutritional  status  is  a  strong  predictor  of  mortality  in 
the  elderly,  and  smoking  is  a  powerful  confounder  of  this  relationship.  The  strength  of  the 
co-morbidity  effects  is  demonstrated  by  the  observation  that  men  who  died  of  CHD  were 
leaner  than  those  who  survived  in  some  of  the  studies  such  as  the  Rancho  Bernardo 
cohort91,  the  Gothenburg  Study92,  and  in  the  Multiple  Risk  Factor  Intervention  Trial93 
Thus  it  is  plausible  that  failure  to  control  for  confounding  by  co-morbidity  is  responsible 
for  the  lack  of  association  between  raised  insulin  levels  and  cardiovascular  disease  in 
several  cohort  studies. 
McKeigue  and  Davey9°  have  proposed  that  the  key  question  for  public  health  is  not 
whether  raised  insulin  levels  are  an  independent  risk  factor  for  CHD,  but  whether 
measures  to  alleviate  the  syndrome  of  metabolic  disturbances  associated  with  insulin 
resistance  and  central  obesity  will  reduce  the  risk  of  CHD. 
In  summary,  the  reasons  for  the  relative  excess  of  NIDDM  and  CHD  in  South  Asians 
remain  unclear  but  features  associated  with  the  insulin  resistance  syndrome  remain  a  strong 
candidate  for  providing  a  unifying  explanation.  Thus  preventative  strategies  to  reduce  the 
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emphases  to  those  designed  for  European  groups.  For  instance  the  most  important 
intervention  in  South  Asians  may  constitute  alleviation  of  insulin  resistance.  There  remain 
many  gaps  in  our  knowledge  about  the  relationship  between  body  fat  distribution 
(especially  central  obesity),  insulin  resistance  and  lipid  metabolism.  This  study  was 
designed  to  investigate  some  of  these. 
1.5.  Measurement  of  insulin  resistance 
In  contrast  to  clinical  syndromes  of  insulin  resistance  which  are  rare  and  typified  by 
striking  clinical  features  such  as  acanthosis  nigricans  and  ovarian  hyperandrogenism  in 
women,  the  insulin  resistance  and  its  related  metabolic  disturbances  that  most  people  get, 
and  has  been  thus  far  referred  to,  develops  insidiously  and  without  symptoms.  Dose- 
response  studies  point  against  an  insulin  receptor  binding  defect  in  the  majority  of  people 
with  insulin  resistance,  but  suggest  instead  changes  in  post  receptor  signalling  or 
intracellular  response.  Glucose  metabolism  and  storage  have  been  the  focus  of 
investigations  into  alterations  in  intracellular  metabolism.  Indirect  calorimetry  and  isotopic 
studies  have  demonstrated  reduced  glucose  oxidation94  and  diminished  insulin-stimulated 
glycogen  synthesis95  in  insulin  resistant  subjects  at  lower  and  higher  insulin  concentrations, 
respectively. 
Insulin  is  important  in  the  regulation  of  substrate  metabolism.  Insulin  regulates  glucose 
metabolism  (causes  glycogen  synthesis,  and  prevents  gluconeogenesis)  as  well  as  fat 
metabolism  (anti-lipolytic  effect;  suppresses  production  of  NEFA  from  adipocytes)  and 
protein  metabolism.  Most  studies  quantitate  insulin  action  in  terms  of  its  glucose 
regulatory  effects.  This  is  due  in  large  part  to  the  technical  ease  of  measurement  of 
glucose  concentration. 
Traditionally  in  epidemiological  studies  insulin  resistance  has  been  "approximated"  by  the 
surrogate  measure  of  plasma  insulin  level,  often  in  response  to  an  oral  glucose  load.  This 
provides  an  indirect  measure  of  insulin  action,  but  alterations  in  insulin  secretion  and/or 
clearance  can  alter  insulin  concentrations  in  the  absence  of  any  change  in  insulin  action. 
The  correlations  of  fasting  and  post-glucose  insulin  levels  with  insulin  sensitivity  evaluated 
by  the  euglycaemic  clamp  technique  range  at  most  from  0.6  to  0.796.  Thus  measurement 
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objective  of  which  is  to  compare  insulin  sensitivity  in  South  Asians  and  Europeans,  and  to 
study  its  relationship  specifically  with  obesity.  We  wanted  to  measure  insulin  sensitivity 
more  accurately,  and  more  reflective  of  the  dynamic  situation  in  vivo.  The  choice  of 
methods  available  to  do  this  is  summarised  below. 
1.5.1.  Clamp  techniques 
The  euglycaemic  hyperinsulinaemic  clamp  technique97  is  currently  regarded  as  the  "gold 
standard"  for  measuring  insulin  sensitivity  in  vivo,  against  which  other  methods  are 
compared98-102.  It  involves  artificial  elevation  of  plasma  insulin  using  an  infusion  of 
exogenous  insulin  over  a  period  of  3  to  6  hours.  Plasma  glucose  is  kept  at  a  physiological 
level  by  infusing  glucose  at  a  rate  adjusted  to  the  prevailing  insulin  concentration.  Samples 
are  taken  from  an  arterialised  hand  vein  for  the  duration  of  the  study.  The  rate  of  glucose 
infusion  represents  insulin-mediated  glucose  disposal  assuming  that  the  steady  state  insulin 
level  is  sufficient  to  suppress  hepatic  glucose  production.  This  assumption  can  be  tested  by 
infusing  labelled  glucose  and  measuring  the  ratio  of  labelled  to  unlabelled  (endogenously 
produced)  glucose  in  the  plasma. 
A  hyperglycaemic  hyperinsulinaemic  clamp  can  be  used  to  measure  acute  and  steady-state 
glucose-stimulated  insulin  secretion,  in  addition  to  insulin-mediated  glucose  disposal. 
Overall  the  clamp  techniques  relate  net  blood  glucose  elimination  rate  to  the  plasma  insulin 
concentration. 
However,  clamp  techniques  are  complex,  prolonged,  invasive  and  expensive,  and  not 
suitable  for  large  numbers  of  subjects.  In  absolute  terms  the  clamp  may  considerably 
overestimate  insulin  sensitivity  by  the  presence  of  sustained  hyperinsulinaemia  and  the 
increasing  rate  of  glucose  infusion  required  to  maintain  euglycaemia.  This  creates  a  non- 
physiological  state,  because  in  normal  physiology  there  is  never  such  sustained 
hyperinsulinaemia.  Thus  while  clamp-derived  measures  provide  an  adequate  reference, 
their  use  in  epidemiological  studies  should  be  viewed  with  caution. 
Epidemiology  of  CHD  in  S.  Asians  1-31 1.5.2.  Intravenous  glucose  tolerance  test  and  minimal  modelling 
Minimal  model  analysis  of  glucose  and  insulin  concentration  profiles  during  an  intravenous 
glucose  tolerance  test  (IVGTT)  avoids  the  procedural  difficulties  of  the  clamp.  Minimal 
model  analysis  uses  mathematical  analysis  of  the  non-steady  state  glucose  and  insulin 
concentrations  during  an  IVGTT  to  provide  a  measure  of  the  constant  that  best  relates 
change  in  glucose  disposal  rate  to  change  in  plasma  insulin  concentration.  An  IVGTT 
involves  a  bolus  injection  of  glucose  into  an  antecubital  vein,  and  frequent  sampling  from 
the  contralateral  arm.  The  modelling  technique  was  originally  described  by  Bergman  in 
197999.  The  index  of  insulin  sensitivity  derived  during  minimal  modelling  represents  the 
ability  of  insulin  to  enhance  total  net  glucose  disappearance  from  the  extracellular  fluid  (by 
suppressing  glucose  production  as  well  as  by  increasing  its  utilisation). 
The  complexity  of  this  method  lies  in  the  computer  modelling  rather  than  in  the  metabolic 
test  itself.  The  test  is  moderately  invasive  and  time-consuming  (3  hours)  but  does  not 
require  sophisticated  equipment.  One  disadvantage  is  that  intravenous  administration  of 
glucose  bypasses  gastrointestinally  stimulated  secretion  of  insulin  via  substances  such  as 
cholecystokinin-pancreozymin  (CCK-PZ),  and  so  the  peak  insulin  secreted  is  less  than  that 
in  response  to  an  oral  challenge.  Additionally,  although  a  physiological  insulin  dynamic  is 
employed  (in  comparison  with  the  clamp),  the  technique  depends  on  there  being  a 
sufficient  insulin  response  (i.  e.  beta  cell  response). 
1.5.3.  Insulin  suppression  test 
In  this  test  endogenous  insulin  secretion  is  suppressed  with  somatostatin  (or  with 
intravenous  propranolol  and  adrenaline),  coupled  with  a  fixed  constant  glucose  and  insulin 
infusion'o,  'o4  Steady-state  plasma  glucose  (SSPG)  represents  an  index  (the  higher  the 
glucose,  the  greater  the  magnitude  of  insulin  resistance).  Although  relatively  simple  to 
perform,  it  assesses  the  ability  of  both  insulin  and  glucose  to  facilitate  glucose  uptake. 
Interpretation  may  be  confounded  by  the  effect  of  the  agents  used  to  inhibit  insulin 
secretion  on  insulin  action  and  by  differences  in  urinary  glucose  excretion  since  plasma 
glucose  may  exceed  the  renal  threshold  in  some  but  not  all  subjects  during  study. 
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The  measurement  of  glucose  disappearance  from  plasma  after  intravenous  insulin  injection 
is  the  basis  of  the  insulin  tolerance  test,  which  has  been  used  widely  to  estimate  in  vivo 
insulin  action105'°a  There  are  however  two  main  criticisms  of  the  insulin  tolerance  test:  (a) 
insulin  induced  fall  in  glucose  results  in  a  counter-regulatory  hormonal  response  (which 
includes  secretion  of  glucagon,  catecholamines,  growth  hormone  and  cortisol),  which  in 
turn  slows  the  glucose  disappearance  rate  from  plasma106'107,109,  and  (b)  insulin  injection 
may  induce  hypoglycaemia  which  is  both  unpleasant  and  potentially  dangerous. 
Both  these  problems  can  be  overcome  by  modification  of  the  test.  Firstly  the  blood 
glucose  decline  can  be  measured  over  the  initial  15  minutes,  before  the  onset  of  the 
counter-regulatory  response  which  usually  sets  in  about  20  minutes  after  insulin 
injection10-1z  Secondly,  to  avoid  symptomatic  hypoglycaemia  in  healthy  subjects,  a 
reduced  dose  of  insulin  bolus  (0.05  units  per  kg)  can  be  used102,  "3  This  is  a  modification 
of  the  insulin  dose  of  0.1  units  per  kg  body  weight  which  has  been  validated  against  the 
euglycaemic  hyperinsulinaemic  clamp  in  normal,  obese  and  diabetic  individuals100" 
With  these  modifications  the  low  dose  short  insulin  tolerance  test  (SITT)  is  derived.  In  this 
test,  glucose  levels  are  measured  every  2  minutes  from  an  arterialised  hand  vein  after  the 
injection  of  a  bolus  of  short  acting  insulin,  and  the  test  terminated  at  15  minutes  with 
intravenous  glucose.  The  rate  of  disappearance  of  glucose  (KITT)  is  calculated  as  0.693/t'h 
the  glucose  half  life  (tv2)  being  derived  from  the  slope  of  the  plasma  glucose  concentration 
curve  from  3  to  15  minutes101.  This  K  TT  is  equivalent  to  multiplying  the  slope  (of  the 
decline  in  log  transformed  blood  glucose  concentration  from  3  to  15  minutes)  by  a  -100 
factor13  The  glucose  decline  occurring  in  the  first  15  minutes  after  insulin  administration 
is  the  function  of  insulin-stimulated  glucose  uptake  by  tissues,  as  well  as  insulin-inhibited 
glucose  output  by  the  liver. 
The  advantages  of  the  SITT  include  simplicity,  safety  and  brevity.  Even  at  the  lower  dose 
of  insulin  (0.05  u/kg)  the  intra-individual  reproducibility  has  been  shown  to  be  good 
(coefficient  of  variation  6.9  ±  2.6  %  102),  with  close  correlation  of  the  SITT  derived  insulin 
'02 
sensitivity  with  that  derived  from  euglycaemic  clamp  studies  (r  =  0.81,  p<0.005) 
The  choice  of  the  SITT  for  the  current  study  is defended  in  section  5.10.1. 
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A  whole  host  of  potential  risk  factors  for  CHD  have  been  proposed  over  the  past  few 
years.  Evidence  for  the  possible  role  of  some  of  these  risk  factors  in  explaining  the  higher 
CHD  risk  in  South  Asians  is  beginning  to  emerge. 
Elevated  level  of  lipoprotein(a)  [Lp(a)]  has  been  reported  to  be  an  independent  risk  factor 
for  CHD114,115  Lp(a)  is  an  LDL-like  substance  containing  a  highly  carbohydrate-rich 
protein,  apo(a),  with  striking  homology  with  plasminogen,  a  key  protein  of  the  coagulation 
process.  Higher  Lp(a)  levels  have  been  reported  in  South  Asians  compared  with 
Europeans  16'"'  and  compared  with  Malay  and  Chinese  residents  of  Singapore"8.  The 
extent  to  which  Lp(a)  could  account  for  the  ethnic  differences  in  CHD  mortality  has  not  as 
yet  been  examined. 
Evidence  for  the  association  between  concentrations  of  total  plasma  homocysteine  and 
vascular  disease  has  recently  been  reviewed19  It  has  been  suggested  that  raised 
homocysteine  levels  in  South  Asians  may  contribute  to  their  excess  CHD  risk12o 
It  has  been  suggested  that  the  occurrence  of  a  procoagulant  and proinflammatory  state  in 
the  vasculature  may  be  associated  with  increased  coronary  risk.  A  recent  review  presents 
the  evidence  for  how  triglyceride  rich  lipoproteins  may  promote  atherosclerotic  vascular 
disease  by  adverse  effects  on  platelet  function,  coagulation  and  vascular  inflammation12' 
. 
There  is  also  a  growing  body  of  evidence  that  C-reactive  protein,  a  marker  of 
inflammation,  is  associated  with  CHD122.  No  studies  of  an  ethnic  comparison  of  C-reactive 
protein  have  been  reported  in  the  literature. 
Some  studies  have  reported  associations  between  CHD  and  persistent  bacterial  infection 
with  Chlamydia  pneumoniae  and  Helicobacter  pylori123,  '24,  although  there  is  still 
uncertainty  about  how  far  these  associations  can  be  accounted  for  by  residual  confounding 
by  factors  such  as  smoking  and  socio-economic  status'23-125.  Whether  these  chronic 
infections  may  be  associated  with  the  higher  CHD  risk  in  South  Asians  is  as  yet  unknown. 
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2.1.  The  association  of  postprandial  lipids  with  CHD 
2.1.1.  Relation  between  fasting  triglyceride  concentration  and  CHD 
A  high  fasting  plasma  triglyceride  concentration  has  long  been  implicated  as  a  risk  factor 
for  coronary  heart  disease  (CHD).  The  first  case-control  study  of  this  association  showed 
elevated  fasting  triglyceride  levels  among  CHD  cases  compared  with  controls12'.  The 
earliest  prospective  study  demonstrated  an  increased  incidence  of  CHD  among  men  with 
elevated  triglyceride  levels  at  baseline,  compared  with  men  with  lower  levels127.  However 
even  in  this  early  study  it  was  speculated  that  the  triglyceride  association  may  not  be 
independent  of  other  plasma  lipid  levels.  In  the  decades  of  research  since  then  the 
independent  role  of  triglycerides  remained  controversial  as  a  number  of  studies  found  that 
while  fasting  triglyceride  was  univariately  associated  with  CHD,  this  association  did  not 
remain  statistically  significant  after  controlling  for  other  lipid  risk  factors,  especially 
HDL-cholesterol128.  Part  of  the  reason  for  this  cancellation  of  effect  of  triglyceride  may 
have  been  due  to  the  fact  that  there  is  a  strong  inverse  association  between  triglyceride  and 
HDL-cholesterol  levels,  resulting  in  multi-colinearity  in  multivariate  statistical  models. 
However,  Hokanson  and  Austin  performed  a  meta-analysis  of  population  based  prospective 
studies  of  the  relation  between  fasting  triglyceride  level  and  CHD129.  They  showed  that 
based  on  combined  data  from  17  studies,  even after  adjustment  for  HDL-cholesterol  there 
was  an  independent  association  between  fasting  triglyceride  and  CHD  incidence  in  men 
[RR  1.14,95%  CI  1.05  to  1.28]  and  women  [RR  1.37,95%  Cl  1.13  to  1.66].  These 
relative  risks  were  calculated  and  standardised  with  respect  to  a1  mmol/l  increase  in 
triglyceride  concentration. 
It  has  been  previously  shown  that  plasma  triglyceride  levels  were  strongly  associated  with 
prevalent  myocardial  infarction  in  South  Asians,  but  the  ethnic  differences  (South  Asian 
vs.  European)  in  all  fasting  lipid  fractions,  including  triglyceride,  were  small  and 
inconsistent22.  Two  decades  ago  Zilversmit  hypothesised  that  postprandial  triglyceride-rich 
Postprandial  lipids  2-35 lipoproteins  (chylomicron  remnants)  may  be  important  in  atherogenesis130.  Since  then 
there  have  been  several  studies  of  the  relation  between  postprandial  triglyceride  levels  and 
the  risk  for  CHD. 
2.1.2.  Relation  between  postprandial  triglyceride  concentration  and  CH  D 
In  a  case-control  study  of  101  men,  Patsch  et  a113'  showed  that  postprandial 
hypertriglyceridaemia  was  associated  with  coronary  stenosis  defined  angiographically.  In 
this  study  single  postprandial  triglyceride  levels  at  6  and  8  hours  after  the  meal  were  highly 
discriminatory  (p  <0.001)  between  cases  and  controls,  even  after  adjusting  for  the  effect  of 
fasting  triglyceride  level.  The  triglyceride  levels  at  6  and  8  hour  time  points  exhibited  a 
greater  difference  between  cases  and  control  subjects  than  did  the  global  magnitude  of 
postprandial  lipaemia. 
Supplementation  of  the  test  meal  with  vitamin  A  and  subsequent  measurement  of  retinyl 
palmitate  (retinyl  ester)  in  plasma  provides  a  reliable  marker  of  chylomicron  and 
chylomicron  remnant  metabolism,  and  is  a  more  sensitive  index  of  the  nature  of  the 
particles  that  contain  triglyceride  than  the  measurement  of  triglyceride  level  alone132-'35.  In 
a  smaller  study  of  40  normolipidaemic  cases  and  controls,  Groot  et  a1136  showed  that 
patients  with  angiographic  coronary  artery  disease  showed  a  marked  delay  in  the  clearance 
of  postprandial  retinyl  esters  as  well  as  in  the  normalisation  of  plasma  triglyceride 
concentrations  between  6  to  12  after  the  test  meal  compared  with  controls.  The  authors 
argued  that  this  delayed  clearance  was  due  to  a  slower  rate  of  chylomicron  remnant 
removal. 
In  a  further  case-control  study  of  170  normolipidaemic  people  Weintraub  et  al137 
demonstrated  that  the  area  below  the  chylomicron  remnant  retinyl  palmitate  curve  was 
significantly  increased  in  the  coronary  artery  disease  (CAD)  group  (mean  23.4  µmol/l.  h, 
SD  15.0)  as  compared  with  controls  (mean  15.3  µmol/l.  h,  SD  8.9),  p<0.001.  This  was 
following  a  fat  meal  of  50g  fat  per  square  metre  of  body  surface.  The  association  of 
postprandial  response  with  CAD  was  highly  significant  before  (p=0.0001)  and  after 
(p=0.001)  adjusting  for  differences  in  basal  triglycerides.  The  authors  argued  that  the 
higher  level  of  chylomicron  remnants  in  normolipidaemic  patients  with  CAD  may  explain 
their  susceptibility  to  atherosclerosis.  Further,  Simpson  et  a1138  showed  that  the  magnitude 
of  postprandial  lipaemia  is  higher  in  CAD  patients,  irrespective  of  whether 
Postprandial  lipids  2-36 hypercholesterolaernic  or  not.  Fenofibrate  was  able  to  decrease  lipidaemia  in  cases  and 
controls,  but  did  not  abolish  the  differences  between  these  groups. 
Additional  evidence  for  an  association  of  postprandial  lipaemia  with  atherosclerotic  risk  is 
provided  by  the  offspring  study  of  Uiterwall  et  a1139.  Although  80  sons  of  men  with  severe 
CAD  and  55  sons  of  control  individuals  had  similar  post  absorptive  concentrations  of 
plasma  triglycerides,  postprandial  responses  to  a  liquid  challenge  meal  providing  77.5  g  fat 
per  m2  of  body  surface  area  differed  significantly.  The  early  rise  in  serum  triglyceride 
concentrations  and  the  maximum  concentrations  reached  at  4-6  hours  after  the  meal  were 
comparable  in  the  two  groups.  However,  triglyceride  concentrations  remained 
significantly  higher  8h  (+27%),  10h  (+33%)  and  12h  (+17%)  after  the  meal  in  the  sons 
of  patients,  suggesting  delayed  clearance  compared  with  the  sons  of  control  individuals. 
There  is  convincing  evidence  for  the  role  of  postprandial  triglyceride  rich  lipoproteins 
(TGRL)  in  CHD  risk  among  people  of  European  descent1  ',  '4'  Whether  ethnic  differences 
in  postprandial  triglyceride  level  could  account  for  different  rates  of  CHD  in  Europeans 
and  South  Asians  is  not  known.  No  one  has  reported  on  postprandial  triglyceride  levels  in 
a  comparative  study  of  South  Asians  and  Europeans,  and  the  role  of  postprandial  lipids  in 
insulin  resistance  or  risk  for  CHD  has  not  been  examined  among  South  Asians.  We 
hypothesise  that  South  Asians  are  likely  to  have  elevated  levels  of  postprandial  lipids 
compared  with  Europeans,  and  that  ethnic  differences  in  postprandial  triglyceride  level  will 
accompany  the  ethnic  differences  in  central  obesity,  plasma  lipids  and  insulin  resistance. 
We  wanted  to  test  whether  ethnic  differences  in  insulin  sensitivity  could  be  accounted  for 
by  body  fat  distribution  (including  measurement  of  visceral  fat  area  directly  by  CT  scan). 
Meal  tolerance  tests  are  difficult  and  laborious  to  perform  on  large  numbers  of  subjects  as 
they  involve  giving  a  fatty  meal  in  the  fasting  state,  followed  by  a  further  12  hour  period  of 
fasting,  and  several  measurements  of  lipids  at  hourly  intervals  in  this  period.  One  study, 
however,  demonstrated  that  postprandial  measurements  were  more  reproducible  than 
fasting  triglyceride  determinations,  and  that  reliable  postprandial  measurements  can  be 
implemented  in  epidemiologic  studies  by  using  a  modified  fat  tolerance  test142.  In  this 
study  it  was  shown  that  the  correlation  between  postprandial  triglyceride  levels  (for  a 
single  postprandial  triglyceride  concentration  measured  at  9  hours  after  a  fatty  meal),  over 
a  wide  range  of  levels  at  two  visits  was  strong  (r=0.87).  In  addition,  the  reliability 
coefficient  (percentage  of  total  variation  in  analyte  which  is  attributable  to  between 
participant  variation)  was  85%  for  the  postprandial  triglyceride,  compared  with  64%  for 
Postprandial  lipids  2-37 the  fasting  triglyceride  level14'.  It  has  also  been  proposed  by  Patsch  13  '  and  Weintraub  137 
that  a  single  8  hour  postprandial  triglyceride  level  can  discriminate  well  between  cases  of 
CAD  on  angiography  and  matched  controls. 
2.2.  Relation  between  postprandial  triglyceride  concentration 
and  insulin  resistance 
By  the  1970's  the  highly  significant  associations  between  fasting  triglyceride,  insulin 
resistance  and  hyperinsulinaemia  were  defined143  However,  very  little  information  has 
been  available  about  the  relationship  between  insulin  resistance  and  postprandial  lipaemia. 
The  potential  importance  of  this  association  is  due  to  two  reported  research  findings. 
Firstly,  as  discussed  above  it  has  been  proposed  that  postprandial  lipaemia  might  play  a 
part  in  the  pathogenesis  of  CHD.  Secondly,  it  has  been  proposed  that  resistance  to  glucose 
disposal  and/or  compensatory  hyperinsulinaemia  may  also  increase  the  risk  of  CHD44 
Few  studies  have  now  addressed  this  issue. 
Reaven's  group14'  showed  in  a  study  of  37  non-diabetic  individuals  that  insulin  resistance 
[measured  by  the  steady  state  plasma  glucose  (SSPG)  in  an  insulin  suppression  test]  was 
associated  with  plasma  total  postprandial  triglyceride  concentration  (r=0.66,  p<0.001) 
and  retinyl  palmitate  (r  =  0.51,  p<0.01)  . 
The  association  was  also  strong  for  postprandial 
triglyceride  concentration  and  retinyl  palmitate  in  both  Sf  (Svedberg  flotation)  >  400 
(chylomicrons)  and  Sf  20  to  400  (chylomicron  remnants  and  VLDL)  fractions.  They 
concluded  that  insulin  resistance  plays  an  important  role  in  regulating  the  postprandial 
concentration  of  TGRL,  including  those  of  intestinal  origin.  However  a  limitation  of  this 
study  is  that  no  adjustment  was  made  for  the  fasting  triglyceride  level,  which  is  known  to 
be  a  strong  predictor  of  the  postprandial  triglyceride  response.  Thus  we  don't  know  if 
postprandial  triglyceride  concentration  was  an  independent  associate  of  insulin  resistance. 
In  contrast  Byrne  et  a1145  failed  to  find  an  association  between  features  of  the  insulin 
resistance  syndrome  and  postprandial  triglyceride  concentration  in  a  study  of  57  men. 
Also  Weintraub  et  al133  did  not  find  a  significant  association  between  fasting  insulin  and  the 
postprandial  triglyceride  response  in  a  study  of  15  subjects.  However,  another  group 
found  an  association  between  fasting  insulin  level  and postprandial  triglyceride  in  a  study 
Postprandial  lipids  2-38 of  113  young  (mean  age  26  years),  healthy,  normal  weight  men146.  They  found  that  fasting 
and  postprandial  triglyceride  peak values  showed  a  bimodal  frequency  distribution,  with  a 
low  fasting  and  a  high  fasting  triglyceride  group,  and  "normal"  responders  and  "high" 
responders  to  the  fat-load.  Fasting  insulin  levels  were  significantly  higher  in  high 
responders  than  in  normal  responders,  whereas  they  did  not  differ  between  the  low  and 
high  fasting  triglyceride  group.  In  a  recent  study  in  men,  Couillard  et  a1147  showed  that 
visceral  obesity  is  associated  with  an  impaired  postprandial  triglyceride  clearance,  and  that 
visceral  obesity  may  contribute  to  fasting  and  postprandial  hypertriglyceridaemia  by 
altering  NEFA  metabolism  in  the  postprandial  state.  They  reported  that  features  of  the 
insulin  resistance  syndrome,  namely  fasting  hypertriglyceridaemia,  hyperinsulinaemia  and 
low  HDL-cholesterol  concentrations  as  well  as  increased  visceral  adipose  tissue 
accumulation  were  all  significant  correlates  of  an  impaired  postprandial  TGRL  clearance. 
A  recent  cross-sectional  study  of  26  men  has  shown  that  healthy  first  degree  relatives  of 
patients  with  type  2  diabetes  are  insulin  resistant  and  have  50%  higher  6-hour  incremental 
area  under  the  curve  compared  with  a  control  group"' 
Although  studies  of  relation  between  postprandial  lipaemia  and  insulin  resistance  are  few, 
there  exist  studies  of  the  relation  between  postprandial  lipaemia  and  diabetes.  Postprandial 
lipaemia  is  increased  in  NIDDM,  together  with  a  defective  removal  of  remnant 
particles  149,150  It  is  not  clear  what  the  underlying  mechanism  is  for  postprandial  lipaemia 
in  NIDDM,  but  it  seems  that  there  might  be  a  defect  in  the  removal  of  remnant  particles. 
Curtin  et  al's'  showed  that  NIDDM  patients  had  an  altered  pattern  of  apoB-48  in  response 
to  an  oral  fat  load.  ApoB-48  is  the  structural  protein  of  chylomicrons  and  is  a  more 
specific  marker  for  remnant  particles  than  is  retinyl  palmitate.  It  has  been  shown  that 
elevated  postprandial  lipaemia  is  mainly  due  to  an  increase  in  apoB-100  (structural  protein 
of  endogenous,  or  hepatic  derived  VLDL-triglyceride)  containing  particles  and  only  a 
minor  part  represents  the  apoB-48  particles140  A  competition  between  apoB-48  and 
apoB-100  particles  for  removal  could  explain  the  accumulation  of  apoB-100  containing 
particles  in  the  postprandial  state,  particularly  if  VLDL-apoB-100  production  is  increased, 
as  occurs  in  NIDDM. 
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postprandial  I  ipaemia 
It  has  been  long  debated  which  comes  first  in  the  sequence  of  events:  hyperinsulinaemia, 
insulin  resistance  or  dyslipoproteinaemia.  Evidence  from  prospective  studies  is  sparse,  but 
tends  to  support  the  concept  that  insulin  resistance  and  compensatory  hyperinsulinaemia 
precedes  the  development  of  hypertriglyceridaemia  and  an  atherogenic  lipoprotein 
phenotype152,153  Another  study  has  shown  that  families  with  endogenous 
hypertriglyceridaemia  are  at  an  increased  risk  of  developing  glucose  intolerance  and 
NIDDM  during  a  10  year  follow-up  period154  However,  no  prospective  data  are  available 
for  postprandial  triglyceride. 
On  the  other  side  of  the  argument,  there  is  a  growing  body  of  opinion  that  lipid 
disturbances  come  first,  leading  to  development  of  insulin  resistance  and  NIDDM.  The 
evidence  for  a  key  role  of  continuously  elevated  levels  of  NEFA  in  the  pathogenesis  of 
insulin  resistance  and  NIDDM  has  been  reviewed  in  an  excellent  review  by  Boden155.  It  is 
proposed  that  NEFA  provide  an  important  link  between  obesity  (particularly  central 
obesity)  and  insulin  resistance.  However  Frayn156  proposes  that  it  is  a  bit  simplistic  to 
think  of  any  one  change  as  'primary'.  Rather  the  many  associations  of  insulin  resistance 
are  so  interrelated  that  disturbance  to  any  one  may  bring  about  the  whole  pattern  of 
metabolic  disturbance. 
The  mechanism  by  which  insulin  resistance  is  related  to  postprandial  lipaemia  is  not  clearly 
understood.  The  normal  effect  of  insulin  is  most  pronounced  in  the  postprandial  period 
and  is  mediated  both  through  inhibition  of  the  intracellular  hormone-sensitive  lipase  and 
through  an  increase  in  the  re-esterification  of  fatty  acids  within  adipose  tissue  117 
. 
The 
reduced  delivery  of  NEFA  to  the  liver,  coupled  with  the  direct  suppressive  effect  of 
insulin,  leads  to  postprandial  diminution  of  hepatic  VLDL-triglyceride  secretion  under 
normal  circumstances.  Insulin  also  stimulates  the  activity  of  peripheral  LPL,  aiding  the 
removal  of  TGRL  from  the  circulation.  In  insulin  resistance  increased  flux  of  NEFA  to 
the  liver  secondary  to  a  failure  of  insulin  to  suppress  NEFA  release  from  adipose  tissue  is 
an  important  factor  leading  to  the  elevation  of  circulating  TGRL46'  158,159  Thus  hepatic 
VLDL-triglyceride  secretion  may  continue  in  the  postprandial  period,  with  enlargement  of 
the  circulating  triglyceride  pool.  Furthermore,  the  insulin  activation  of  adipose  tissue  LPL 
is  blunted  in  the  insulin  resistance  syndrome,  which  impedes  the  clearance  of  VLDL 
Postprandial  lipids  2-40 particles  and  lowers  HDL-cholesterol  levels156  It  has  been  argued  by  Frayn160  that 
inappropriate  release  of  NEFA  in  the  postprandial  period  is  likely  both  to  reduce  the 
sensitivity  of  glucose  metabolism  to  insulin  and  to  accentuate  postprandial  lipaemia. 
It  has  been  shown  that  increased  visceral  obesity  is  related  to  insulin  resistance74-76.  It  has 
also  been  shown  that  visceral  obesity  is  related  to  postprandial  lipaemia'a'"161,16z  Thus 
visceral  obesity  is  an  obvious  link  between  insulin  resistance  and  postprandial  lipaemia. 
2.3.  Mechanism  of  association  between  postprandial  Iipaemia 
and  CH  D  risk 
Postprandial  lipaemia  could  affect  the  atherosclerotic  process  directly  through  the 
postprandial  lipoproteins,  or  indirectly  through  its  effects  on  other  lipoproteins  such  as 
LDL  and  HDL  cholesterol.  Other  mechanisms  may  be  involved 
,  such  as  induction  of 
platelet  function  that  may  favour  thrombosis"'. 
2.3.1.  Direct  mechanisms 
The  hypothesis  first  put  forward  by  Zilversmit13°  focused  on  the  atherogenic  potential  of 
chylomicron  remnants  of  exogenous  (dietary)  origin.  However,  the  "triglyceride 
intolerance  hypothesis"  formulated  by  Miesenböck  and  Patsch13"'64  suggests  that 
hypertriglyceridaemia  is  potentially  atherogenic  through  cholesterol  transferred  from 
cholesterol-rich  lipoproteins  such  as  HDL  and  LDL  to  triglyceride-rich  lipoproteins 
(VLDL),  which  owing  to  their  enrichment  with  cholesteryl  esters  (CE),  cannot  be 
degraded  properly  and  end  up  in  the  vessel  wall.  When  the  integrated  level  of  TGRL's  in 
the  postprandial  state  is  high,  cholesteryl  ester  transfer  protein  (CETP)  -  mediated  transfer 
of  CE  from  HDL  and  LDL  to  TGRL's  in  exchange  for  triglycerides  is  extensive.  Hence 
HDL-cholesterol  levels  decrease,  LDL  particle  size  is  reduced,  and  CE-rich  remnants  of 
TGRL's  are  formed.  Each  of  these  consequences  of  postprandial  triglyceride  metabolism 
is  potentially  atherogenic.  Rapp  et  a!  165  isolated  intact  TGRL  from  human  atherosclerotic 
plaque  tissue.  These  lipoproteins  resembled  the  TGRL  encountered  in  plasma,  except  for  a 
slightly  larger  particle  size  and  enrichment  in  apolipoprotein  E.  Thus  this  study 
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the  authors  did  not  emphasise  that  plasma  contained  apolipoprotein  B-48,  whereas  the 
plaques  did  not.  From  this  it  could  be  interpreted  that  chylomicron  remnants  are  not 
directly  implicated  in  atherogenesis.  Instead,  their  metabolism  might  induce  atherogenic 
alterations  in  the  properties  of  other  cholesterol  containing  lipoproteins.  In  an  extensive 
review  of  the  relation  between  triglyceride  and  CHD,  Karpe  and  Hamsten166  speculate  that 
the  metabolism  of  postprandial  TGRL  represents  a  repeated  daily  atherogenic  influence  on 
other  lipoprotein  species  in  the  plasma,  rather  than  inducing  atherosclerosis  per  se. 
2.3.1.1.  Direct  effects  on  the  vascular  endothelium 
It  has  been  suggested  that  postprandial  lipaemia  could  directly  affect  the  vascular 
endothelium.  Sattar167  has  reviewed  the  accumulating  evidence  which  suggests  that  TGRL 
may  be  directly  damaging  to  the  endothelium.  It  is  suggested  that  TGRL  can  cross  the 
endothelial  barrier  and  enter  the  arterial  wall,  and  bring  about  endothelial  damage  possibly 
through  oxidative  mechanisms.  Impaired  endothelial  function  is  considered  a  marker  of 
atherogenesis.  Recent  technology  has  allowed  the  study  of  flow-mediated  dilatation 
(FMD)  of  the  brachial  artery  by  ultrasound  as  a  marker  of  endothelial  function.  Thus 
reduced  FMD  is  considered  a  marker  of  endothelial  dysfunction. 
One  study  showed  a  significant  reduction  in  FMD  in  the  brachial  artery  following  a  single 
high-fat  meal  in  10  normocholesterolaemic  volunteers  168.  The  same  group  also  found  that 
pre-treatment  with  vitamin  C  and  vitamin  E  blocked  this  effect,  supporting  the  hypothesis 
that  oxidative  stress  is  a  link  between  postprandial  TGRL  and  endothelial  damage169 
Another  group10  measured  FMD  after  inducing  a  transient  hypertriglyceridaemia  by 
infusion  of  a  lipid  containing  solution  (Intralipid®).  They  found  that  FMD  decreased  from 
7%  to  1.6%  in  response  to  the  intralipid  infusion,  showing  that  transient  triglyceridaemia 
decreases  vascular  reactivity.  It  is  plausible  that  repeated  elevations  of  postprandial 
triglyceride  could  have  more  permanent  effects  on  the  endothelium. 
2.3.2.  Indirect  mechanisms 
Postprandial  lipaemia  could  be  atherogenic  in  an  indirect  way  by  modifying  other 
lipoproteins  important  in  atherosclerosis  such  as  LDL  and  HDL.  The  magnitude  of 
Postprandial  lipids  2-42 lipaemia  is  positively  associated  with  the  plasma  levels  of  apoB"',  possibly  reflecting  a 
tendency  for  an  individual  with  poor  fat  tolerance  to  overproduce  apoB  containing 
lipoproteins.  A  mechanism  leading  to  loss  of  HDL2  as  a  result  of  pronounced  postprandial 
lipaemia  has  been  demonstrated'  2.  The  levels  of  HDL2  exhibit  a  negative  association  with 
CHD  at  least  as  powerful  as  all  other  known  risk  factors.  Postprandial  lipaemia  could 
affect  LDL  in  regard  to  its  atherogenecity.  LDL  was  the  first  lipoprotein  species  with  a 
demonstrated  role  in  atherosclerosis  13.  Modified  LDL  are  taken  up  by  macrophages  and 
endothelial  cells,  leading  to  the  formation  of  foam  cells,  one  of  the  first  steps  in 
atherosclerosis1'.  Individuals  with  triglyceride  intolerance  and  the  triglyceride  intolerance 
syndrome  usually  exhibit  a  preponderance  of  smaller  denser  LDL15;  also,  during 
postprandial  lipaemia,  LDL  are  more  oxidisable  and  can  lead  to  CE  accumulation  in 
macrophages16.  Thus  postprandial  lipaemia  can  exert  its  atherogenic  potential  through  its 
effect  on  LDL. 
In  conclusion  postprandial  lipaemia  affects  all  three  major  lipoprotein  classes,  i.  e.  TGRL 
become  enriched  in  CE,  LDL  size  is  reduced,  and  HDL  cholesterol  levels  are  lowered, 
leading  to  foam  cell  formation  and  atherosclerosis.  Magnitude  and  duration  of 
postprandial  lipaemia  determine  how  much  cholesterol  is  diverted  from  LDL  and  HDL  into 
TGRL  through  which  it  causes  atherosclerosis. 
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3.1.  Muscle  triglyceride  stores  as  a  possible  mediator  of  relation 
of  obesity  to  impaired  insulin  action 
3.1.1.  The  mechanism 
Although  numerous  experimental  studies  in  humans  and  animals  have  demonstrated  that 
weight  gain  increases  insulin  resistance  while  weight  loss  ameliorates  it,  the  mechanism  of 
the  association  between  obesity  (including  central  obesity)  and  insulin  resistance  is  poorly 
understood.  Most  insulin-mediated  glucose  disposal  takes  place  in  skeletal  muscle"',  "', 
and  in  insulin  resistant  individuals  there  is  an  impairment  in  the  ability  of  muscle  to  take  up 
glucose  and  store  it  as  glycogen1',  180  This  is  associated  with  impaired  glycogen  synthase 
activity  in  muscle18',  but  the  cause  of  this  defect  is  not  clear. 
One  possible  physiological  mechanism  for  insulin  resistance  is  the  glucose-fatty  acid  cycle, 
in  which  glucose  and  non-esterified  fatty  acids  (NEFA)  compete  for  utilisation  by 
muscle182°'s3  The  key  points  of  this  cycle  are  as  follows:  the  increased  availability  of 
NEFA  in  blood  produces  an  increase  in  intra-muscular  acetyl-CoA  and  citrate  content; 
acetyl-CoA  inhibits  pyruvate  dehydrogenase,  and  this  in  turn  reduces  glucose  oxidation; 
citrate  inhibits  phosphofructokinase  1  and  thus  glycolysis  itself,  eventually  resulting  in  the 
impairment  of  glucose  uptake.  However,  this  hypothesis  has  come  into  question  because 
many  groups"'-ßs6  have  not  been  able  to  reproduce  the  findings  in  rat  skeletal  muscle  that 
Randle  et  al  demonstrated  in  rat  heart  muscle.  While  the  suppressive  effect  of  NEFA  on 
carbohydrate  oxidation  has  been  generally  confirmed  by  others,  it  remains  controversial 
whether  NEFA  also  inhibits  insulin-stimulated  glucose  uptake  (i.  e.,  causes  peripheral 
insulin  resistance).  However,  in  an  extensive  review  Boden"'  argues  that  the  reason  many 
studies  failed  to  find  inhibition  of  glucose  uptake  by  NEFA  is  because  this  inhibition 
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been  given  in  these  studies  (about  2h). 
There  have  been  several  attempts  to  pursue  the  hypothesis  that  insulin-stimulated  glucose 
uptake  is  blocked  by  elevated  NEFA  levels  in  plasma1'.  Although  such  an  effect  can  be 
demonstrated  experimentally'  87,  several  lines  of  evidence  indicate  that  elevated  plasma 
NEFA  levels  are  unlikely  to  be  an  important  determinant  of  insulin  resistance  in  the 
population.  In  normoglycaemic  individuals  steady-state  measurements  of  resistance  to 
insulin-mediated  glucose  uptake  do  not  correlate  with  the  plasma  NEFA  response  to  a 
meal188.  Although  South  Asians  are  on  average  more  insulin-resistant  than  Europeans, 
fasting  and  post-challenge  NEFA  levels  are  no  higher  in  South  Asians  than  in 
Europeans15s 
In  their  original  hypothesis,  however,  Randle  and  Hales  did  not  suggest  that  insulin 
resistance  in  non-insulin  dependent  diabetes  resulted  only  from  elevated  plasma  NEFA 
levels.  They  proposed  that  glucose  uptake  was  inhibited  also  by  NEFA  derived  from 
breakdown  of  triglyceride  stores  within  muscle  cells182.  Thus  there  are  two  potential  ways 
in  which  NEFA  may  promote  insulin  resistance.  Firstly  it  is  possible  that  there  is  substrate 
competition  between  glucose  and  muscle-cell  derived  NEFA,  which  could  cause  insulin 
resistance.  Another  possibility  is  that  NEFA  induce  insulin  resistance  by  a  direct 
impairment  of  glucose  transport. 
There  is  now  a  growing  body  of  evidence  for  the  latter  possibility.  Boden  et  a1189  have 
shown  that  increasing  concentration  of  NEFA  decreases  glucose  uptake  in  a  dose- 
dependent  fashion.  The  decrease  is  caused  (i)  mainly  by  a  reduction  in  glycogen  synthesis 
(either  due  to  impairment  of  glycogen  synthase  activity,  or  due  to  a  reduction  in  glucose 
transport/phosphorylation),  and  (ii)  to  a  lesser  extent  by  a  reduction  in  carbohydrate 
oxidation.  Roden  et  al  have  further  shown  that  NEFA  induce  insulin  resistance  by  initial 
inhibition  of  skeletal  muscle  glucose  transport/phosphorylation19o,  '9'  which  is  then  followed 
by  a  50%  reduction  in  both  the  rate  of  muscle  glycogen  synthesis  and  glucose  oxidation190. 
Roden  et  al  conclude  that  in  contrast  to  the  mechanism  of  substrate  competition  between 
NEFA  and  glucose  as  a  cause  of  insulin  resistance,  elevation  of  plasma  NEFA  causes 
insulin  resistance  by  inhibition  of  glucose  transport  and/or  phosphorylation,  with  a 
subsequent  decrease  in  rates  of  glucose  oxidation  and  muscle  glycogen  synthesis190.  More 
support  for  this  mechanism  of  inhibition  of  glucose  transport  activity  by  elevated  NEFA 
has  come  more  recently  from  Shulman's  group192.  They  found  that  rates  of  whole-body 
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following  a  lipid  infusion  (compared  to  a  glycerol  infusion),  and  were  associated  with  a 
90%  decrease  in  the  increment  in  intramuscular  glucose-6-phosphate  concentration, 
implying  diminished  glucose  transport  or  phosphorylation  activity.  To  distinguish  between 
these  two  possibilities,  intracellular  glucose  concentration  was  measured  and  found  to  be 
significantly  lower  in  the  lipid  infusion  studies,  implying  that  glucose  transport  is  the  rate- 
controlling  step. 
3.1.2.  Evidence  for  the  role  of  intramyocellular  lipid  in  insulin  resistance 
Recent  evidence  from  animal  studies  supports  the  idea  that  triglyceride  stores  in  skeletal 
muscle  are  an  important  determinant  of  insulin  resistance.  Correlations  of  around  -0.90 
were  reported  between  insulin-stimulated  glucose  uptake  and  triglyceride  levels  in  the 
hindquarter  muscles  of  rats  by  Storlien  et  a1193.  In  comparison,  the  correlation  between 
muscle  triglyceride  levels  and plasma  triglyceride  was  only  0.44.  High  fat  diets  increase 
muscle  triglyceride  levels  in  rats  and  also  induce  insulin  resistance;  the  drug  benfluorex 
blocks  both  these  effects  194 
Evidence  for  the  role  of  intramyocellular  lipid  (IMCL)  in  insulin  resistance  in  humans  is 
slowly  accumulating.  In  a  study  of  patients  undergoing  minor  surgery,  mean  triglyceride 
levels  in  muscle  biopsies  taken  from  the  rectus  abdominis  muscle  were  six  times  higher  in 
patients  with  non-insulin  dependent  diabetes  than  in  controls"'.  It  has  been  shown  that 
IMCL  content  in  muscle  biopsies  is  an  important  source  of  energy  within  the  muscle196  and 
that  increased  IMCL  content  is  associated  with  impaired  insulin-stimulated  glucose  uptake 
in  type  I  diabetes  mellitus197.  Lithell  et  a1198  have  shown  that  the  energy  supply  to  the 
muscles  during  heavy  physical  work  (such  as  long  distance  skiing)  is  partly  derived  from 
intracellularly  stored  lipid.  Their  group,  and  others199  have  shown  that  slow  twitch  fibres 
(or  type  I  fibres)  have  a  larger  content  of  triglyceride  than  fast  twitch  fibres  (or  type  II 
fibres).  Lithell  et  a1198  showed  that  during  heavy  exercise  triglyceride  stores  in  slow  twitch 
fibres  are  decreased. 
Intramyocellular  lipid  content  measured  in  gastrocnemius  muscle  biopsy  in  a  study  of 
normoglycaemic  women  was  negatively  associated  with  glycogen  synthase  activation, 
demonstrating  that  increased  muscle  triglyceride  stores  are  associated  with  decreased 
insulin-stimulated  glycogen  synthase  activity200.  In  addition  IMCL  content  was  positively 
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fasting  NEFA)200.  However  in  this  study  there  was  no  association  between  insulin 
sensitivity  measured  directly  by  the  short  insulin  tolerance  test  and  IMCL  content.  No 
mention  was  made  of  the  level  of  physical  activity  of  the  27  participants.  The  authors  of 
this  study  argued  that  one  of  the  reasons  for  the  lack  of  association  between  insulin 
sensitivity  and  IMCL  content  could  be  due  to  a  poor  correlation  between  the  biopsy  lipid 
content  and  the  overall  skeletal  muscle  lipid  content  in  the  subjects  (which  would  determine 
insulin  sensitivity).  They  cite  in  favour  of  this  argument  the  fact  that  the  triglyceride 
content  of  skeletal  muscle  is  extremely  variable  both  within  any  one  muscle  and  between 
different  muscles201.  It  is  probably  related  to  the  fact  that  gastrocnemius  muscle  does  not 
contain  as  high  a  density  of  type  I  or  slow  twitch  fibres  as  other  muscles,  especially  the 
soleus. 
Another  study  measured  IMCL  content  in  biopsy  specimens  of  the  vastus  lateralis  muscle 
of  38  non-diabetic  Pima  Indian  men  and  quantified  insulin  sensitivity  by  the  euglycaemic 
clamp202.  Percent  body  fat  was  measured  by  under  water  weighing.  A  negative 
relationship  was  found  between  IMCL  and  insulin  sensitivity  (r=-0.53,  p<0.001).  Insulin 
resistance  was  significantly  related  to  IMCL  content  independently  of  all  measures  of 
obesity  (percent  body  fat,  waist  to  thigh  ratio  and  BMI). 
3.2.  Non-invasive  measurement  of  intramyocellular  lipid 
Until  recently  the  studies  of  this  relationship  were  limited  due  to  the  invasive  nature  of 
muscle  biopsy  to  measure  IMCL.  However  a  group  of  physicists  in  Tubingen,  Germany 
reported  in  1993  that  muscle  cell  triglyceride  stores  can  be  detected  in  vivo  by  nuclear 
magnetic  resonance  (NMR)  spectroscopy203.  Using  double  spin  echo  localisation 
technique,  they  were  able  to  identify  proton  NMR  signals  in  human  soleus  muscle  from 
two  different  compartments  containing  fatty  acids  or  triglycerides  of  similar  composition. 
One  of  these  compartments  corresponds  to  triglyceride  within  adipocytes  and  the  other  to 
triglyceride  within  muscle  cells.  Other  groups  have  also  found  the  same204  and  validated 
the  technique20S.  One  group  in  London  has  also  used  this  technique  and  performed 
reproducibility  studies206.  They  reported  that  the  intra-examination  coefficient  of  variation 
for  proton  NMR  spectroscopy  measurements  of  IMCL  in  the  soleus  muscle  was  4%  and 
Intramyocellular  lipid  and  insulin  resistance  3-47 the  inter-examination  coefficient  of  variation  for  repeated  determinations  in  three  different 
examinations  was  11  %20'.  This  is  much  lower  than  the  24%  coefficient  of  variability  in 
repeated  biopsies  of  human  skeletal  muscle207.  As  described  above  (section  3.1.2)  the 
intracellular  lipid  content  of  biopsy  specimens  is  determined  to  a  large  extent  by  fibre  type 
198  (slow  twitch  or  fast  twitch),  which  in  turn  is  dependent  upon  the  choice  of  muscle  type 
for  study.  Use  of  NMR  spectroscopy  of  soleus  muscle  takes  away  this  limitation,  as 
reflected  in  the  lower  coefficients  of  variation  for  repeat  measurements. 
Since  this  non  invasive  technique  of  NMR  spectroscopy  for  the  quantification  of  IMCL  has 
become  available,  few  studies  of  relation  of  IMCL  content  and  insulin  resistance  have  been 
reported.  One  recently  reported  by  Krssak  et  a1208  in  23  healthy  people  showed  an  inverse 
correlation  between  IMCL  content  and  insulin  sensitivity  measured  by  the  euglycaemic 
hyperinsulinaemic  clamp  (r=  -0.69,  p=0.002).  They  also  found  that  IMCL  was  not 
related  to  BMI,  fasting  triglyceride,  NEFA,  glucose  or  insulin.  In  a  series  of  small  studies 
McGarry's  group  have  also  reported  increased  IMCL  content  in  association  with  insulin 
resistance  209-21.  Two  very  recent  studies  have  reported  increased  IMCL  content  in  non- 
diabetic  offspring  of  type  2  diabetic  parents212,213.  The  number  of  studies  in  Europeans  is 
limited,  and  performed  in  small  numbers  of  subjects,  and  no  such  studies  have  been 
performed  in  South  Asians. 
In  summary:  the  hypothesis  that  IMCL  content  is  an  important  determinant  of  insulin 
resistance  is  attractive  because  it  can  provide  an  explanation  for  the  experimental 
dissociation  of  the  effects  of  changes  in  energy  balance  and  obesity  on  insulin  resistance. 
In  humans  a  hyperinsulinaemic  response  to  glucose  challenge  can  be  induced  by 
hyperalimentation  or  reversed  by  calorie-restricted  diets  within  a  few  days,  before  there 
has  been  any  appreciable  change  in  total  body  fat  stores214'215  It  may  even  be  possible  to 
account  for  the  relation  of  insulin  resistance  with  central  obesity,  since  NEFA  derived 
from  adipocytes  drained  by  the  portal  vein  would  drive  hepatic  synthesis  of  very-low- 
density  lipoprotein  (VLDL)  triglyceride  particles46  which  deliver  triglyceride  to  peripheral 
tissues. 
Based  on  the  above  evidence  we  wanted  to  test  three  closely  related  hypotheses: 
1.  That  insulin  resistance  is  associated  with  high  IMCL  content; 
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3.  That  high  IMCL  content  is  associated  with  central  obesity 
If  our  main  (first)  hypothesis  is  confirmed,  in  future  studies  one  can  hope  to  define 
behavioural  and  pharmacological  interventions  that  reduce  muscle  cell  triglyceride  stores 
and  reverse  insulin  resistance. 
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It  is  now  clear  that  the  high  prevalence  of  diabetes  mellitus  in  South  Asian  people  is  one 
manifestation  of  a  pattern  of  metabolic  disturbances  related  to  central  obesity  and  insulin 
resistance  in  this  group.  It  is  not  clear  whether  central  obesity  is  the  primary  defect  in  this 
syndrome,  or  whether  some  other  more  fundamental  disturbance  underlies  resistance  to 
insulin  action,  central  obesity  and  lipid  disturbances  in  South  Asians.  Although  CHD  risk 
in  South  Asians  is  strongly  associated  with  raised  plasma  triglyceride  levels,  the 
differences  between  South  Asians  and  Europeans  in  fasting  plasma  lipid  levels  are  too 
small  to  account  for  the  excess  coronary  risk  in  South  Asians  compared  with  Europeans. 
There  remain  many  gaps  in  our  knowledge  about  ethnic  differences  in  the  relationship 
between  body  fat  distribution  (especially  central  obesity),  insulin  resistance  and  lipid 
metabolism.  This  study  was  designed  to  investigate  some  of  these  closely  related  issues. 
Our  specific  hypotheses,  objectives  and  aims  were  as  follows: 
4.1.  Hypotheses: 
1.  That  central  obesity  is  the  primary  disturbance  underlying  the  resistance  to  insulin 
action  and  disturbances  of  lipid  metabolism  in  South  Asians 
2.  That  central  obesity  will  account  for  the  ethnic  difference  in  insulin  resistance 
3.  That  disturbances  of  postprandial  lipids,  rather  than  fasting  lipids,  may  mediate  the 
excess  coronary  risk  in  South  Asians  compared  with  Europeans,  and  that  elevated 
postprandial  triglyceride  is  part  of  the  cluster  of  CHD  risk  factors  associated  with  the 
insulin  resistance  syndrome 
4.  That  the  relation  between  insulin-mediated  glucose  uptake  and  central  obesity  is 
mediated  through  triglyceride  stores  in  skeletal  muscle 
To  test  these  hypotheses  specific  objectives  and  aims  were  defined  as  follows: 
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1.  To  test  whether  differences  in  body  fat  distribution  can  account  statistically  for  the 
difference  in  insulin  sensitivity  between  South  Asians  and  Europeans 
2.  To  test  whether  there  are  differences  in  postprandial  lipid  handling  between  South 
Asians  and  Europeans  sufficient  to  account  for  the  excess  coronary  risk  in  South 
Asians 
3.  To  test  whether  muscle  cell  triglyceride  stores  can  account  for  the  relationship  of 
insulin  resistance  to  central  obesity  and  ethnicity 
4.3.  Aims 
1.  To  determine  whether  the  tendency  to  insulin  resistance  in  South  Asians  compared  with 
Europeans  is  present  at  all  levels  of  adiposity,  or  only  at  high  levels  of  adiposity  [i.  e. 
are  the  regression  lines  for  the  association  between  insulin  sensitivity  and  obesity 
parallel,  or  do  they  cross  over  with  varying  adiposity] 
2.  To  test  whether  the  ethnic  difference  in  insulin  resistance  can  be  explained  by  central 
adiposity  (when  measured  accurately  by  CT  scan) 
3.  To  test  whether  elevated  postprandial  triglyceride  levels  are  associated  with  insulin 
sensitivity  and  obesity,  and  whether  the  ethnic  difference  in  insulin  sensitivity  (and 
hence  in  the  risk  for  CHD)  can  be  accounted  for  by  postprandial  triglyceride  level 
4.  To  test  whether  excess  triglyceride  stores  in  skeletal  muscle  (measured  non-invasively 
by  nuclear  magnetic  resonance  spectroscopy)  can  account  for  the  relationships  of 
ethnicity  and  central  adiposity  to  insulin  resistance 
5.  To  test  whether  bio-electrical  impedance  analysis  is  a  valid  and  reproducible 
epidemiological  field  method  to  measure  total  percent  body  fat  in  South  Asians 
Although  not  part  of  the  original  a  priori  hypotheses  and  objectives  of  this  study,  the 
opportunity  to  measure  ethnic  differences  in  plasma  concentrations  of  a  marker  of 
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rationale  for  doing  this,  and  the  results  and  the  relevant  discussion  relating  to  this  are 
presented  in  chapter  9. 
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5.1.  Study  design  and  setting 
The  most  appropriate  study  design  to  achieve  the  objectives  of  this  study  (section  4.2)  was 
a  cross  sectional  study  of  European  and  South  Asian  men  and  women.  We  wanted  to  study 
individuals  who  were  young  enough  to  not  have  already  developed  chronic  illnesses  of 
interest  (CHD  and  diabetes),  and  thus  an  age  group  of  40  to  55  year  old  people  was 
chosen.  We  also  wanted  to  study  people  over  a  wide  range  of  body  size;  thus  we  decided 
to  include  people  with  body  mass  index  (BMI)  ranging  from  17  to  34  kg/m2. 
The  London  Borough  of  Ealing  was  chosen  as  the  setting  for  the  study  for  two  main 
reasons:  (i)  good  contact  already  exists  with  general  practitioners  in  the  area,  with 
successful  collaboration  in  previous  studies",  ",  (ii)  the  Borough  has  the  second  largest 
ethnic  minority  population  of  the  outer  London  boroughs,  one  in  three  of  its  residents 
being  born  outside  the  United  Kingdom21'.  In  the  1991  Census,  over  52,000  or  19%  of  the 
population  of  Ealing  defined  themselves  as  Indian,  Pakistani,  or  Bangladeshi.  This  reflects 
immigration  predominantly  of  Sikhs  from  the  Indian  state  of  Punjab,  and  to  a  lesser  extent, 
of  Gujarati  Hindus  and  Pakistani  Muslims,  which  occurred  largely  in  the  late  1960s  and 
1970s. 
5.2.  Sample  size 
The  sample  size  was  calculated  on  the  basis  that  we  wanted  to  be  able  to  detect  a  difference 
of  0.3  %/min/kgm  2  in  the  slope  of  the  relationship  of  insulin  sensitivity  to  body  mass  index 
(BMI)  between  South  Asians  and  Europeans.  Having  42  people  of  each  ethnic  group 
would  have  90%  power  to  detect  such  a  difference  at  the  5%  significance  level.  This 
difference  in  slope  would  mean  that  if  at  a  BMI  of  20  kg/m2  there  is  no  ethnic  difference  in 
insulin  sensitivity,  then  at  a  BMI  of  25  kg/m2  there  would  be  a  mean  ethnic  difference  in 
insulin  sensitivity  of  1.5%  min-'.  This  difference  would  be  equivalent  to  the  difference  in 
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sample  size  was  increased  to  60  people  of  each  ethnicity,  to  allow  for  (i)  analyses 
separately  by  sex  group  if  necessary,  (ii)  other  objectives  of  the  study  (such  as  the 
postprandial  lipid  comparisons),  (iii)  tests  for  interactions  and  (iv)  drop-outs  from  the 
study. 
5.3.  Ethical  approval  and  consent  for  study 
Ethical  approval  for  the  study  was  obtained  from  the  local  ethical  committees  of  the 
London  School  of  Hygiene  &  Tropical  Medicine  and  Ealing  Hospital  NHS  Trust. 
Additional  ethical  approval  was  obtained  for  the  nuclear  magnetic  resonance  spectroscopy 
(see  5.5.7  below)  from  the  ethical  committees  of  the  London  School  of  Hygiene  & 
Tropical  Medicine  and  the  Hammersmith  Hospital.  Written  informed  consent  was 
obtained  from  all  participants  for  the  whole  study  at  the  first  visit.  Further  written 
informed  consent  was  obtained  at  each  of  the  separate  visits  for  the  short  insulin  tolerance 
test  and  the  fat  tolerance  test. 
5.4.  Subject  recruitment 
We  wrote  to  partners  at  six  general  practices  in  the  Southall  and  Greenford  areas  of  the 
Borough  of  Ealing.  We  sent  them  a  full  copy  of  the  study  protocol  and  explained  the 
planned  nature  of  research.  We  asked  for  their  participation  in  the  study  and  for  their 
consent  to  download  copies  of  their  practice  lists  held  by  the  Ealing  and  Hammersmith 
Health  Authority  and  to  contact  eligible  patients.  Four  of  the  practices  gave  written 
consent  to  participate.  This  enabled  the  release  from  the  Ealing  and  Hammersmith  Health 
Authority  of  names,  sex,  dates  of  birth,  NHS  numbers  and  addresses  of  all  patients 
registered  with  those  4  practices.  From  this  a  list  was  made  only  of  people  qualifying  on 
age  criteria  of  between  40  to  55  years  old.  Permission  was  then  gained  to  go  through  each 
of  these  names  individually  on  the  practice  database  (computerised  in  3  practices,  but  done 
manually  from  GP  records  in  1  practice),  to  delete  from  the  list  any  subjects  who  had  any 
of  the  exclusion  criteria,  which  are  summarised  below 
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practice  manager  could  identify  as  being  of  other  than  South  Asian  or  European  ethnicity 
were  excluded  at  this  stage.  If  the  practice  records  had  a  note  of  the  patient's  BMI,  those 
falling  outside  the  range  of  17  to  34  kg/m2  were  also  excluded. 
5.4.1.  Exclusion  criteria  for  the  study 
Age:  Age  outside  the  range  40  to  55  years 
Illness:  People  were  excluded  if  there  was  a  history  of  diabetes  mellitus,  ischaemic  heart 
disease,  epilepsy,  gall  bladder  or  liver  disease,  chronic  severe  illness,  or  any  weight  losing 
conditions  including  cancer  or  malabsorption.  People  with  known  psychiatric  illness, 
alcohol  abuse  or  drug  abuse  were  also  excluded.  Any  patients  with  known  HIV  positive 
status  or  Hepatitis  B  positive  status  were  also  excluded. 
Body  mass  index  (BMI):  Persons  with  BMI  outside  the  range  of  17  to  34  kg/m2  were 
excluded.  This  information  on  BMI  was  available  from  GP  records  in  some  patients,  but 
was  calculated  from  the  height  and  weight  information  provided  in  the  short  questionnaire 
that  was  sent  to  all  potential  participants. 
Drugs:  People  on  any  drugs  influencing  insulin  resistance  or  glucose  metabolism  were 
excluded  from  the  study;  these  included  beta-blockers,  ACE-inhibitors,  thiazide  diuretics 
and  loop  diuretics.  Women  who  were  on  hormone  replacement  therapy  or  the  oral 
contraceptive  pill  were  excluded  because  of  potential  influence  on  lipids  in  the  fat  tolerance 
test.  Lipid  lowering  drugs  also  constituted  an  exclusion  criterion. 
Pregnancy:  Women  were  asked  to  state  clearly  if  there  was  any  chance  of  them  being 
pregnant.  If  there  was,  or  if  they  were  breast-feeding,  they  were  excluded  from  the  study. 
Ethnicity:  Any  persons  who  were  of  any  other  ethnicity  except  of  South  Asian  origin  or 
European  origin  were  excluded  from  the  study. 
Other:  People  who  declared  that  they  were  planning  to  move  out  of  the  area  within  the 
next  year  were  also  excluded,  as  it  would  be  difficult  to  trace  them,  and  also  attendance 
may  have  become  difficult  for  five  separate  visits,  if  they  had  moved  outside  the  study 
area. 
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South  Asians  and  Europeans  were  approached.  Each  eligible  person  was  sent  an  invitation 
letter  with  a  covering  letter  signed  by  their  General  Practitioner  recommending  the 
research  project,  an  information  sheet,  and  a  brief  reply  questionnaire.  The  questionnaire 
was  designed  to  collect  basic  information  such  as  telephone  number,  current  height  and 
weight  to  calculate  BMI,  medical  diagnoses  and  drug  history  to  establish  eligibility.  Those 
who  responded  with  a  completed  questionnaire  were  then  sent  a  second,  more  detailed 
information  sheet,  to  enable  potential  participants  to  decide  whether  they  wanted  to  commit 
themselves  to  what  was  going  to  be  quite  an  involved  study,  requiring  at  least  5  separate 
visits  to  the  hospital.  A  breakdown  of  the  response  rates,  eligibility  and  withdrawal  after 
the  second  information  sheet  is  as  follows: 
Total  number  mailed  1638 
Total  responded  351  (21.5%) 
Ineligible  89 
Withdrew  52  (after  reading  2nd  information  sheet) 
Eligible  210 
In  reserve  67  (as  enough  numbers  consented  to  participate) 
Attended  for  screening  143 
5.5.  The  protocol  for  study  visits 
To  complete  all  the  tests  to  achieve  the  study  objectives  it  was  necessary  for  each 
participant  to  attend  for  five  separate  visits.  The  tests  and  measurements  at  these  visits 
were  as  follows. 
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Prior  to  this  visit  a  letter  of  appointment  was  sent  to  each  participant  detailing  the  need  for 
overnight  fasting  for  12  hours,  and  to  bring  with  them  a  completed  self-administered 
questionnaire.  On  arrival  at  Ealing  Hospital  each  person  was  welcomed,  and  the  health 
check  explained  in  detail,  in  English,  Hindi  or  Punjabi,  as  appropriate.  Consent  was 
taken,  fasting  status  confirmed,  and  then  each  person  started  on  the  same  sequence  of 
screening  investigations  as  follows. 
Blood  pressure  was  measured  twice  with  an  automated  sphygmomanometer  (OMRON, 
U.  K.  )  after  resting  for  five  minutes  in  a  chair. 
The  participant  was  then  sent  to  the  "anthropometry  station"  where  he/she  was  given  a 
gown,  and  asked  to  remove  clothes  down  to  underwear.  Height  was  measured  by  a 
stadiometer  and  weight  on  an  electronic  weighing  scales  (Soehnle).  BMI  was  calculated  as 
weight  in  kg  divided  by  the  square  of  the  height  in  metres.  Measurement  of  waist  (at  the 
midway  point  between  iliac  crest  and  lower  end  of  rib  cage)  and  hip  (across  the  greater 
trochanters)  circumferences  were  performed  using  a  spring-loaded  measuring  tape. 
After  dressing,  the  participant  then  had  measurement  of  bio-electrical  impedance 
(Bodystat-  single  frequency  BIA)  to  give  a  measure  of  percent  body  fat.  For  this  an 
electrode  each  was  placed  on  the  right  foot  and  wrist  as  per  manufacturer's  instructions  and 
a  tiny  800  µamp  current  passed.  The  participant's  height  and  weight  were  entered  into  the 
machine.  A  reading  for  impedance  and  percent  body  fat  was  obtained. 
Lastly  the  subject  went  to  the  phlebotomy  station  where  a  fasting  venous  sample  was  taken 
for  triglyceride,  glucose  and  insulin  assays,  and  then  a  75g  oral  glucose  load  given  in  the 
form  of  Lucozade  (donated  by  Smith  Kline  Beecham),  consumed  steadily  over  5  minutes  to 
perform  the  standard  oral  glucose  tolerance  test  (OGTT)21.  At  this  point  we  reviewed  the 
self-completed  questionnaire  with  the  participant  to  complete  any  unanswered  questions  or 
to  seek  clarification.  Participants  were  then  given  a  slip  of  paper  detailing  the  time  at 
which  they  should  return  for  their  2-hour  sample  after  emphasising  the  need  to  continue 
fasting  and  refrain  from  smoking.  After  the  completion  of  the  OGTT  the  participants  were 
offered  breakfast. 
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On  the  basis  of  results  from  screening,  participants  were  referred  to  their  general 
practitioners  for  further  management  if  any  of  the  following  were  identified: 
i)  systolic  blood  pressure  greater  than  140  mmHg 
ii)  diastolic  blood  pressure  greater  than  90  mmHg 
iii)  serum  fasting  triglycerides  greater  than  2.3  mmol/1 
iv)  impaired  glucose  tolerance  (two-hour  glucose  >  7.8  but  less  than  11.1  mmol/l) 
v)  diabetes  mellitus  (two-hour  glucose  >  11.1  mmol/1) 
Those  with  fasting  triglyceride  level  >  3.5  mmol/l  were  excluded  from  the  rest  of  the 
study  as  performing  the  fat  tolerance  test  could  potentially  result  in  acute  pancreatitis  in 
such  individuals.  Those  with  newly  diagnosed  diabetes  were  also  excluded,  but  those  with 
impaired  glucose  tolerance  were  requested  to  continue  with  the  study. 
5.5.1.2.  Frequency  matching  on  BMI 
Once  the  information  on  BMI  was  available  after  the  screening  visit,  only  those 
participants  who  had  BMI  between  17  and  34  kg/m2  were  invited  to  continue  with  the  rest 
of  the  study.  We  wanted  to  study  people  over  a  wide  range  of  BMI  so  that  the  relation 
between  obesity  and  insulin  resistance  could  be  assessed  over  a  wide  range.  Efforts  were 
made  to  achieve  equal  numbers  of  participants  (in  each  of  the  4  sex  and  ethnic  groups)  in 
categories  of  BMI  <  23.0,23.0  to  25.9,26.0  to  28.9  and  >  29.0. 
5.5.2.  Visit  two  for  DEXA  scan 
The  DEXA  scans  were  performed  according  to  standardised  protocols  at  the  Medical 
Physics  Department  of  the  Northwick  Park  Hospital.  They  were  performed  by  the  same 
operator  on  each  occasion  (Consultant  Medical  Physicist,  Mr  U.  Bhonsle).  The  operator 
was  not  blinded  to  the  sex  or  ethnicity  of  the  participants,  but  the  degree  of  automation  of 
the  scanning  procedure  makes  operator  bias  unlikely.  Measurements  were  made  with  a 
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distribution  measured  using  both  a  default  option  and  manually  determined  regions.  The 
machine  uses  a  dual  energy  (100kVp  &  140kVp)  x-ray  fan  beam  and  the  subject  receives  an 
entrance  exposure  of  about  1  mR,  (=  8.6  p.  Gy).  Each  whole  body  scan  takes  about  5 
minutes.  The  subject  lies  supine,  with  their  arms  by  their  side.  The  whole  body  image  is 
divided  into  10  regions  of  interest  (ROI):  head,  left  and  right  arms,  left  and  right  legs, 
pelvis,  lumbar  spine,  thoracic  spine  and  left  and  right  ribs.  Using  the  ROI,  fat,  lean  tissue 
and  bone  regions  are  determined,  and  their  values  calculated.  By  comparing  these  values 
to  the  spine  phantom  (provided  by  the  manufacturer)  a  fat/lean  tissue  ratio  is  found.  The 
masses  of  fat,  lean  tissue  and  bone  are  then  calculated. 
The  main  measurement  of  interest  to  this  study  was  the  total  percent  body  fat,  so  that  the 
measurement  of  the  same  by  BIA  (as  a  field  method)  could  be  validated  in  South  Asians, 
which  has  not  been  done  before.  A  by-product  of  the  scan,  of  interest  to  the  participants, 
was  measurement  of  bone  mineral  density  (BMD)  to  screen  for  risk  of  osteoporosis. 
Participants  and  their  general  practitioners  were  informed  of  presence  of  osteopaenia  or 
osteoporosis  in  the  lumbar  and  hip  regions  (according  to  standard  guidelines  by  the  WHO), 
so  that  appropriate  action  could  be  taken. 
5.5.3.  Visit  three  for  CT  scan 
All  participants  were  sent  a  detailed  letter  to  explain  what  was  involved  in  this  visit, 
including  the  dose  of  radiation  they  would  be  exposed  to.  To  determine  the  visceral 
adipose  tissue  area,  a  single-slice  CT  scan  of  the  abdomen  at  the  level  of  L4-L5  was  taken. 
The  standard  protocol  for  CT  was  followed  at  the  Radiology  Department  of  Ealing 
Hospital.  Abdominal  fat  was  measured  by  a  single  slice  (10  mm  thickness)  CT  scan  at  the 
level  of  L4-L5  using  a  Toshiba  X-speed  scanner,  with  exposure  time  2.7  seconds  and 
exposure  factors  160  mA  and  120  kV.  Participants  were  scanned  in  a  supine  position  with 
arms  stretched  above  their  heads.  Total  fat  area  (TFA)  of  the  abdomen  was  calculated  by 
delineating  the  surface  of  the  scan  with  a  graph  pen  and  computing  the  area  in  the 
attenuation  range  of  -190  to  -30  HU.  The  visceral  fat  area  (VFA)  was  measured  by 
drawing  a  line  within  the  muscle  wall  surrounding  the  abdominal  cavity218.  Subcutaneous 
fat  area  (SFA)  was  calculated  as  the  difference  between  TFA  and  VFA. 
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x-ray  beam.  All  scans  were  performed  by  two  designated  CT  radiographers. 
Both  the  visits  for  scanning  (DEXA  and  CT  scan)  were  performed  on  weekends  in  between 
the  visits  for  metabolic  measurements. 
5.5.4.  Visit  four  for  the  short  insulin  tolerance  test  (SITT) 
The  subjects  were  asked  to  attend  after  a  12  hour  overnight  fast.  They  were  asked  to 
abstain  from  alcohol  and  smoking  during  the  fasting  period 
A  cannula  was  inserted  retrogradely  into  a  dorsal  right  hand  vein  for  venous  access  for  test 
samples,  and  a  winged  butterfly  inserted  in  the  ipsilateral  antecubital  vein  for 
administration  of  insulin  and  intravenous  glucose.  The  hand  was  placed  in  a  warm  water 
bath  (Grant  Beckerman)  maintained  at  43°C  to  "arterialise"  the  venous  blood.  Arterialised 
blood  was  taken  because  of  the  previous  finding  that  no  significant  correlation  between  the 
euglycaemic  insulin  clamp  and  SITT  measured  insulin  sensitivity  indices  was  found  with 
venous  blood  sampling,  while  a  close  correlation  was  found  when  arterialised  blood  was 
used10°.  It  has  been  shown  that  a  heated  superficial  hand  vein  can  adequately  "replace"  the 
artery  for  the  measurement  of  total  body  glucose  kinetics21'.  Twenty  minutes  later  a 
baseline  `arterialised'  blood  sample  was  taken  for  the  zero  minute  sample.  Immediately 
following  that  a  bolus  of  human  actrapid  insulin  was  administered  intravenously  into  the 
antecubital  vein  at  a  dose  of  0.05  units/kg  body  weight.  Blood  samples  were  then  taken  at 
3,5,7,9,11,13,  and  15  minutes  for  measurement  of  blood  glucose,  and  at  5  minutes  for 
insulin  measurement.  The  test  was  terminated  at  15  minutes  with  25  ml  of  50%  dextrose 
intravenously  into  the  antecubital  vein  and  the  blood  glucose  checked  again  using  a 
glucometer  (Boehringer  Mannheim).  If  glucose  level  was  below  4.5  mmol/l  oral  Lucozade 
was  offered,  biscuits  given  and  a  further  bolus  of  intravenous  glucose  given  if  necessary 
until  the  glucose  level  rose  above  4.5  mmol/l.  All  participants  were  additionally  given  a 
full  breakfast  before  leaving  the  hospital  building. 
None  of  the  participants  suffered  a  frank  (biochemically  confirmed)  hypoglycaemic  attack. 
In  general  there  were  no  problems  with  the  test,  except  in  one  lady  who  had  a  swollen  arm 
as  a  result  of  inadvertent  extravasation  of  the  dextrose  solution  into  the  tissues.  She 
recovered  fully.  Some  participants  complained  of  a  strong  sense  of  tingling  and  discomfort 
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of  the  test,  but  this  passed  away  in  every  case,  within  30  minutes  of  the  injection,  with  no 
sequelae. 
5.5.5.  Visit  five  for  the  fat  tolerance  test 
The  fat  tolerance  test  was  performed  using  the  method  of  Patsch171'220.  Participants 
attended  after  an  overnight  fast  of  12  hours.  On  arrival  the  protocol  for  the  fat  tolerance 
test  was  explained  in  detail  and  any  questions  answered.  A  fasting  sample  of  blood  was 
taken  for  baseline  measurement  of  lipids.  Then  the  participants  drank  the  test  meal  over  5 
to  15  minutes.  The  test  meal  consisted  of  a  cream-  based  liquid  containing  65  gram  of  fat 
per  square  meter  of  body  surface  area.  The  meal  was  made  by  the  registrant  prior  to  each 
visit,  according  to  the  following  recipe:  350  ml  of  heavy  whipping  cream  (39.5  %  fat),  20  g 
of  chocolate  flavoured  Nesquik®,  15  g  of  granulated  sugar,  and  12  g  of  instant  non-fat  dry 
skimmed  milk,  made  up  per  2  square  meters  of  body  surface  area.  To  this  was  added 
100,000  IU  of  vitamin  A  drops  (Roche,  U.  K.  ),  the  rationale  for  which  is  described  in 
section  2.1.2.  This  recipe  provided  1400  kcal  per  2  square  meters  of  which  83%  were 
derived  from  fat  (138g),  14%  from  carbohydrate  (48g)  and  3%  from  protein  (9.5g).  The 
volume  of  the  test  meal  was  reduced  in  proportion  to  the  participant's  body  surface  area 
(using  the  formula:  volume  =  175  ml  x  body  surface  area). 
The  participants  were  then  asked  to  consume  only  plain  water  or  up  to  2  cups  of  plain 
(sugarless,  black)  tea  or  coffee,  refrain  from  any  food,  smoking  and  any  vigorous  exercise 
until  their  return  for  the  postprandial  sample.  For  most  participants  this  was  a  single 
sample  at  8  hours,  but  in  those  who  consented  and were  able  to  attend  twice  (n=35),  two 
postprandial  samples  were  collected  at  6  hours  and  8  hours.  All  participants  were  then 
offered  a  meal  in  the  hospital  canteen. 
The  test  meal  was  tolerated  well.  A  few  participants  reported  feeling  nauseated  but  only 
one  person  vomited  after  the  meal.  (Some  people  actually  enjoyed  the  drink  and  asked  for 
the  recipe!  ).  No  one  reported  gastrointestinal  discomfort  or  symptoms  of  malabsorption. 
The  details  of  the  lipid  analyses  and  the  laboratory  protocol  for  these  are  given  below  in 
section  5.8. 
Subjects  and  methods 
5-62 5.5.6.  Total  number  participating  after  the  screening  visit 
Of  the  143  people  who  attended  for  the  screening  health  check  (visit  1)  a  number  of  people 
were  not  eligible  and  some  withdrew  from  the  study.  The  reasons  for  these  were  as 
follows: 
Ineligibility:  A  total  of  11  people  were  ineligible  (TG  >  3.5  mmol/l  in  4  European  men, 
BMI  <  17  in  1  European  man,  HRT  use  in  1  European  woman,  newly  diagnosed  diabetes 
on  OGTT  in  1  South  Asian  woman,  diagnosis  of  cancer  in  1  European  man  and 
"inappropriate"  ethnicity  -  n=3). 
Withdrawals:  A  total  of  12  people  withdrew  from  the  study  (3  -  no  reason  given;  3- 
moved  away;  2-  lack  of  time;  2-  road  traffic  accident;  2-  felt  tests  too  invasive). 
5.5.6.1.  Numbers  completing  each  part  of  study 
The  number  who  participated  in  each  of  the  subsequent  visits  is  shown  in  Table  1  below. 
Table  1:  Number  of  people  attending  for  various  stages  of  the  study  by  sex  and 
ethnic  groups. 
European  South  Asian 
Men  Women  Men  Women  Total 
DEXA  scan  31  30  27  31  119 
CT  scan  30  31  30  29  120 
SITT  29  28  27  30  114 
FTT  28  29  28  28  113 
5.5.7.  Visit  six  for  nuclear  magnetic  resonance  spectroscopy 
This  part  of  the  study  was  performed  in  a  sub-sample  of  40  men  only. 
This  method  for  measuring  triglyceride  stores  in  skeletal  muscle  became  available  during 
the  course  of  the  study  (the  technique  was  being  developed  and  validated  at  the  start  of  the 
study).  20  men  of  each  ethnic  group  were  randomly  chosen  from  among  the  men  who  had 
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implants  from  any  source,  including  previous  surgery  were  excluded,  as  this  technique 
uses  strong  magnetic  fields.  Standard  protocol  for  MRI  scan  in  use  at  the  Robert  Steiner 
MRI  Unit  at  the  Hammersmith  Hospital  was  applied.  Briefly,  the  participant  was  asked  to 
lie  on  a  narrow  couch,  having  removed  all  metal  objects  including  jewellery,  watch  and 
rings.  The  region  of  interest  was  the  left  lower  leg  -  in  particular  a  region  of  the  soleus 
muscle  that  contains  no  visible  septa  or  adipose  tissue.  Subjects  were  positioned  supine, 
with  their  left  leg  immobilised  in  a  30  cm  diameter  quadrature  bird  cage  coil.  The  couch 
was  then  moved  into  the  MRI  scanner,  with  the  head  of  the  participant  remaining  outside 
the  scanner  whenever  possible.  The  scanning  was  done  over  a  period  of  20  minutes. 
Magnetic  resonance  spectroscopy  data  were  acquired  on  a  1.5T  Picker  prototype  system. 
Transverse  T1  weighted  MR  images  (TR  300,  TE  30  ms)  were  acquired  to  determine  the 
placement  of  the  'H-MRS  voxels,  with  a  slice  thickness  of  10  mm,  a  14  cm  field  of  view 
and  128x256  data  matrix.  Spectra  were  obtained  using  a  double  spin  echo-  PRESS  (Point 
RESolved  Spectroscopy)  sequence206  with  TE/TR  =135/  1500  ms  and  an  8  cm3  voxel. 
Spectra  were  acquired  with  both  the  creatine  signal  and  the  water  signal  as  an  internal 
standard. 
Spectra  were  analysed  as  previously  described206.  Briefly,  the  muscle  spectra  were 
analysed  by  VARPRO,  an  iterative  non-linear  least  square  fitting  method  operating  in  the 
time  domain.  The  water  peak  was  quantified  by  using  one  exponentially  decaying  sinusoid 
(corresponding  to  one  Lorentzian  line  in  the  frequency  domain),  while  total  creatine  (TCr 
=  PCr  +  free  Cr)  and  choline  (Cho)  resonances  were  modelled  as  two  single  Gaussian 
decaying  sinusoids  with  equal  damping  factors.  The  (-CH2-)n  and  -CH3  resonances  from 
intracellular  and  extracellular  triglycerides  were  deconvoluted  and  modelled  as  one 
Gaussian  decaying  sinusoid  each.  Peak  areas  for  each  signal  were  obtained  and  lipid 
resonances  were  quantitated  with  reference  to  internal  water  or  to  total  creatine  after 
correcting  for  Ti  and  T2.  The  spectrum  generates  4  lipid  peaks  [corresponding  to  -CH3 
and  -CH2  moieties  in  myocytes  and  adipocytes]  -  as  shown  in  Figure  1.  There  is  a 
difference  in  resonance  frequencies  of  about  0.2  ppm  (Larmor  frequency  difference 
12-13  Hz  at  1.5  T)  between  adipocyte  (1.6  ppm)  and  intramyocellular  (1.4  ppm)  TG 
methylene  proton  signals.  Spectral  analysis  then  resolves  the  lipid  peaks  to  give  a  single 
measurement  of  the  myocellular  triglyceride  content  (in  mmol/kg  dry  weight),  using 
creatine  as  an  internal  standard.  This  technique  has  been  validated  against  muscle  biopsy, 
Subjects  and  methods  5-64 and  reproducibility  studies  at  the  Hammersmith  Hospital  have  shown  intra  and  inter- 
examination  coefficient  of  variation  of  4  and  13  %  respectively  (8  subjects  examined  3 
separate  times)2o6 
ET(-CH2-)n 
i,  fIý.. 
3210 
chemical  shift  /  ppm 
Cho:  Choline  containing  compounds;  TCr:  total  creatine;  (-CH2-)n  and  -CH3  resonances  of 
extramuscular  (ET)  and  intramuscular  (IT)  triglyceride;  ppm:  parts  per  million 
Figure  1:  Typical  magnetic  resonance  spectra  of  the  soleus  muscle 
Subjects  and  methods 
5-65 5.6.  Questionnaire  data 
A  self-administered  questionnaire,  sent  by  post,  was  filled  out  by  all  participants  prior  to 
attending  for  the  first  visit  for  the  study.  It  included  questions  on  personal  medical  history, 
family  history,  drug  history,  smoking  and  alcohol  consumption,  occupation,  diet  and 
exercise.  At  the  first  (screening)  visit  we  reviewed  the  self-completed  questionnaire  with 
the  participant  to  complete  any  unanswered  questions  or  to  seek  clarification.  If 
communication  in  English  was  a  problem,  clarification  was  provided  in  Hindi  or  Punjabi. 
All  questionnaires  were  fully  completed. 
Occupational  social  class  was  coded  as  manual  or  non-manual  based  on  the  Registrar 
General's  Classification.  Data  on  physical  activity  and  smoking  were  coded  as  follows: 
5.6.1.  Physical  activity 
i.  The  subjects  stated  if  they  participated  in  any  regular  sport  (%  active) 
ii.  How  far  they  walked  daily  (<  %  mile  [1],  %  to  1  mile  [2],  1-3  miles  [3],  or 
>3  miles  [4]  ).  From  this  was  derived  a  walking  score  as  follows:  upto  I  mile/day 
[1],  1-3  miles/day  [2]  or  >3  miles/day  [3] 
iii.  The  number  of  hours  per  week  spent  in  watching  television  (<  8h  [1],  9-15  h  [2]  or 
>  15  h  [3]) 
iv.  The  subjects  self-rated  the  amount  of  exercise  they  took  on  a  regular  basis  The  latter 
was  recoded  to  an  activity  score  as  follows:  much  less  active  [1],  somewhat  less 
active  [2],  about  as  active  [3],  somewhat  more  active  [4],  or  much  more  active  [5], 
compared  to  others  their  age 
5.6.2.  Smoking 
Questions  on  smoking  elicited  a  response  to  whether  the  participant  was  a  current  smoker, 
an  ex-smoker  or  a  never  smoker.  The  category  of  ever  smoker  included  ex-smokers  and 
current  smokers. 
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laboratory 
The  protocols  for  sample  preparation  at  the  specimen  collection  site  at  Ealing  Hospital 
were  as  follows: 
5.7.1.  Screening  visit 
At  0  hours:  Take  20  ml  blood  from  participant  into  syringe,  and  divide  it  as  follows: 
"  10  ml  into  Lithium  Heparinised  tube,  place  on  ice,  mix,  spin  within  30  minutes  (3000 
rpm,  10-15  minutes).  Then  store  (at  -20°C)  1.0  ml  aliquots  of  plasma  in  Eppendorf 
tubes  for  glucose  and  insulin  assays  (and  a  spare  sample  for  backup). 
"5  ml  into  EDTA  tube,  place  on  ice,  mix,  spin  within  30  minutes  (3000  rpm,  10-15 
minutes).  Then  store  a  1.0  ml  aliquot  at  -20°C  for  a  backup  sample.  Leave  cells  and  1 
mm  above  the  buffy  coat:  save  this  in  the  EDTA  tube  itself  (at  -70°C)  as  "BUFFY 
COAT"  for  future  DNA  analysis. 
"5  ml  into  Plain  tube,  keep  at  room  temp  for  30  -45  minutes  until  clot  forms,  spin  (3000 
rpm,  10-15  minutes),  spin  again  if  supernatant  not  clean  looking.  Then  store  (at  -20°C) 
1.0  ml  aliquots  in  Eppendorf  tubes  for  fasting  triglyceride  and  NEFA  assays  (and  a 
spare  sample  for  backup). 
At  2  hours  (post  glucose  load)  :  Take  16  ml  blood  from  patient  into  a  syringe  and  divide 
as  follows: 
"  10  ml  into  Lithium  Heparinised  tube,  place  on  ice,  mix,  spin  within  30  minutes  (3000 
rpm,  10-15  minutes).  Then  store  (at  -20°C)  1.0  ml  aliquots  of  plasma  in  Eppendorf 
tubes  for  glucose  and  insulin  assays  (and  a  spare  sample  for  backup). 
"6  ml  into  Plain  tube,  keep  at  room  temp  for  30  -45  minutes,  spin  (3000  rpm,  10-15 
minutes),  spin  again  if  supernatant  not  clean  looking 
serum  for  NEFA  and  a  spare  one  for  backup  at  -20°C. 
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5-67 5.7.2.  Visit  for  the  short  insulin  tolerance  test 
During  this  test  4  ml  samples  of  blood  were  drawn  from  the  arterialised  hand  vein  at  -6,0, 
3,5,7,9,11,13  and  15  minutes  and  placed  into  Lithium  Heparinised  tubes.  The  same 
protocol  was  followed  for  sample  preparation  and  storage  as  above  for  glucose  levels  at  all 
time  points,  and  for  insulin  levels  at  -6  and  5  minutes. 
5.7.3.  Visit  for  the  fat  tolerance  test 
"  At  0  hr  (fasting):  40-45  ml  blood  was  drawn  and  placed  into  4  EDTA  (10  ml)  tubes  and 
1  Sodium  -  Citrate  (5  ml)  tube. 
"  At  8  hr  (postprandial):  35-40  ml  blood  was  drawn  and  placed  into  4  EDTA  tubes. 
The  tubes  were  immediately  placed  on  ice  and  spun  in  a  centrifuge  as  soon  as  possible  at 
3000  rpm  for  15  minutes.  The  supernatant  was  then  divided  into  aliquots  for  storage  or 
transport  to  the  laboratory  as  summarised  in  Table  2. 
Table  2:  Summary  of  protocol  for  handling  of  samples 
EDTA  Aliquot  size/type/n  Label/timing  transport  Storage/analysis 
1x  6ml  (0h)  FRESH  LIPID  Oh  ice/dry  ice  -70°C  or  analyse  in 
batches  (for  VLDL) 
2x  6m1  (8h)  FRESH  LIPID  8h  ice  1.  chylo  spin* 
2.  freeze  for  VLDL 
2xI  ml  (0h)  LIPID  1&2,  Oh  ice/dry  ice  analyse  (total  &  HDL 
cholesterol,  TG,  NEFA) 
2xI  ml  (8h)  LIPID  1&2,8h  ice/dry  ice  analyse  (TG,  NEFA) 
0.5  ml  x2  preservative  ApoB48  &100  (Oh,  8h)  ice/dry  ice  freeze  -20/70°C 
1  ml  (wrapped  in  foil)  RP  8h  ice/dry  ice  freeze  -20/70°C 
RP  =  retinyl  palmitate,  TG  =  triglyceride,  VLDL  =  very  low  density  lipoprotein,  NEFA  =  non- 
esterified  fatty  acids. 
*  The  8-hour  (postprandial)  "fresh  lipid"  sample  was  subjected  to  ultracentrifugation  on  receipt  at 
the  laboratory  to  separate  into  chylomicron  and  non-chylomicron  fractions.  The  protocol  for  this 
is  summarised  in  section  5.8.6. 
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CETP,  leptin,  C-reactive  protein,  anti-oxidants,  and  LDL-subfractions.  Two  further  spare 
aliquots  were  also  stored.  Three  aliquots  of  sodium-citrate  plasma  were  also  stored  (at 
-70°C)  for  future  analyses  for  coagulation  factors  including  PAI-1. 
5.8.  Laboratory  analyses 
All  laboratory  analyses  were  performed  at  the  Wynn  Division  of  Metabolic  Medicine 
(Wellington  Road,  St.  John's  Wood,  London,  NW8).  The  laboratory's  own  Standard 
Operating  Procedures  with  good  quality  control  were  used.  However  there  was  no 
previously  established  procedure  at  the  Wynn  Laboratory  for  the  separation  of  the 
chylomicron  and  non-chylomicron  fractions  of  plasma.  Hence  there  was  no  established 
quality  control  for  this  particular  procedure.  Technical  problems  associated  with  this 
procedure  are  explained  in  section  5.8.6.  Details  of  the  laboratory  methods  were  as 
follows. 
5.8.1.  Glucose 
Glucose  was  measured  on  samples  collected  in  lithium-heparinised  tubes.  The  plasma 
aliquots  were  transported  to  the  laboratory  on  dry  ice  in  batches.  Prior  to  analysis  the 
plasma  samples  were  thawed  and  centrifuged  in  the  lab.  Using  kits  supplied  by  Boehringer 
Mannheim  the  glucose  assay  was  performed  using  a  Cobas  Mira  discrete  analyser  (Roche, 
Switzerland).  Glucose  was  converted  to  gluconate  and  hydrogen  peroxide  by  glucose 
oxidase.  Peroxidase  then  catalysed  the  reaction  between  hydrogen  peroxide  and 
4-aminophenazone  to  form  a  chromogen  which  was  measured  colorimetrically.  The 
resulting  absorbance  was  proportional  to  the  initial  glucose  concentration.  Internal  quality 
was  assessed  using  control  sera  and  assayed  chemistry  controls  supplied  by  Medical 
Analysis  Systems,  US  and  Randox  Laboratories,  (Co.  Antrim,  Ireland)  respectively. 
External  quality  control  was  assessed  using  the  Randox  Laboratories  system.  Within-  and 
between-assay  coefficients  of  variation  were  <1%  and  <  2.5  %  respectively. 
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Plasma  insulin  concentration  was  determined  by  a  microplate-based  chemiluminometric 
assay  specific  for  plasma  insulin  (supplied  by  Molecular  Light  Technology  Research 
Limited,  Cardiff,  U.  K.  ).  Samples  were  kept  at  -20°C  at  Ealing  Hospital  and  transferred  in 
batches,  on  dry  ice,  to  the  laboratory,  where  they  were  stored  at  -70°C.  Insulin 
concentration  was  measured  in  one  batch  once  all  the  samples  had  been  stored.  The 
samples  kept  at  -70°C  were  thawed  at  room  temperature  before  centrifuging  at  3000  rpm 
for  10  minutes.  The  assay  demonstrated  negligible  (below  2%)  molar  cross-reactivity  with 
intact  proinsulin,  split  32-33  proinsulin  and  des  31,32  proinsulin.  No  detectable  cross- 
reactivity  was  observed  with  C-peptide  at  levels  up  to  18ng/mL.  Between  assay  coefficient 
of  variation  was  less  than  7%  (range  13-110  micro  Units/ml). 
5.8.3.  Total  cholesterol 
This  was  measured  with  colorimetric  assay  using  a  MIRA  analyser  on  fresh  samples  of 
EDTA  plasma.  The  enzymatic  reagent  ("CHOL"  from  Boehringer  Mannheim)  cleaves 
cholesteryl  esters  to  release  free  cholesterol,  then  sets  up  a  colour-producing  reaction  with 
the  free  cholesterol.  Standardisation  was  performed  using  Precinorm-L  (human  based 
material  supplied  lyophilised  and  stored  at  2-6°C)  obtained  from  Boehringer  Mannheim. 
Internal  quality  control  was  performed  using  the  HDL  plus  series  (1,2  and  3)  obtained 
from  Biostat.  External  quality  control  was  assessed  using  the  Randox  Laboratories  system 
(as  above).  Between-assay  coefficient  of  variation  was  <2%. 
5.8.4.  HDL-cholesterol 
HDL-cholesterol  measurement  was  performed  on  fresh  plasma  samples  stored  at  4°C 
within  48  hours  of  being  taken.  HDL  was  separated  from  chylomicrons,  VLDL,  IDL  and 
LDL  by  spinning  for  an  hour  with  a  manganese  chloride  and  heparin  solution.  Under 
these  conditions,  the  apolipoprotein  B  present  in  other  lipoproteins  (but  not  HDL 
cholesterol)  forms  complexes  with  mucopolysaccharides.  The  complexes  sedimented  to 
form  a  pellet,  and  HDL-cholesterol  was  measured  in  the  supernatant  using  colorimetric 
assay  and  a  Cobas  Mira  analyser.  Internal  quality  control  was  performed  using  the  HDL 
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assays  <1%.  External  quality  control  was  assessed  using  the  Randox  Laboratories  system 
(Crumlin,  Co.  Antrim,  Ireland). 
5.8.5.  Triglycerides 
Triglyceride  levels  were  measured  using  a  colorimetric  assay  in  fresh  whole  plasma 
samples  kept  at  4°C  and  transported  to  the  lab  on  ice  within  48  hours  of  collection. 
Triglycerides  were  cleaved  with  Triglycerides  N  (WAKO,  Alpha  Laboratories,  Eastleigh, 
U.  K.  )  to  release  glycerol  and  free  fatty  acids.  The  ensuing  colour-producing  reaction 
between  glycerol  and  reagent  was  measured  with  a  Cobas  Mira  analyser.  Thus  in  effect  it 
is  total  glycerol  that  is  measured  in  this  assay,  rather  than  triglyceride.  Plasma  glycerol 
levels  depend  on  the  rate  of  lipolysis  by  hormone-sensitive  lipase  in  fat  cells  and  by 
lipoprotein  lipase  at  the  vessel  wall........  If  there  are  differences  in  lipolytic  activity  or  in 
the  half  life  of  glycerol  between  the  two  ethnic  groups,  this  could  affect  interpretation  of 
the  triglyceride  concentration.  Internal  quality  control  was  assessed  using  the  HDL  plus 
series  (Biostat).  Within-assay  CV  was  <1%  and  between-assay  CV  <4%.  External 
quality  control  was  assessed  using  the  Randox  Laboratories  system  as  above.  Triglyceride 
in  the  non-chylomicron  fraction  was  also  measured  as  above,  while  triglyceride  in  the 
chylomicron  fraction  was  derived  from  subtraction  of  non-chylomicron  TG  from  whole 
plasma  TG.  The  procedure  for  chylomicron  separation  was  as  follows. 
5.8.6.  Chylomicron  separation 
Ultracentrifugation  was  performed  to  separate  the  chylomicron  and  non-chylomicron 
fractions  of  the  8  hour  (postprandial)  plasma.  Aliquots  from  each  of  these  two  fractions 
were  then  stored  for  future  analysis  of  ApoB-48,  ApoB-100  and  retinyl  palmitate. 
Four  ml  plasma  was  pipetted  into  swing-out  rotor  (SW40  Ti)  ultracentrifuge  tubes 
(Polyallomer  14x95  mm  centrifuge  tubes  obtained  from  Beckman).  This  was  overlaid  with 
1.006  g/ml  density  KBr  solution  up  to  1  cm  from  the  top.  This  solution  was  made  by 
adding  8.436g  solid  KBr  (Merck,  product  number  10195)  to  1.0  litre  of  distilled  de-ionised 
water.  Overlaying  was  best  done  using  a  fine-tip  Pastette  (Alpha  LW4060)  and  letting  the 
salt  solution  ooze  out  at  the  level  of  the  meniscus,  no  higher  and  no  lower.  This  process  is 
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placed  into  accurate  positions  on  the  rotor,  and  then  spun  at  18,000  rpm  for  20  minutes  at 
4°C. 
The  supernatant,  which  forms  the  chylomicron  fraction,  (top  2.5  ml  of  the  density  layer) 
was  taken  off  ,  mixed,  and  aliquotted  as  follows.  0.5  ml  aliquots,  mixed  with 
preservative,  were  stored  at  -20°C  for  future  analysis  of  ApoB-48  and  ApoB-100  in  the 
chylomicron  fraction  of  plasma.  A  1.0  ml  sample  was  stored  wrapped  in  foil  at  -70°C  for 
future  analysis  of  retinyl  palmitate  in  the  chylomicron  fraction  of  plasma.  One  0.5  ml 
aliquot  was  kept  as  a  spare  8h  sample  of  the  chylomicron  fraction  (at  -70°C). 
The  infranatant  was  made  up  to  10  ml  with  density  solution  1.006  g/ml  in  plain  10  ml 
tubes  (white  cap).  This  formed  the  non-chylomicron  fraction  of  plasma  and  was  mixed  and 
aliquotted  in  an  identical  way  as  for  the  chylomicron  fraction  above.  In  addition 
triglyceride  level  was  measured  in  a  0.5  ml  aliquot  of  the  non-chylomicron  fraction  of 
plasma. 
Quality  control  was  established  using  blood  from  4  healthy  members  of  the  laboratory  staff 
4  hours  after  a  high  fat  meal  at  an  Indian  Restaurant.  Forty  mls  of  blood  from  each 
volunteer  was  collected  into  EDTA  tubes  and  spun  at  3000  rpm  in  a  Mistral  centrifuge  for 
15  minutes.  Five  ultracentrifugal  spins  were  set  up  every  day  with  2  pooled  plasma 
samples  in  each  spin  for  three  consecutive  days.  Chylomicrons  were  separated  as  per  the 
procedure  above  and  total  triglyceride  and  non-chylomicron  triglyceride  concentration  was 
measured  on  each  of  the  samples.  Chylomicron  triglyceride  level  was  obtained  by 
subtracting  the  non-chylomicron  triglyceride  concentration  from  the  total  triglyceride 
concentration.  The  coefficients  of  variation  for  between  assay  were  1.03%  for  total 
triglyceride,  2.2%  for  non-chylomicron  triglyceride  and  1.8%  for  chylomicron  triglyceride 
concentration. 
There  was  an  unforeseen  problem  with  the  chylomicron  separation  procedure  in  the 
laboratory.  The  Biochemist  who  had  devised  a  written  protocol  for  the  procedure,  left  his 
post  unexpectedly.  Any  technical  problems  associated  with  this  procedure  (new  for  this 
particular  laboratory)  were  thus  dealt  with  by  non  lipid-specialist  laboratory  staff.  This 
remains  a  limitation  of  this  part  of  the  study. 
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Two  ml  plasma  was  transferred  to  an  Ultra-Clear  tube.  The  tube  was  then  filled  to  within 
2  cm  of  the  top  by  gently  overlaying  the  sample  with  d1.006  g/ml  KBr  solution,  which  was 
made  as  described  above.  The  tubes  were  balanced  and  placed  into  accurate  positions  on 
the  rotor,  and  then  spun  at  18,000  rpm  for  20  minutes  at  4°C.  The  supernatant,  which 
forms  the  chylomicron  fraction,  was  then  removed.  The  tubes  were  topped  up  again  with 
the  density  solution  up  to  2  cm  below  the  top,  and  capped.  They  were  weighed  and  paired 
within  1  gram  of  their  weight,  ready  to  be  spun.  The  centrifuge  tubes  were  placed  in  the 
rotor  and  spun  for  18  hours  at  32,000  rpm  at  4°C  (overnight).  The  next  morning  the 
ultracentrifuge  was  stopped  and  the  vacuum  turned  off.  The  centrifuge  tubes  were 
carefully  removed  and  placed  in  order  (tubes  1-44). 
Each  centrifuge  tube  was  carefully  uncapped  and  the  upper  2.0  ml  containing  VLDL 
harvested  into  a  2.0  ml  volumetric  flask,  draining  off  the  supernatant  at  the  level  of  the 
meniscus.  A  set  of  2.5  ml  tubes  numbered  1-44  were  used  to  transfer  the  product.  For 
VLDL-cholesterol  measurement  the  HDL  cholesterol  assay  was  used  [see  5.8.4].  For 
VLDL-triglyceride  measurement  the  triglyceride  assay  was  used  as  described  above 
[section  5.8.5]. 
5.8.8.  Non-esterified  fatty  acids  (NEFA) 
Non-esterified  fatty  acid  (NEFA)  concentrations  were  measured  on  serum  (from  visit  one, 
on  frozen  samples)  and  EDTA  plasma  (from  fat  tolerance  visit,  on  fresh  plasma,  within  48 
hours  of  collection),  using  kits  supplied  by  Alpha  Laboratories  (Wako  NEFA-C, 
994-75409).  The  assay  was  performed  using  a  Cobas  Mira  discrete  analyser  (Roche, 
Switzerland)  and  was  based  on  the  acylation  of  coenzyme  A  by  NEFA  in  the  presence  of 
acyl-CoA  synthetase.  The  acyl-CoA  produced  is  oxidised  by  added  acyl-CoA  oxidase  with 
the  generation  of  hydrogen  peroxide.  Hydrogen  peroxide,  in  the  presence  of  peroxidase, 
permits  the  oxidative  condensation  of  3-methyl-N-ethyl-(3-hydroxyethyl)-aniline  with 
4-aminoantipyrine  to  form  a  purple  coloured  adduct  which  can  be  measured 
colorimetrically  at  550nm.  The  assay  was  standardised  against  the  manufacturer's 
provided  standard.  Due  to  the  lability  of  NEFA,  there  are  no  commercially  available 
Quality  Control  materials  that  provide  target  ranges.  At  the  Wynn  Division  of  Metabolic 
Subjects  and  methods 
5-73 Medicine,  internal  quality  control  is  monitored  using  three  commercially  available 
materials  (Lyphocheck)  and  two  internally  prepared  serum  pools.  Also,  due  to  the  lability 
of  NEFA,  there  are  no  external  quality  assurance  schemes  for  NEFA.  The  between  assay 
coefficient  of  variation  at  the  lab  is  <7%  and  the  within  assay  coefficients  of  variation 
(n=10)  are  as  follows: 
Fasting  pool,  mean  concentration  1.0  mEq/1  <1% 
Suppressed  pool,  mean  concentration  0.2  mEq/1  <5% 
5.9.  Data  entry  and  statistical  analyses 
Fox-Pro  and  File  Maker-Pro  databases  were  used  for  double  data  entry.  These  data  were 
converted  into  the  statistical  package  STATA  (version-5,  STATACORP,  Texas,  USA) 
format  using  DBMSCOPY  software  programme.  Some  of  the  laboratory  data  was 
supplied  in  Microsoft  Excel.  This  was  read  directly  into  STATA. 
A  programme  was  written  in  STATA  to  derive  the  insulin  sensitivity  index  (ISI).  For  this 
the  slope  of  the  rate  of  fall  of  log  glucose  over  3  to  15  minutes  during  the  short  insulin 
tolerance  test  was  multiplied  by  -100  giving  the  ISI  in  %  min-'  (see  section  1.5.4).  The 
graph  of  the  relation  between  fall  in  log  glucose  with  time  is  shown  in  Figure  2. 
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Figure  2:  Graph  to  show  the  rate  of  fall  of  In  glucose  with  time  in  Europeans  and 
South  Asians  following  a  bolus  of  i.  v.  insulin  in  the  short  insulin  tolerance  test 
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records.  The  distribution  of  each  continuous  variable  was  examined  for  normality,  and 
those  that  were  skewed  were  log  (natural)  transformed  to  ensure  normality.  Tests  of 
significance  for  ethnic  differences  in  variables  were  based  on  unpaired  students'  t-tests  (and 
standard  errors)  of  mean  values,  and  on  geometric  mean  and  95  %  confidence  intervals  for 
log  transformed  variables.  For  categorical  variables  tests  of  significance  for  differences 
between  groups  were  based  on  the  x2  statistic.  Pearson's  product  moment  correlation 
coefficients  were  used  to  explore  the  univariate  association  between  continuous  variables. 
Multiple  linear  regression  analyses  were  performed  to  examine  the  joint  effect  of  more 
than  one  variable  on  the  dependent  variables.  To  facilitate  comparison  of  strength  of 
association  between  different  explanatory  variables  contributing  to  insulin  sensitivity, 
continuous  variables  were  divided  by  their  standard  deviations.  For  each  of  these  variables 
the  standardised  regression  coefficient  is  the  coefficient  associated  with  increase  of  the 
variable  by  one standard  deviation. 
For  testing  the  significance  of  the  difference  in  slopes  (ß)  between  groups  tests  of 
interaction  were  used. 
5.10.  Justification  for  the  choice  of  methods  used  in  this  study 
In  this  section  I  have  described  the  rationale  for  why  particular  methods  were  chosen  in 
this  study.  The  discussion  focuses  on  the  methods  used  for  measuring  (A)  insulin 
sensitivity,  (B)  postprandial  lipids  and  (C)  percent  body  fat. 
5.10.1.  Measurement  of  insulin  sensitivity 
In  the  current  study  one  of  the  primary  objectives  [section  4.2]  was  to  compare  insulin 
sensitivity  in  South  Asians  and  Europeans,  and  to  study  its  relationship  specifically  with 
obesity.  Thus  we  wanted  to  measure  insulin  sensitivity  accurately.  A  full  discussion  of 
the  choice  of  methods  available  to  do  this  has  been  given  in  section  1.5. 
Practical,  logistic  and  ethical  considerations  led  to  the  short  insulin  tolerance  test  (SITT) 
being  used  as  the  method  of  choice  for  measuring  insulin  sensitivity  in  this  study.  This 
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people  (n=120),  and  we  wanted  the  test  to  be  valid,  reliable,  safe  and  acceptable.  The 
SITT  fulfils  all  these  criteria  as  shown  in  section  1.5.4.  This  choice  of  method  enabled  the 
participant  to  give  up  a  maximum  of  one  hour  of  their  time  in  the  morning,  and  continue 
with  the  rest  of  the  day's  activities  unchanged  (e.  g.  go  to  work).  This  was  particularly 
important  in  this  study,  where  we  were  already  asking  the  participants  to  take  time  off 
work  for  the  multiple  visits  involved.  The  SITT  was  also  chosen  because  the  registrant 
was  able  to  perform  up  to  four  -  six  of  these  tests  in  a  morning  with  minimal  help  (which 
often  entailed  only  time  keeping). 
5.10.2.  Measurement  of  postprandial  lipids 
The  methods  available  to  measure  lipids  in  the  postprandial  state  all  require  the 
administration,  orally  or  intravenously,  of  a  fat  containing  meal  (amount  of  fat  varies 
according  to  the  meal  chosen),  before  and  after  which  blood  lipids  are  measured  -  fat 
tolerance  test.  Patsch's  test  meal  171,220  has  been  used  extensively  before  to  test  the 
difference  between  cases  and  controls  of  coronary  artery  disease.  They  have  specifically 
suggested  that  a  single  postprandial  sample  taken  at  around  6  to  9  hours1  '  142  may  be  just  as 
discriminatory  as  the  area  under  the  curve  of  a  full  fat  tolerance  test  with  hourly  blood 
samples.  This  was  an  important  consideration  in  our  choice  of  method,  due  to  the  multiple 
visits  involved,  to  keep  high  compliance.  We  thus  chose  to  measure  a  single  postprandial 
sample  at  8  hours  after  the  test  meal.  In  some  participants  who  consented  (n=35),  a 
second  sample  was  also  taken  at  6  hours  postprandially. 
5.10.3.  Measurement  of  total  percent  body  fat 
A  number  of  different  methods  are  available  for  quantifying  total  body  fat.  These  include 
underwater  weighing  and  densitometry,  deuterium  dilution,  40K  counting,  bio-electrical 
impedance  analysis  (BIA),  and  DEXA  scan.  The  use  of  BIA  as  a  fast,  cheap  and  efficient 
field  method  has  been  validated  223,224  in  people  of  European  descent,  but  not  in  South 
Asians.  Recommendations  for  the  use  of  BIA  for  estimating  adiposity  have  been  made  by, 
and  reviewed  by  Houtkooper  and  colleagues225.  We  measured  percent  fat  by  DEXA  scan 
as  the  standard,  against  which  we  wanted  to  validate  the  use  of  BIA  in  South  Asians. 
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6.1.  Presentation  of  Results 
6.1.1.  Baseline  characteristics 
135  people  (70  European  and  65  South  Asian)  were  eligible  to  proceed  with  the  study  (with 
fasting  triglyceride  <  3.5  mmol/1  and  non-diabetic  on  OGTT). 
Table  3  summarises  the  distribution  of  baseline  characteristics  among  Europeans  and  South 
Asians.  The  mean  age  of  participants  was  46.9  (range:  40.2-56.4,  sd:  4.7)  years.  The 
mean  age  was  similar  across  all  sex  and  ethnic  groups.  Prevalence  of  ever-smoking  was 
much  lower  in  South  Asians  compared  with  Europeans.  There  was  no  significant  ethnic 
difference  in  blood  pressure.  A  higher  number  of  South  Asians  were  in  manual 
occupations  [48  %  of  Europeans  and  71  %  of  South  Asians  reported  manual  occupations] 
though  the  difference  was  only  significant  among  women.  Levels  of  physical  activity  were 
low  in  both  groups,  and  especially  so  in  South  Asian  women. 
There  was  no  significant  ethnic  difference  in  the  reported  family  history  of  ischaemic  heart 
disease  (48%  in  Europeans,  52%  in  South  Asians),  hypertension  (18%  in  Europeans,  22% 
in  South  Asians),  or  stroke  (21  %  in  Europeans  and  South  Asians).  There  was  a  trend 
towards  higher  prevalence  of  family  history  of  diabetes  in  South  Asians  (20.6%)  compared 
with  Europeans  (10.6%;  p=0.116).  73.5  %  of  European  women,  and  77.4  %  of  South 
Asian  women  were  pre-menopausal.  Only  4%  of  Europeans  but  48%  of  South  Asians 
described  themselves  as  vegetarian  (p  <  0.001). 
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Men  Women 
European  S.  Asian  P  European  S.  Asian  p 
n  32  33  38  32 
Age  (years)  47.3  ±  0.8  46.6  ±  0.9  NS  47.7  ±  0.8  45.7  ±  0.7  0.081 
%  Ever  smoker  62.5  21.2  0.001  60.5  0  <0.001 
%  in  manual 
occupation 
57.1  71.0  NS  40.6  72.0  0.018 
Mean  'activity' 
score  (1-5) 
2.28_0.16  +  1.97_0.17  NS  2.31±0.15  1.75±0.17  0.016 
Mean  walking 
score  (1-3) 
1.94  ±  0.13  1.54  ±  0.12  0.030  1.53  ±  0.09  1.47  ±  0.12  NS 
%  active  in  sport  25.0  21.2  NS  39.5  9.4  0.004 
Mean  TV-hours 
score  (1-3) 
2.19±0.13  1.57±0.13  0.001  1.97±0.14  1.37±0.13  0.003 
Mean  systolic 
BP  (mmHg) 
124.1  ±  2.8  126.8  ±  2.7  NS  112.2  ±  2.4  112.9  ±  3.2  NS 
Mean  diastolic 
BP  (mmHg) 
81.2  ±  2.0  84.9  ±  2.0  NS  72.5  ±  1.4  76.4  ±  1.8  0.095 
Values  are  mean  and  SEM,  except  when  percentages  are  given.  Details  of  physical  activity 
measures  and  smoking  are  given  in  sections  5.6.1  and  5.6.2  respectively 
6.1.2.  Differences  in  fat  distribution 
Although  mean  BMI,  waist  girth  and  WHR  were  similar  between  the  ethnic  groups  of  both 
sexes,  South  Asian  women  had  greater  total  percent  fat  than  European  women  (Table  4). 
The  range  of  BMI  for  the  whole  group  was  from  17  to  34.3  kg/m2.  Mean  VFA  was 
generally  higher  in  South  Asians  compared  with  Europeans,  but  in  men  this  did  not  reach 
statistical  significance.  South  Asian  women  had  significantly  greater  VFA  than  European 
women  [P=0.36,  se=0.10,  p=0.001,  adjusted  R2  =25%].  This  ethnic  difference  in 
women  persisted  after  adjustment  for  SFA  and  percent  fat  [ß=0.21,  se=0.10,  p-0.047, 
adjusted  R'=42%].  However  when  further  adjustment  was  also  made  for  TFA,  the  ethnic 
difference  in  VFA  was  abolished  [ß=0.003,  se=0.04,  p=0.928,  adjusted  R2=93%].  As 
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central  obesity  than  men  (lower  waist  girth,  WHR,  and  VFA;  p<0.001  for  sex  difference 
in  each  central  obesity  measure  in  both  ethnic  groups). 
The  correlations  of  VFA  measured  by  CT  scan  with  both  waist  girth  and  WHR  were  high 
(p<0.0001)  in  all  groups  (except  p=0.003  for  association  between  WHR  and  VFA  in 
European  women)  as  follows.  Correlation  coefficients  (r)  between  VFA  and  waist  girth: 
0.81  and  0.70  in  European  men  and  women,  and  0.70  and  0.80  in  South  Asian  men  and 
women  respectively;  Correlation  coefficients  (r)  between  VFA  and  WHR:  0.72  and  0.51 
in  European  men  and  women,  and  0.69  and  0.71  in  South  Asian  men  and  women 
respectively. 
Table  4:  Distribution  of  anthropometric  variables  in  men  and  women  of  European 
and  South  Asian  descent. 
Men  Women 
European  S.  Asian  P  European  S.  Asian  p 
n  32  33  38  32 
BMI  (kg/m2)  25.8  (0.7)  25.9  (0.5)  NS  25.2  (0.6)  25.8  (0.6)  NS 
Waist  girth  (cm)  87.6  (1.9)  88.8  (1.6)  NS  77.1  (1.6)  79.3  (1.5)  NS 
Waist  hip  ratio  0.90  (0.01)  0.92  (0.01)  NS  0.79  (0.01)  0.80  (0.01)  NS 
%fat(DEXA)  22.9(1.3)  25.7(1.2)  NS  35.0(1.2)  39.8(1.0)  0.003 
fat  (BIA)  21.9  (0.7)  23.3  (0.5)  NS  33.6  (0.9)  37.2  (0.9)  0.007 
Visceral  fat 
area*  (cm2) 
111.5 
[91  -  137] 
126.1 
[108-  148] 
NS  65.8 
[57-  76] 
86.4 
[73-  102] 
0.019 
Subcutaneous 
fat  area  (cm2) 
193.6  (15.8)  230.1  (16.2)  0.112  263.4  (19.5)  284.2  (15.8)  NS 
Total  fat  area 
(cm2) 
323.2  (25.9)  366.4  (21.8)  NS  334.7  (22.5)  379.5  (21.1)  NS 
*:  geometric  means  of  (backtransformed)  log(natural)  variables  and  95%  confidence  intervals; 
otherwise  means  and  SEM  are  given 
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The  pattern  of  glucose  and  insulin  concentrations  was  consistent  with  greater  insulin 
resistance  in  South  Asians  (Table  5).  Fasting  insulin  and  2h  glucose  levels  were 
significantly  higher  among  South  Asians  and  there  was  a  much  exaggerated  post-glucose 
insulin  response  in  South  Asians  compared  with  Europeans.  Three  South  Asian  men  and  5 
South  Asian  women  had  glucose  intolerance  (2h  glucose  >  7.8  but  less  than  11.1  mmol/1), 
while  all  Europeans  were  normoglycaemic.  Mean  ISI  was  higher  among  Europeans  than 
South  Asians  [(mean  and  SEM  3.5  ±  0.2  and  2.9  ±  0.6  %/min.  respectively,  p=0.010), 
and  (ß  =  -0.71,95  %  Cl  -1.18  to  -0.25,  p=0.003  for  South  Asians  versus  Europeans  in  age 
and  sex  adjusted  regression  analysis)]. 
Table  5:  Mean  level  of  glucose,  insulin  and  insulin  sensitivity  index  by  sex  and  ethnic 
group 
Men  Women 
European  S.  Asian  p  European  S.  Asian  p 
n  32  33  38  32 
Fasting  glucose 
(mmol/1) 
5.3  ±  0.1  5.4  ±  0.1  NS  4.9  ±  0.1  5.1  ±  0.1  0.106 
2  hr  glucose 
(mmol/1) 
4.9±0.2  5.7±0.3  0.010  4.8±0.2  6.2±0.3  <0.001 
Fasting  insulin* 
(µu/ml) 
4.9 
[4.0-6.1] 
8.7 
[6.9-  11.1] 
0.001  4.6 
[4.0-5.3] 
6.1 
[4.9-7.6] 
0.037 
2  hr  insulin* 
(µu/ml) 
10.5 
[7.4  -  14.8] 
42.2 
[27.4-  65.1] 
<0.001  17.2 
[13.8-  21.6] 
34.8 
[25.8-  47.0] 
<0.001 
Insulin  (%o/min) 
sensitivity  index 
3.3  ±  0.3 
(n  =  29) 
2.4±0.2 
(n  =  27) 
0.024  3.7±0.2 
(n  =  28) 
3.2  ±  0.2 
(n  =  30) 
NS 
*:  geometric  means  of  (backtransformed)  log(natural)  variables  and  95%  confidence  intervals; 
otherwise  mean  and  SEM  are  given 
When  the  sexes  were  analysed  separately,  this  difference  was  significant  only  among  men 
(Table  5).  When  the  analysis  was  restricted  to  those  with  normal  glucose  tolerance  during 
the  OGTT  the  findings  were  unchanged.  Among  South  Asians,  women  had  higher  ISI  and 
lower  fasting  insulin  and  fasting  glucose  than  men  [p=0.009,  p=0.036  and  p=0.019 
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(p  <  0.001),  but  there  was  no  significant  sex  difference  in  2h  glucose,  insulin  or  ISI. 
The  strength  of  association  between  ISI  and  other  markers  of  insulin  sensitivity  was 
generally  greater  in  South  Asians  compared  with  Europeans  (Table  6). 
Table  6:  Correlation  coefficients  for  relation  between  ISI  and  glucose  and  insulin 
levels 
Europeans  South  Asians 
r  p  r  p 
Fasting  glucose  (mmol/I)  -0.21  NS  -0.40  0.002 
2h  glucose  (mmol/I)  -0.18  NS  -0.35  0.008 
Fasting  insulin*  (µu/ml)  -0.37  0.005  -0.51  <0.001 
2h  insulin*  (µu/ml)  -0.37  0.005  -0.45  <0.001 
*:  log  (natural  transformed) 
6.1.4.  Differences  in  lipids  including  postprandial  triglyceride  levels 
These  results  are  summarised  in  Table  7  and  Table  8.  There  was  no  significant  ethnic 
difference  in  the  fasting  levels  of  total  cholesterol  or  HDL-cholesterol,  though  the  latter 
was  significantly  higher  in  South  Asian  women  than  men.  Fasting  triglyceride  level  was 
higher  in  South  Asian  men  than  European  men,  but  not  significantly  so  (Table  7).  The 
8-hour  postprandial  triglyceride  level  was  higher  in  South  Asian  men  than  European  men, 
with  a  61  %  increase  over  the  fasting  level  among  South  Asian  men.  In  women  there  was 
no  ethnic  difference  in  the  postprandial  triglyceride  level.  At  8  hours  women  of  both 
ethnic  groups  had  a  more  favourable  postprandial  lipid  profile  (with  lower  triglyceride 
level)  than  men.  The  validity  of  the  data  for  the  proportion  of  triglyceride  concentration  at 
8  hours  in  the  chylomicron  and  non-chylomicron  plasma  fractions  is  uncertain,  as  there  is 
an  unusually  high  amount  in  the  chylomicron  fraction.  It  is  possible  that  there  were 
technical  problems  with  the  preparation  of  the  plasma  fractions  in  the  laboratory  as 
referred  to  in  section  6.3.4. 
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Asian  men,  even  though  the  numbers  of  subjects  studied  at  this  time  were  small  (Table  7). 
For  both  fasting  and  2h  NEFA  level  during  the  OGTT,  and  fasting  NEFA  level  during  the 
fat  tolerance  test,  South  Asian  women  tended  to  have  higher  NEFA  levels  than  European 
women.  There  was  no  ethnic  difference  in  levels  of  VLDL-triglyceride  or 
VLDL-cholesterol  but  there  was  a  significant  sex  difference  in  both  ethnic  groups,  with 
lower  levels  in  women  compared  with  men. 
Table  7:  Mean  fasting  and  postprandial  triglyceride  levels,  and  fasting  total  and  HDL- 
cholesterol  in  South  Asian  and  European  men  and  women 
Men  Women 
Lipids: 
(mmol/I)  European  S.  Asian  p  European  S.  Asian  p  p1  p2 
n  28  28  29  28 
Fasting  5.65  ±  0.24  5.40  ±  0.17  NS  5.24  ±  0.16  5.15  ±  0.17  NS  NS  NS 
Choi* 
Fasting  1.39  1.26  NS  1.56  1.51  NS  0.106  0.004 
HDL-Choi  [1.25-  1.55]  [1.16-  1.38]  [1.43-  1.71]  [1.40-  1.62] 
Fasting  TG  1.58  1.72  NS  1.24  1.27  NS  0.056  0.036 
[1.30-  1.92]  [1.45-  2.04]  [1.06-  1.44]  [1.02-  1.58] 
8h  TG  1.97  2.51  NS  1.45  1.39  NS  0.060  0.003 
[1.56-2.48]  [1.96-3.21]  [1.17-  1.79]  [1.06-  1.83] 
8h  Chylo  1.34  1.75  0.137  0.97  0.92  NS  0.059  0.002 
TG  [1.05-  1.71]  [1.36-  2.25]  [0.79-  1.20]  [0.70-  1.24] 
8h  Non-  0.62  0.75  NS  0.47  0.48  0.098  0.074  0.016 
chylo  TG  [0.51-  0.76]  [0.59-  0.95]  [0.38-  0.59]  [0.36-  0.63] 
6h  TG  3.27  5.71  0.057:  2.58  3.17  NS  NS  0.103 
(n=8)  (n=7)  (n=8)  (n=12) 
[2.15-  4.96]  :  [4.27-  7.62]  [  1.73-  3.85]  11]  [  1.97-  5. 
Geometric  means  and  95%  CI  are  given,  except  for  total  cholesterol  (*)  where  arithmetic  mean 
and  SEM  is  given;  exact  p  values  are  given  for  p<0.150 
p:  p  value  for  ethnic  differences  amongst  men  and  amongst  women 
pl  :p  value  for  sex  differences  in  Europeans;  p2:  p  value  for  sex  differences  in  S.  Asians 
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w Table  8:  Mean  fasting  and  postprandial  lipids  (NEFA,  VLDL-TG  and  VLDL- 
cholesterol)  in  South  Asian  and  European  men  and  women. 
Men  Women 
Lipids: 
(mmol/I)  European  S.  Asian  P  European  S.  Asian  p  p1  p2 
n  28  28  29  28 
Fasting  0.29  0.34  NS  0.33  0.40  0.098  NS  0.100 
NEFA-  [0.25-  0.34]  [0.28-  0.40]  [0.27-  0.40]  [0.35-  0.47] 
OGTT 
2h  NEFA  -  0.07  0.06  1  NS  0.03  0.04  0.065  0.002  1  0.131 
OGTT  [0.04-  0.10]  [0.04-  0.09]  [0.02-  0.04]  [0.03-  0.05] 
Fasting  0.36  0.34  NS  0.35  0.45  0.042  NS  0.048 
NEFA  -  [0.29-  0.45]  [0.27-  0.42]  [0.30-  0.41]  [0.38-  0.54] 
FTT 
8h  0.77  0.89  NS  0.81  0.89  NS  NS  NS 
NEFA  -  [0.68-  0.88]  [0.75-  1.05]  [0.71-  0.92]  [0.80-  0.98] 
FTT 
Fasting  0.49  0.56  NS  0.37  0.36  NS  0.085  0.025 
VLDL-TG  [0.38-  0.62]  [0.44-  0.70]  [0.30-  0.45]  [0.27-  0.48] 
8h  0.43  0.52  NS  0.28  0.23  NS  0.032  0.001 
VLDL-TG  [0.33-  0.57]  [0.40-  0.69]  [0.20-  0.37]  [0.16-  0.33] 
Fasting  0.35  0.38  0.106  0.27  0.24  NS  0.106  0.016 
VLDL-Choi  [0.27-  0.44]  [0.31-  0.47]  [0.22-  0.34]  [0.18-  0.32] 
8h  0.28  0.30  NS  0.17  0.12  NS  0.039  :  0.001 
VLDL-Choi  [0.22-  0.37]  [0.22-  0.40]  [0.12-  0.24]  [0.08-  0.18] 
All  values  are  geometric  means  and  95%  Cl.  exact  p  values  are  given  for  p<0.150 
p:  p  value  for  ethnic  differences  amongst  men  and  amongst  women 
p1:  p  value  for  sex  differences  in  Europeans 
p2:  p  value  for  sex  differences  in  S.  Asians 
The  marked  sex  difference  in  postprandial  triglyceride  in  South  Asians  (with  lower  level  in 
women  vs.  men)  persisted  when  adjusted  for  age  and  percent  fat  [standardised  ß=-0.84, 
se=0.31,  p=  0.008]  or  age  and  SFA  [ß=-0.76,  se  =0.39,  p=  0.061].  But  the  sex 
difference  in  8h  triglyceride  level  was  abolished  when  VFA  was  accounted  for  ß  =0.09, 
se=0.38,  p=0.813].  The  pattern  was  identical  in  Europeans,  i.  e.,  adjusting  for  age, 
Body  fat,  insulin  sensitivity  &  postprandial  lipids  6-84 percent  fat  or  SFA  did  not  account  for  the  lower  8h  triglyceride  level  in  women,  but 
adjusting  for  VFA  abolished  this  difference.  When  also  taking  the  effect  of  fasting 
triglyceride  into  account,  in  South  Asians  the  same  pattern  as  above  was  true,  but  in 
Europeans  the  sex  difference  in  8h  triglyceride  level  was  no  longer  significant  after 
adjusting  for  age  and  fasting  triglyceride. 
6.1.5.  Relation  between  obesity  and  metabolic  variables  (glucose,  insulin,  ISI 
and  triglyceride  concentration) 
Table  9  and  Table  10  show  the  correlations  of  generalised  obesity  (BMI  and percent  fat) 
and  abdominal  obesity  with  ISI,  insulin,  glucose  and  triglyceride  levels  in  men  and  women. 
Table  9:  Pearson's  product  moment  correlation  coefficients  of  obesity  measures  with 
metabolic  variables  in  European  and  South  Asian  men 
7  BMI  %  Fat  WHR  W  girth  VFA  SFA  TFA 
European  men 
Fasting  glucose  0.29  0.27  0.41a  0.33  a  0.05  0.32  0.23 
2h  glucose  0.16  0.17  0.10  0.10  0.17  0.15  0.14 
Fasting  insulin  0.42  a  0.45  a  0.29  0.45  a  0.32  0.57  c  0.51  b 
2h  insulin  0.07  0.28  0.01  0.02  0.19  0.16  0.15 
IS)  -0.38  a  -0.56 
b 
-0.28  -0.43  a  -0.50 
b 
-0.48  a  -0.49 
b 
Fasting  TG  0.35  0.40  a  0.40  a  0.34  0.63  c  0.35  0.51  b 
8h  TG  0.38a  0.48b  0.31  0.32  0.60c  0.46a  0.55b 
S.  Asian  men 
Fasting  glucose  0.11  -0.12  0.18  0.01  0.19  -0.13  0.01 
2h  glucose  0.08  0.06  0.49  b  0.13  0.44  a  -0.14  0.08 
Fasting  insulin  0.59  °  0.38  0.57  b  0.62  c  0.61  °  0.36  0.54b 
2h  insulin  0.54b  0.47a  0.66c  0.60c  0.61°  0.39a  0.53b 
ISI  -0.41 
a  -0.29  -0.55 
b 
-0.47  a  -0.34  -0.29  -0.37  a 
Fasting  TG  0.33  0.10  0.52  b  0.49  b  0.32  0.23  0.27 
8h  TG  0.53  a  0.45  a  0.69'  0.61  c  0.49  0.46  0.51  b 
a  p<0.05,  b  p<0.01,  °  p<0.001,  insulin,  triglyceride  (TG)  and  visceral  fat  area  (VFA)  have  been 
log  (natural)  transformed.  W  girth:  Waist  girth. 
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with  metabolic  variables  in  European  and  South  Asian  women 
BMI  %  Fat  WHR  W  girth  VFA  SFA  TFA 
European  women 
Fasting  glucose  0.46  b  0.46  b  0.24  0.40  a  0.53  b  0.40  a  0.48  b 
2h  glucose  0.33  a  0.18  0.55c  0.44b  0.22  0.15  0.18 
Fasting  insulin  0.61  b  0.55  b  0.44  a  0.640  0.65  `  0.50  b  0.58  c 
2h  insulin  0.22  0.22  0.45  b  0.27  0.28  0.15  0.20 
ISI  0.01  0.03  -0.11 
-0.11  -0.37  a  0.05  -0.04 
Fasting  TG  0.19  0.07  0.55  b  0.39  a  0.37  a  0.13  0.20 
8h  TG  0.19  0.01  0.70  c  0.47b  0.44  a  0.08  0.17 
S 
. 
Asian  women 
Fasting  glucose  0.31  0.17  0.39  a  0.38  a  0.42  a  0.01  0.14 
2h  glucose  0.13  -0.01  0.45  b  0.29  0.35  -0.09  0.04 
Fasting  insulin  0.30  0.09  0.33  0.35  a  0.38  a  0.06  0.16 
2h  insulin  0.19  0.06  0.18  0.16  0.27  0.06  0.11 
ISI  -0.38  a  -0.21  -0.19  -0.30  -0.35  -0.02  -0.13 
Fasting  TG  0.32  0.10  0.58  `  0.49  b  0.56  b  0.16  0.34 
8h  TG  0.13  -0.06  0.42  a  0.26  0.40  a  -0.03  0.13 
a  p<0.05,  b  p<0.01,  °  p<0.001;  Insulin,  triglyceride  (TG)  and  visceral  fat  area  (VFA)  have  been 
log  (natural)  transformed.  W  girth:  waist  girth 
ISI  and  insulin  levels  were  associated  with  all  measures  of  obesity,  and  particularly  with 
central  obesity.  The  main  departure  from  this  pattern  was  that  ISI  in  European  women  was 
not  significantly  associated  with  most  measures  of  obesity  (except  with  VFA).  In  men 
there  was  a  striking  ethnic  difference  in  the  strength  of  the  association  between  insulin 
concentration  and  measures  of  central  obesity:  in  South  Asian  men  these  correlation 
coefficients  were  generally  larger  than  in  European  men.  There  was  a  strong  correlation 
of  measures  of  central  obesity  (VFA,  waist  girth  and  WHR)  with  fasting  and  8h 
triglyceride  level  in  all  4  sex/ethnic  groups.  In  men,  but  not  women,  generalised  obesity, 
TFA  and  SFA  were  also  associated  with  8h  triglyceride  level.  The  correlations  between 
VFA  and  percent  fat  were  stronger  in  men  (r=0.79  in  Europeans  and  0.68  in  South 
Asians)  than  in  women  (r=0.48  in  Europeans  and  0.59  in  South  Asians). 
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obesity 
6.1.6.1.  Insulin  sensitivity  index  as  the  dependent  variable 
6.1.6.1.1.  ISI  and  BMI 
The  relationship  between  ISI  and  BMI  in  all  participants  (n  =114)  of  the  two  ethnic  groups 
is  shown  in  Figure  3. 
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Figure  3:  Relationship  between  insulin  sensitivity  index  and  BMI  in  Europeans  and 
South  Asians 
The  regression  line  for  this  association  was  steeper  in  South  Asians  [ß=-0.15,  p=0.003] 
than  in  Europeans  [P=  -0.08,  p=0.093],  but  the  slopes  were  not  significantly  different 
from  each  other  [p  for  interaction  between  ethnicity  and  BMI  =0.334]  . 
The  slope  of  the 
regression  line  for  the  association  between  ISI  and  BMI,  adjusted  for  age  and  sex  was 
-0.07  (se=0.05,  p=  0.1  50)  in  Europeans  and  -0.14  (se=0.05,  p=0.003)  in  South  Asians 
[also  not  significantly  different;  p  for  interaction  =0.285].  There  was  no  interaction 
Body  fat,  insulin  sensitivity  &  postprandial  lipids  6-87 between  sex  and  BMI,  thus  the  results  have  been  presented  for  the  whole  group  of 
participants. 
6.1.6.1.2.  ISI  and  percent  fat 
There  was  a  significant  interaction  between  sex  and  percent  fat  [p==0.020],  thus  analyses 
were  performed  separately  for  men  and  women.  Among  men  there  was  a  significant 
association  between  percent  fat  and  ISI  in  Europeans  [ß  =  -0.11,  p=0.003]  but  not  in  South 
Asians  [ß=-0.05,  p=0.145],  and  the  slopes  of  the  regression  lines  were  not  significantly 
different  [p  for  interaction  =0.201].  In  women  there  was  no  significant  association 
between  percent  fat  and  ISI. 
6.1.6.1.3.  ISI  and  central  obesity 
The  relationship  between  ISI  and  VFA  in  all  participants  of  the  two  ethnic  groups  is  shown 
in  Figure  4. 
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Figure  4:  Relationship  between  insulin  sensitivity  index  and  visceral  fat  area  in 
Europeans  and  South  Asians 
Body  fat,  insulin  sensitivity  &  postprandial  lipids  6-88 Although  the  association  between  ISI  and  VFA  was  strong  in  each  group,  the  slopes  of  the 
regression  lines  were  not  significantly  different  in  Europeans  [ß=-1.21,  p<0.001]  and 
South  Asians  [ß=-1.05,  p=0.001],  with  p  for  interaction  =0.706.  The  results  were 
similar  in  analyses  adjusted  for  age  and sex,  and  there  was  no  interaction  between  sex  and 
VFA  [p  for  interaction  =0.476].  The  results  were  in  the  same  direction  when  either  waist 
girth  or  WHR  ratio  were  used  as  markers  of  central  obesity. 
6.1.6.2.  Fasting  insulin  level  as  the  dependent  variable 
6.1.6.2.1.  Fasting  insulin  and  BMI 
In  regression analyses  adjusted  for  age  and  sex,  the  association  between  fasting  insulin  and 
BMI  was  strong  in  both  Europeans  [P=0.06,  p<0.001]  and  South  Asians  [P=0.09, 
p<0.001],  but  there  was  no  significant  ethnic  difference  [p  for  interaction  ==0.376]. 
There  was  no  interaction  between  sex  and  BMI  [p=0.407].  Figure  5  shows  graphically 
the  relation  between  fasting  insulin  and  BMI  in  European  and  South  Asian  participants. 
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Figure  5:  Relationship  between  fasting  insulin  and  BMI  in  Europeans  and  South 
Asians 
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There  was  no  evidence  of  interaction  [p=0.267]  between  sex  and  percent  fat,  so  analyses 
are  presented  for  the  whole  group  combined.  In  regression  analysis  of  the  whole  group 
adjusted  for  age  and  sex  the  association  between  percent  fat  and  fasting  insulin  was 
stronger  in  Europeans  [P=0.03,  p<0.0011  than  in  South  Asians  [P=0.03,  p=0.041],  with 
borderline  interaction  between  ethnicity  and  percent  fat  [p=0.1071.  The  crude  association 
between  fasting  insulin  and  percent  fat  was  significant  in  Europeans  [D=0.02,  p-0.015] 
but  not  in  South  Asians  [ß=  -0.006,  p=0.532],  and  is  shown  in  Figure  6. 
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Figure  6:  Relationship  between  fasting  insulin  and  percent  fat  in  Europeans  and 
South  Asians 
6.1.6.2.3.  Fasting  insulin  and  central  obesity 
The  relationship  between  fasting  insulin  and  VFA  in  all  participants  of  the  two  ethnic 
groups  is  shown  in  Figure  7.  The  association  between  fasting  insulin  and  VFA  was  strong 
in  each  group,  with  a  significantly  steeper  slope  [p  for  interaction  =0.060]  in  South  Asians 
[R=0.73,  p<0.0011  than  in  Europeans  [ß=0.37,  p=0.001].  When  the  analysis  was 
repeated  with  additionally  adjusting  for  age  and  sex  [no  interaction  between  sex  and  VFA, 
Body  fat,  insulin  sensitivity  &  postprandial  lipids  6-90 p=0.730],  the  slopes  of  the  regression  lines  were  significantly  different  at  the  5%  level  [p 
for  interaction  =0.045]. 
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Figure  7:  Relationship  between  fasting  insulin  and  visceral  fat  area  in  Europeans  and 
South  Asians 
The  results  were  in  the  same  direction  when  either  waist  girth  (Figure  8)  or  WHR  (Figure 
9)  were  used  as  markers  of  central  obesity. 
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Figure  8:  Relationship  between  fasting  insulin  and  waist  girth  in  Europeans  and 
South  Asians 
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Figure  9:  Relationship  between  fasting  insulin  and  waist/hip  ratio  in  Europeans  and 
South  Asians 
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6.1.6.3.1.2h  insulin  and  BMI 
In  contrast  to  the  lack  of  ethnic  difference  in  association  between  BMI  and  fasting  insulin, 
there  was  a  significant  ethnic  difference  in  the  association  between  BMI  and  2h  insulin. 
The  slope  of  this  association  in  the  whole  group  was  much  steeper  [p  for 
interaction  =0.047]  in  South  Asians  [ß=0.12,  p=0.006]  than  in  Europeans  [ß=0.02, 
p=0.553];  Figure  10.  In  analyses  further  adjusted  for  age  and  sex  the  results  were 
unchanged.  There  was  no  evidence  for  a  sex/BMI  interaction  [p-=0.364]. 
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Figure  10:  Relationship  between  2h-insulin  and  BMI  in  Europeans  and  South  Asians 
6.1.6.3.2.2h  insulin  and  percent  fat 
There  was  an  interaction  [p=0.052]  between  sex  and  percent  fat,  so  analyses  were 
performed  separately  for  men  and  women.  There  was  no  significant  association  between 
2h  insulin  and  percent  fat  except  in  South  Asian  men  [P=0.09,  p=0.019]. 
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The  relationship  between  2h  insulin  and  VFA  in  all  participants  is  shown  in  Figure  11. 
There  was  no  association  between  2h  insulin  and  VFA  in  Europeans  [P=0.04,  p=0.8391, 
but  there  was  a  strong  association  in  South  Asians  [ß=0.93,  p=0.001];  p  for 
interaction  =0.007.  The  results  were  unchanged  when  age  and  sex  were  added  to  the 
models  [p  for  sex/VFA  interaction  =0.300].  The  results  were  in  the  same  direction  (and 
same  order  of  magnitude)  when  either  waist  girth  or  WHR  were  used  as  markers  of  central 
obesity  (Figure  12  and  Figure  13  respectively). 
Europeans  o 
South  Asians  Q 
6QQQ 
QQ 
°  Q°00 
QQ 
EQQ 
QQ 
° 
D4°Q  °°  °°0 
CJ 
oQ  °°  (P 
0 
°Q 
:300  C) 
o°  o00  0°° 
N2°0  ° 
00  00  0 
0°0 
JI  8Q°0Q  °o 
0 
0 
3456 
Ln  visceral  fat  area  (cm2) 
Figure  11:  Relationship  between  2h-insulin  and  visceral  fat  area  in  Europeans  and 
South  Asians 
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Figure  13:  Relationship  between  2h-insulin  and  waist/hip  ratio  in  Europeans  and 
South  Asians 
Body  fat,  insulin  sensitivity  &  postprandial  lipids  6-95 6.1.7.  Relation  between  insulin  sensitivity,  visceral  obesity,  lipids  and  ethnic 
origin 
There  was  a  significant  strong  relationship  of  ISI  and  VFA  in  both  ethnic  groups  [in 
regression  analyses  adjusted  for  sex  and  age:  standardised  P=  -0.64,  se=0.18,  p=0.001, 
adjusted  R2=21%  in  Europeans;  ß=-0.43,  se  =0.17,  p=0.015,  adjusted  R2=20%  in  South 
Asians].  In  the  whole  group  (in  analyses  adjusted  for  age,  ethnicity  and  sex)  there 
persisted  a  significant  relation  between  ISI  and  VFA  after  adjustment  for  %  fat  and  SFA 
[ß=-0.45,  se=0.17,  p=0.009,  adjusted  R2=25%].  However,  this  relationship  was 
eliminated  after  additional  adjustment  for  triglyceride  level  (fasting  and  8h)  [P=0.02, 
se  =  0.19,  p=0.911,  adjusted  R2  =  34  %  ].  The  results  for  the  effect  of  VFA  on  ISI  in  each 
ethnic  group  separately  with  and  without  adjustment  for  overall  obesity  and  triglyceride 
level,  are  shown  in  Table  11. 
Table  11:  Multiple  linear  regression  with  insulin  sensitivity  as  dependent  variable  and 
visceral  fat  area  as  independent  variable,  adjusted  for  age,  sex,  obesity  and  lipids,  in 
Europeans  and  South  Asians. 
Europeans  S.  Asians 
independent  variables  ß  s.  e.  p  R2  %  ß  s.  e.  p 
%  R2 
VFA,  age,  sex  -0.64  0.18  0.001  20.6  -0.43  0.17  0.015  19.8 
VFA,  age,  sex,  %  fat  -0.53  0.26  0.046  19.6  -0.40  0.22  0.076  18.0 
VFA  age,  sex,  %  fat,  SFA  -0.51  0.26  0.054  21.6  -0.41  0.22  0.076  17.7 
VFA,  age,  sex,  % fat, 
SFA,  Oh  TG 
-0.11  0.33  0.743  22.4  0.002  0.25  0.993  28.9 
VFA,  age,  sex,  %  fat, 
SFA,  8h  TG 
0.09  0.32  0.767  28.0  -0.04  0.23  0.854  32.5 
VFA,  age,  sex,  %  fat, 
SFA,  Oh  TG,  8h  TG 
0.03  0.33  0.914  27.3  0.003  0.24  0.989  31.5 
log  (natural)  transformed  values  of  VFA  and  TG  were  used.  VFA=  visceral  fat  area,  TG= 
triglyceride,  ß=  standardised  ß,  R2  =  adjusted  R2  value.  The  standardised  beta  (ß)  is  the  slope 
of  the  relationship  of  ISI  on  VFA,  with  the  continuous  variables  standardised  to  unit  standard 
deviation  (see  methods  section  5.9). 
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and  ISI  in  men  [ß=-  0.55,  se  =0.18,  p=  0.004]  but  not  women  [ß=0.04,  se=0.16, 
p=0.786];  p  value  for  sex/SFA  interaction  =0.014.  In  men,  when  additional  adjustment 
was  made  for  VFA,  the  significance  of  association  with  SFA  was  lost  [ß=-0.28,  se=0.22, 
p=0.210].  Thus  the  association  between  ISI  and  VFA  was  independent  of  SFA,  but  the 
converse  was  not  the  case. 
The  results  were  similar  when  fasting  or  2h  insulin  were  chosen  as  the  marker  of  insulin 
resistance  for  the  whole  group.  That  is,  there  was  a  significant  association  between  fasting 
insulin  and  VFA,  and  2h  insulin  and  VFA  that  was  independent  of  %  fat  and  SFA.  This 
association  was  eliminated  after  additionally  adjusting  for  triglyceride  level  (fasting  or  8h). 
6.1.8.  The  ethnic  difference  in  insulin  sensitivity 
In  standardised  regression analyses  adjusted  for  age  and sex  ISI  was  0.71  %/min  lower  in 
South  Asians  than  in  Europeans  (Table  12).  The  contribution  of  obesity  and  triglyceride 
level  to  the  ethnic  difference  in  ISI  was  examined,  and  is  summarised  in  Table  12. 
Adjustment  for  total  adiposity  (measured  by  BMI  or  percent  fat),  body  fat  distribution  or 
triglyceride  level  did  not  account  for  more  than  one-third  of  the  ethnic  difference  in  ISI. 
In  a  multivariate  model  with  adjustment  for  age,  sex,  percent  fat,  VFA,  as  well  as  fasting 
and  8h  triglyceride  only  42%  of  the  ethnic  difference  in  ISI  was  accounted  for  [P==  -0.41, 
se=0.22,  p==0.066,  adjusted  R2  =33%].  With  additional  adjustment  for  variables 
measuring  level  of  physical  activity,  none  of  the  reported  results  were  significantly  altered, 
and  measures  of  physical  activity  were  not  significant  in  the  model.  Adding  smoking 
status  was  also  not  significant  in  the  model.  However  addition  of  social  class  (manual  vs. 
non-manual  occupation)  was  significant  in  the  model,  and  increased  the  ethnic  difference  in 
ISI  [ß=-0.63,  se=0.24,  p=0.009].  Among  women  adjustment  for  menopausal  status  did 
not  alter  the  model. 
With  fasting  or  2h  insulin  as  dependent  variable  the  results  were  similar;  none  of  the 
measured  variables  accounted  for  more  than  half  the  ethnic  difference. 
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adjusted  association  between  insulin  sensitivity  index  and  ethnicity. 
variables  adjusted  for:  s.  e.  p  2% 
age,  sex  -  0.71  0.24  0.003  11.1 
age,  sex,  BMI 
-  0.71  0.23  0.002  16.8 
age,  sex,  %fat 
-  0.49  0.24  0.045  16.0 
age,  sex,  waist  girth  -  0.66  0.22  0.004  19.8 
age,  sex,  waist-hip  ratio  -0.62  0.23  0.008  15.7 
age,  sex,  visceral  fat  area*  -  0.52  0.23  0.024  24.5 
age,  sex,  subcutaneous  fat  area  -  0.66  0.24  0.007  14.6 
age,  sex,  visceral/subcutaneous  fat  area  ratio*  -  0.69  0.24  0.004  14.1 
age,  sex,  total  fat  area  -  0.61  0.23  0.010  18.0 
age,  sex,  fasting  triglyceride*  -  0.59  0.22  0.009  23.5 
age,  sex,  8h  postprandial  triglyceride* 
L-  1  -  0.57  1  0.21  0.008  29.4 
1 
Independent  variable  of  primary  interest:  ethnic  group  coded  as  ethnicity:  2=South  Asian, 
1=European;  n=114.  Dependent  variable:  insulin  sensitivity  index.  *:  log  (natural)  transformed 
variables;  all  obesity  and  metabolic  variables  are  standardised  continuous  variables. 
standardised  ß,  R2  =  adjusted  R2  value. 
6.1.9.  Relation  between  postprandial  triglyceride  concentration  and  insulin 
resistance 
Univariate  associations  of  postprandial  triglyceride  level  and  features  associated  with  the 
insulin  resistance  syndrome  are  presented  in  Table  13.  This  shows  that  postprandial 
triglyceride  level  was  associated  with  features  of  the  metabolic  syndrome  in  all  4  sex/ethnic 
groups.  To  assess  whether  there  was  an  independent  association  of  postprandial 
triglyceride  with  insulin  resistance,  multivariate  analyses  were  performed  for  the  entire 
group  (adjusted  for  age,  sex  and  ethnic  group)  with  and  without  adjustment  for  fasting 
triglyceride  level.  The  results  are  presented  in  Table  14  and  show  that  by  and  large 
postprandial  triglyceride  concentration  had  an  independent  association  with  features  of  the 
insulin  resistance  syndrome. 
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between  8h  triglyceride  level  and  metabolic  and  obesity  features  of  the  insulin 
resistance  syndrome 
Men  Women 
European  S.  Asian  European  S.  Asian 
ISI  (%/min) 
-0.29  -0.64b  -0.42d  -0.45d 
Fasting  insulin*  (µu/ml)  0.454  0.64b  0.51°  0.62k 
2h  insulin*  (µu/ml)  0.31  0.75a  0.61b  0.424 
Fasting  glucose  (mmol/I)  -0.05  -0.04  0.09  0.47d 
2h  glucose  (mmol/I)  0.35e  0.36d  0.22  0.41" 
HDL-cholesteroi*  (mmol/I)  -0.44d  -0.76a  -0.53`  -0.32' 
Fasting  NEFA*  (mmol/I)  0.11  0.03  0.07  0.49` 
8h  NEFA*  (mmol/I)  0.35e  0.38d  0.19  0.66b 
Fasting  VLDL-TG*  (mmol/I)  0.78a  0.616  0.73a  0.80a 
8h  VLDL-TG*  (mmol/I)  0.87a  0.80a  0.90a  0.93a 
Fasting  VLDL-Choi*  (mmol/I)  0.71a  0.60b  0.72a  0.77a 
8h  VLDL-Chol*  (mmol/I)  0.73'  0.66a  0.85a  0.87a 
Fasting  triglyceride*  (mmol/I)  0.77a  0.76a  0.81a  0.91a 
VFA*  (cm2)  0.60b  0.49`  0.44d  0.40d 
SFA  (cm2)  0.46d  0.46d  0.08  -0.03 
Waist  girth  (cm)  0.32e  0.61b  0.47  c  0.26 
Waist-hip  ratio  0.30  0.69k  0.70a  0.424 
BMI  (kg/m2)  0.38d  0.53`  0.19  0.13 
Percent  fat  (%)  d  0.47  d  0.45  0.01  -0.06 
*These  variables  were  log  (natural)  transformed;  a=p<0.0001;  b=p<0.001;  c=p<0.01;  d=p<0.05; 
e=p<O.  1 
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(dependent  variable)  and  features  of  the  insulin  resistance  syndrome,  adjusted  for 
sex,  ethnicity,  and  age,  with  and  without  adjustment  for  fasting  triglyceride  level 
independent  variables: 
age  sex  ethnic  group  + 
No  adjustment  for  fasting  TG  Adjustment  for  fasting  TG 
,  , 
se  p  %R2  se  p  %  R2 
ISI  (%/min)  -0.31  0.06  <0.001  25.9  -0.12  0.04  0.004  70.3 
Fasting  insulin*  (µu/ml)  0.37  0.05  <0.001  36.2  0.16  0.04  <0.001  71.8 
2h  insulin*  (µu/ml)  0.37  0.06  <0.001  31.4  0.18  0.04  <0.001  72.9 
2h  glucose  (mmol/I)  0.24  0.06  <0.001  18.4  0.10  0.04  0.010  71.6 
HDL-Chol*  (mmol/I)  -0.35  0.06  <0.001  31.8  -0.16  0.04  <0.001  74.1 
Oh  NEFA*  (mmol/I)  0.11  0.06  0.086  10.4  -0.06  0.04  0.092  70.6 
8h  NEFA*  (mmol/I)  0.25  0.06  <0.001  21.5  0.10  0.04  0.005  71.9 
Oh  VLDL-TG*  (mmol/I)  0.50  0.04  <0.001  58.3  0.03  0.08  0.709  69.8 
8h  VLDL-TG*  (mmol/I)  0.61  0.03  <0.001  78.8  0.43  0.05  <0.001  81.7 
Oh  VLDL-Chol*  (mmol/I)  0.47  0.05  <0.001  53.5  0.05  0.06  0.458  70.0 
8h  VLDL-Chol*  (mmol/1)  0.55  0.04  <0.001  64.8  0.26  0.05  <0.001  74.8 
Visceral  fat  area*  (cm2)  0.36  0.06  <0.001  28.4  0.07  0.05  0.118  70.8 
SFA  (cm2)  0.16  0.07  0.018  12.3  0.04  0.04  0.304  70.4 
Waist  girth  (cm)  0.31  0.07  <0.001  22.4  0.05  0.05  0.266  70.2 
WHIR  0.47  0.08  <0.001  31.0  0.11  0.06  0.073  70.7 
BMI  0.20  0.06  0.003  15.5  0.04  0.04  0.355  70.1 
Percent  fat  (%)  0.20  0.09  0.029  11.2  0.07  0.05  0.189  68.8 
*=  log  (natural)  transformed  values  of  these  variables  were  used;  R2  :  Adjusted  R2  values;  ß= 
standardised  beta  coefficient.  (see  methods  section  5.9) 
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The  results  in  this  chapter  can  be  summarised  as  follows: 
1.  South  Asians  compared  with  Europeans  tended  to  have 
0  Higher  levels  of  overall  obesity  (greater  percent  fat),  and  central  obesity 
(greater  VFA),  especially  so  in  women. 
"  Greater  prevalence  of  insulin  resistance  (higher  glucose  and  insulin  levels  and 
lower  ISI) 
0  Higher  levels  of  postprandial  triglyceride  in  men  (significant  at  6h,  but  not  at 
8h) 
2.  All  measures  of  insulin  sensitivity  (ISI,  fasting  insulin  and  2h  insulin)  were  strongly 
related  with  obesity  in  all  groups,  especially  central  obesity.  In  particular  there  was  a 
strong  association  between  VFA  and  ISI  that  was  independent  of  SFA  and  percent  fat. 
There  was  also  a  strong  association  between  SFA  and  ISI,  but  this  association  was 
eliminated  when  adjustment  was  made  for  VFA. 
3.  The  strong  association  between  ISI  and  VFA  persisted  when  adjusted  for  overall 
obesity  (percent  fat),  but  was  eliminated  when  adjustment  was  made  for  triglyceride 
level  (fasting  or  8h). 
4.  The  slopes  of  the  regression  lines  for  the  association  between  ISI  and  BMI,  and 
between  ISI  and  VFA  were  not  significantly  different  between  Europeans  and  South 
Asians.  However,  the  slopes  of  the  regression  lines  for  the  association  between  fasting 
insulin  and  VFA  (as  well  as  waist  girth  and  WHR),  and  between  2h  insulin  and  BMI, 
and  2h  insulin  and  VFA  (as  well  as  waist  girth  and  WHR)  were  significantly  different 
in  Europeans  and  South  Asians,  with  the  latter  group  having  steeper  slopes. 
5.  Less  than  half  the  ethnic  difference  in  insulin  sensitivity  (ISI,  or  insulin  level)  was 
accounted  for  by  obesity,  body  fat  distribution  and  triglyceride  level. 
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association  was  independent  of  the  fasting  triglyceride  level  in  both  Europeans  and 
South  Asians. 
6.3.  Discussion  of  results 
While  it  has  been  suggested  that  in  South  Asians  central  obesity  is  related  to  the  high 
prevalence  of  insulin  resistance,  diabetes  and  CHD29,  no  one  has  used  direct  measures  to 
study  the  relationship  between  central  obesity  and  insulin  resistance  in  South  Asians  and 
Europeans.  The  results  from  this  study  are  the  first  to  address  this  issue  using  direct 
measures. 
We  found  overall  higher  levels  of  total  obesity  (percent  fat),  central  obesity  (VFA), 
postprandial  triglyceride  level  and  insulin  resistance  (lower  ISI  and  higher  insulin  level)  in 
South  Asians  than  Europeans  who  were  frequency  matched  for  BMI.  The  level  of  obesity 
was  significantly  different  in  women  but  not  men;  there  was  a  trend  towards  higher 
postprandial  triglyceride  concentration  in  men  (significant  at  6h  in  a  small  number,  but  not 
at  8h  in  the  whole  group)  but  not  women;  the  greater  insulin  resistance  in  South  Asians 
was  significant  among  men  for  ISI,  but  both  for  ISI  and  insulin  level  among  women.  We 
have  shown  that  postprandial  triglyceride  level  has  a  strong  relation  with  both  central 
obesity  and  insulin  sensitivity,  and  statistically  accounts  for  the  association  between  them. 
We  also  report  that  the  ethnic  difference  in  insulin  sensitivity  is  not  accounted  for  by 
central  obesity. 
6.3.1.  Ethnic  differences  in  obesity 
We  have  found  that  South  Asians  had  higher  overall  obesity  (total  percent  body  fat)  than 
Europeans  at  any  given  level  of  BMI.  Among  the  sexes  separately,  this  was  significantly 
so  in  women  but  not  men,  though  the  trend  in  men  was  also  in  the  same  direction.  This  is 
a  novel  finding  as  there  are  no  previous  studies  of  South  Asian  -  European  ethnic 
comparison  that  have  quantified  percent  body  fat  measured  accurately  by  DEXA  scan. 
However  some  previous  studies  have  attempted  to  quantify  percent  body  fat  by  measuring 
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have  not  fully  accounted  for  ethnic  differences  in  body  composition. 
The  greater  level  of  percent  fat  in  South  Asians  compared  with  Europeans  could  be  due  to 
genetic  differences,  environmental  and  life-style  factors  and  lower  levels  of  exercise,  or  a 
combination  of  these.  In  this  study  reported  levels  of  physical  activity  were  low  in  both 
groups,  and  even  lower  in  South  Asians  than  Europeans.  The  only  exception  to  this  was 
that  South  Asians  reported  significantly  lower  number  of  hours  spent  watching  television 
than  Europeans.  This  could  be  because  of  cultural  differences  in  the  way  that  periods  of 
physical  inactivity  are  spent.  It  is  possible  that  South  Asians  spend  more  time  socialising 
for  example  than  watching  television.  There  might  also  be  differences  in  the  way  exercise 
is  taken;  for  example  it  is  noteworthy  that  none  of  the  South  Asian  women  rode  a  bicycle. 
There  are  many  limitations  due  to  cultural/ethnic  factors  in  assessing  levels  of  physical 
activity  from  self-report.  The  most  objective  way  to  quantify  physical  fitness  would  have 
been  to  measure  maximal  aerobic  power  (V02-max).  However,  this  was  not  possible  in 
the  current  study  because  the  study  protocol  already  involved  multiple  tests  on  multiple 
visits,  and  it  was  not  feasible  to  fit  in  any  more  formal  tests. 
It  is  also  noteworthy  that  although  there  were  no  ethnic  differences  in  mean  waist  girth  or 
WHR,  mean  VFA  measured  by  CT  scan  was  higher  in  South  Asians  than  in  Europeans, 
although  this  difference  was  statistically  significant  only  in  women.  We  have  previously 
reported  that  in  comparison  with  European  men  and  women,  South  Asian  men  and  women 
have  higher  levels  of  central  obesity,  (as  measured  by  WHR,  sagittal  abdominal  diameter 
or  trunk  skinfolds),  than  Europeans29.  The  failure  to  detect  a  significant  ethnic  difference 
in  VFA  in  men  in  this  and  another  smaller  study  comparing  South  Asians  and 
Europeans226,  may  be  a  chance  result,  as  differences  in  abdominal  obesity  have  consistently 
been  detected  in  larger  surveys  using  anthropometry. 
6.3.2.  Ethnic  difference  in  insulin  sensitivity 
Higher  average  levels  of  insulin  resistance  in  South  Asians  compared  with  Europeans  have 
been  demonstrated  in  epidemiological  studies  measuring  fasting  and  post-load  insulin 
levels.  In  a  steady-state  study  using  the  insulin  suppression  test227,  the  ethnic  difference  in 
insulin  resistance  (measured  by  the  steady-state  plasma  glucose  level)  between  weight- 
matched  South  Asians  and  Europeans  was  of  comparable  size  to  that  typically  observed 
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insulin-stimulated  glucose  uptake,  the  short  insulin  tolerance  test  has  been  validated  against 
the  euglycaemic  clamp  with  correlation  coefficients  of  0.81  to  0.86100-10'.  The  higher 
insulin  sensitivity  in  women  compared  with  men  of  similar  BMI  in  the  present  study  is  in 
keeping  with  a  previous  study228  which  measured  ISI  by  the  frequently  sampled  intravenous 
glucose  tolerance  test.  The  ethnic  difference  in  ISI  in  the  current  study  was  statistically 
significant  among  men  but  not  women.  However  insulin  levels  (fasting  and  2h)  were 
markedly  higher  in  South  Asians  than  in  Europeans  in  both  men  and  women,  as  previously 
observed  in  a  larger  epidemiological  study  in  this  population29. 
This  suggests  that  the  defect  in  insulin-mediated  glucose  disposal  in  South  Asians  may  be 
more  evident  after  a  glucose  load  than  in  the  fasting  state.  Furthermore,  although  the  short 
insulin  tolerance  test  has  been  validated  against  the  euglycaemic  clamp,  it  has  never 
specifically  been  validated  in  South  Asians.  It  is  likely  to  be  valid  in  South  Asians  as  one 
group  has  successfully  employed  it  in  a  study  of  an  ethnic  comparison  of  prevalence  of 
insulin  resistance  in  non-diabetic  relatives  of  patients  with  diabetes53.  Nonetheless,  specific 
validation  in  South  Asians  should  be  undertaken  before  it  is  used  in  further  studies  of 
ethnic  comparison. 
6.3.3.  Ethnic  differences  in  relation  between  insulin  sensitivity  and  obesity 
ISI  and  insulin  levels  were  correlated  with  VFA  in  each  ethnic  group  and  in  the  whole 
group,  and  this  relationship  was  independent  of  percent  body  fat.  This  contrasts  with  a 
smaller  study  in  India229  in  which  there  was  no  significant  relation  of  insulin  level  to  CT- 
scan-measured  abdominal  fat  areas  in  South  Asians. 
Also,  the  significant  association  between  ISI  and  VFA  was  independent  of  SFA,  but  the 
converse  was  not  the  case.  This  finding  is  directly  in  contrast  with  a  study  by  Goodpaster 
et  aff,  where  SFA  was  the  strongest  correlate  of  insulin  sensitivity  (measured  by  the 
glucose  clamp  technique),  independently  of  VFA.  The  primary  importance  of  visceral 
adipose  tissue  versus  subcutaneous  abdominal  obesity  has  also  been  challenged  by 
others231'232  One  reason  for  the  difference  in  our  results  could  be  that  Goodpaster  et  al's 
study  was  based  on  a  smaller  number  of  subjects  (n=54),  who  were  recruited  by  public 
advertisement. 
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tolerance  test  cannot  be  accounted  for  by  central  obesity  based  on  3  lines  of  evidence  in 
this  study  -  (A)  the  ethnic  difference  in  ISI  did  not  disappear  with  the  addition  of  VFA  in 
regression  analysis;  (B)  the  slopes  of  the  regression  lines  for  the  association  between  ISI 
and  VFA  or  ISI  and  BMI  were  not  significantly  different  -  i.  e.  the  reduction  in  ISI  with 
increasing  BMI  or  VFA  did  not  differ  significantly  between  the  ethnic  groups;  and  (C)  the 
results  did  not  fit  a  sex  pattern:  in  men  there  was  a  large  ethnic  difference  in  ISI  but  not  in 
VFA,  whereas  in  women  there  was  no  significant  difference  in  ISI  but  a  large  ethnic 
difference  in  VFA. 
If  accumulation  of  visceral  fat  accounts  for  the  greater  susceptibility  of  South  Asians  to 
insulin  resistance,  in  comparison  with  Europeans,  we  would  predict  that  (i)  adjusting  for 
direct  measures  of  visceral  fat  would  account  for  the  ethnic  difference  in  insulin  resistance, 
and  (ii)  the  slope  of  the  relationship  between  insulin  resistance  and  percent  body  fat  would 
be  steeper  in  South  Asians  than  in  Europeans  because  in  the  leanest  individuals  visceral  fat 
stores  are  low  in  both  ethnic  groups.  Neither  of  these  two  predictions  was  confirmed. 
South  Asians  had  lower  insulin  sensitivity  (ISI)  than  Europeans  at  all  levels  of  overall 
adiposity,  even  when  lean.  Central  obesity  did  not  account  statistically  for  the  ethnic 
difference  in  insulin  sensitivity.  Our  finding  that  the  ethnic  difference  in  insulin  sensitivity 
was  statistically  significant  only  in  men,  while  the  ethnic  difference  in  VFA  was 
statistically  significant  only  in  women  is  not  consistent  with  the  hypothesis  that  central 
obesity  has  a  primary  role  in  the  ethnic  difference  in  insulin  sensitivity. 
However,  when  insulin  level  was  used  as  the  measure  of  insulin  sensitivity  there  was  an 
interaction  between  ethnicity  and  VFA.  This  suggests  that  lean  individuals  of  either  ethnic 
group  had  low  insulin  levels,  but  as  visceral  obesity  increased,  South  Asians  had 
significantly  higher  insulin  levels  than  Europeans.  This  was  shown  clearly  by  the  crossing 
over  or  diverging  of  the  regression  lines  (in  Europeans  and  South  Asians)  in  the  graphs  of 
the  relationship  between  insulin  concentration  and  measures  of  central  obesity  (figures  7- 
9  and  11  -  13)  as  well  as  by  the  differences  in  the  correlation  coefficients  of  the  relation 
between  insulin  concentration  and  measures  of  central  obesity  (especially  in  men;  Table  9). 
This  difference  in  finding  with  insulin  concentration  versus  ISI  as  the  outcome  measure 
could  be  due  to  reasons  discussed  before  in  section  6.3.2,  and  has  also  been  further 
addressed  in  chapter  10  (section  10.3.6.1).  The  finding  of  greater  increases  among  South 
Asians  in  insulin  concentration  with  increasing  levels  of  central  adiposity  is  of  potential 
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than  in  Europeans,  efforts  to  control  central  adiposity  should  form  the  focus  of  efforts  to 
reduce  insulin  resistance  (as  indexed  by  insulin  concentration),  and  hence  CHD.  This 
subject  is  further  discussed  in  section  10.5. 
Even  though  central  (visceral)  obesity  did  not  account  for  the  ethnic  difference  in  insulin 
sensitivity  in  this  study,  nonetheless  it  was  strongly  and  independently  associated  with 
insulin  sensitivity  in  each  ethnic  group.  The  mechanism  by  which  accumulation  of  fat  in 
visceral  depots  is  associated  with  insulin  resistance  is  not  fully  understood.  It  is  postulated 
that  greater  lipolytic  activity  of  centrally  located  adipocytes  contributes  to  portal  venous 
elevations  of  NEFA,  because  omental  fat  cells  in  vitro  are  resistant  to  insulin-mediated 
suppression  of  lipolysis233.  Elevated  NEFA  decrease  hepatic  insulin  extraction  13'  and 
promote  synthesis  of  apolipoprotein  B  lipoproteins46,95,95,235,235  Thus  NEFA  derived  from 
visceral  fat  might  selectively  potentiate  peripheral  hyperinsulinaemia  and  dyslipidaemia236 
Recent  evidence  suggests  that  resistance  to  insulin-mediated  glucose  uptake  is  strongly 
related  to  the  level  of  triglyceride  stores  in  muscle  cells208'209  Triglyceride  levels  in  muscle 
are  likely  to  depend  upon  plasma  triglyceride  levels,  which  in  turn  are  highly  correlated 
with  central  adiposity. 
6.3.4.  The  role  of  postprandial  triglyceride  in  the  relation  between  insulin 
sensitivity  and  obesity 
Triglyceride  levels  at  8h  after  a  fat  load  in  this  study  were  strongly  correlated  with 
measures  of  central  adiposity  including  waist/hip  ratio  and  VFA.  This  relationship  is  what 
we  would  expect  to  observe:  the  accumulation  of  fat  in  intra-abdominal  depots  could  lead 
to  a  sustained  production  of  VLDL  and  an  impaired  clearance  of  triglyceride-rich 
lipoproteins  in  the  postprandial  period147,23'  8h  triglyceride  was  also  strongly  associated 
with  insulin  sensitivity,  and  accounted  statistically  for  the  association  between  central 
adiposity  and  insulin  sensitivity. 
Both  at  8h  and  in  a  smaller  number  at  6h,  there  was  a  higher  postprandial  triglyceride  level 
in  South  Asian  men  versus  European  men,  but  there  was  no  significant  ethnic  difference 
between  women.  This  is  probably  because  most  of  the  women  in  this  study  were 
premenopausal,  and  as  such  are  probably  relatively  "protected"  from  an  adverse  lipaemic 
response.  In  both  ethnic  groups  the  sex  difference  in  8h  triglyceride  level  persisted  when 
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difference  in  VFA.  This  suggests  that  the  higher  level  of  visceral  fat  in  men  compared 
with  women  is  related  to  their  more  adverse  postprandial  lipaemic  response.  This 
argument  is  supported  by  the  finding  that  when  this  sex  difference  in  body  fat  distribution 
is  taken  into  account,  no  sex  difference  in  lipaemic  response  remains.  This  has  been 
shown  before  for  sex  differences  in  fasting  triglyceride  level238,  but  never  before  to  our 
knowledge,  for  sex  differences  in  postprandial  triglyceride. 
We  have  shown  that  postprandial  triglyceride  level  was,  independently  of  fasting 
triglyceride  level,  associated  with  the  metabolic  syndrome  or  the  insulin  resistance 
syndrome.  Thus  we  propose  that  postprandial  triglyceride  forms  part  of  the  cluster  of 
CHD  risk  factors  associated  with  the  metabolic  syndrome  in  both  Europeans  and  South 
Asians.  This  is  a  new  finding  in  South  Asians,  not  previously  reported.  Although  in 
people  of  European  descent  it  has  been  suggested  previously  that  elevated  postprandial 
triglyceride  level  is  part  of  the  cluster  of  features  that  form  the  metabolic 
syndrome  144,146,147,  it  is  still  not  widely  accepted,  and  it  remains  controversial  whether  this 
association  is  independent  of  fasting  triglyceride  level.  Some  groups  have  failed  altogether 
to  find  an  association  between  insulin  resistance  (or  insulin  level)  and  postprandial 
trig  lyceride133,145  In  a  recent  study  in  men,  Couillard  et  a1147  showed  that  visceral  obesity 
is  associated  with  an  impaired  postprandial  triglyceride  clearance,  and  that  visceral  obesity 
may  contribute  to  fasting  and  postprandial  hypertriglyceridaemia  by  altering  NEFA 
metabolism  in  the  postprandial  state.  They  reported  that  features  of  the  insulin  resistance 
syndrome  were  all  significant  correlates  of  an  impaired  postprandial  TGRL  clearance. 
However,  in  the  current  study  even  after  adjusting  for  central  obesity  and  triglyceride  level 
(fasting  and  8h),  there  remained  a  significant  ethnic  difference  in  insulin  sensitivity.  For 
this  epidemiological  study,  rather  than  undertake  a  full  fat  tolerance  test  with  hourly  blood 
samples,  we  took  a  single  post-load  sample  at  8h,  plus  a  6h  measurement  in  a  sub-sample. 
This  was  based  on  previous  studies  showing  that  a  single  measurement  at  8h  correlates 
with  the  extent  of  coronary  disease  at  angiography13'  . 
As  the  ethnic  differences  in 
postprandial  triglyceride  level  were  greater  at  6h  than  at  8h,  it  is  possible  that  we  have 
underestimated  the  ethnic  difference  in  postprandial  triglyceride  level  by  relying  on  a 
single  measurement  at  8h  in  most  participants.  If  so,  then  it  is  possible  that  we  have  also 
underestimated  the  extent  to  which  differences  in  postprandial  triglyceride  levels  could 
account  for  the  ethnic  difference  in  insulin  sensitivity.  From  the  limited  information  that 
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the  fat  tolerance  test  that  are  not  detectable  at  8  h,  at  least  not  with  total  triglyceride. 
There  may  have  been  subtle  differences  in  fractions  of  the  postprandial  response  that  were 
possibly  not  evident  in  the  measurement  of  total  triglyceride  level  alone.  We  wanted  to 
measure  apoB-48  and  apoB-100,  as  well  as  plasma  retinyl  palmitate  in  chylomicron  and 
non-chylomicron  plasma  fractions  to  see  whether  there  were  ethnic  differences  in  the 
exogenous  (dietary;  apoB-48  and  retinyl  palmitate)  and/or  endogenous  (hepatic  derived; 
apoB-100)  levels  of  triglyceride.  However,  although  samples  were  collected,  due  to 
technical  problems  and  lack  of  a  laboratory  that  was  able  to  measure  these  for  us  on  a 
collaborative  basis,  we  were  unable  to  do  so.  This  remains  a  limitation  of  this  part  of  the 
study.  As  a  compromise  we  did  measure  triglyceride  level  in  the  chylomicron  and  non- 
chylomicron  fractions  of  the  plasma  at  8  hours,  but  found  there  to  be  no  ethnic  difference 
in  these.  However  the  validity  of  the  data  obtained  for  triglyceride  concentration  in  the 
two  fractions  is  open  to  question,  as  there  were  technical  problems  associated  with  the 
preparation  in  the  laboratory. 
In  conclusion,  our  results  suggest  that  the  greater  resistance  to  insulin-mediated  glucose 
uptake  in  South  Asians  compared  with  Europeans  cannot  be  fully  accounted  for  by 
differences  in  body  fat  pattern,  or  in  plasma  triglyceride  levels.  In  both  ethnic  groups  the 
relationships  of  insulin  sensitivity  to  visceral  fat  were  eliminated  by  adjusting  for 
postprandial  triglyceride  level,  suggesting  that  an  underlying  alteration  of  lipid  metabolism 
may  be  responsible  for  the  relationship  between  these  variables.  Ethnic  differences  in 
plasma  lipids  appear  to  be  larger  in  the  postprandial  state  than  in  the  fasting  state,  and  this 
may  be  relevant  to  the  excess  risk  of  CHD  in  South  Asians  compared  with  other  groups. 
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7.1.  Presentation  of  results 
7.1.1.  Basic  characteristics  and  general  associations  of  IMCL 
Mean  (±  SEM)  IMCL  content  (measured  with  creatine  as  the  internal  standard)  was  higher 
in  South  Asians  than  in  Europeans  [72.1  ±  7.5  vs.  53.6  ±  4.9  mmol/kg  dry  weight 
respectively,  p=0.046].  The  clinical  and  metabolic  measurements  of  the  participants,  and 
their  correlation  with  IMCL  are  summarised  in  Table  15. 
South  Asian  men  had  significantly  higher  percent  body  fat  and  insulin  resistance  than 
European  men.  In  Europeans  IMCL  was  positively  correlated  with  indices  of  generalised 
obesity  and  central  obesity  (Table  15),  and  inversely  correlated  with  ISI  (Figure  14).  In 
South  Asians  IMCL  was  not  significantly  correlated  with  any  measured  variable. 
European  men  smoked  more  and  had  a  higher  mean  walking  score  than  South  Asians, 
though  both  groups  took  little  exercise.  The  distribution  of  ISI  by  BMI  in  the  two  groups 
is  shown  in  Figure  15. 
One  possible  reason  for  the  lack  of  association  of  IMCL  with  the  measured  obesity  and 
metabolic  variables  among  South  Asian  men  could  be  because  of  one  South  Asian  "outlier", 
who  had  very  low  IMCL  and  low  ISI  (figure  14).  Thus  the  analysis  was  repeated  with  the 
exclusion  of  this  outlier.  This  did  not  make  any  difference  to  the  observed  associations.  In 
particular  the  slope  (beta  coefficient)  of  the  ISI/IMCL  association  in  South  Asian  men  was 
+0.05  (p  =  0.891)  with  all  men,  and  -0.08  (p  =  0.875)  with  the  outlier  excluded.  The 
correlation  coefficient  (r)  for  this  association  changed  from  +0.03  (p  =  0.891)  to  -0.04  (p  = 
0.875)  with  the  exclusion  of  the  outlier. 
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coefficients  (r)  with  intramyocellular  lipid  in  men  by  ethnic  group 
European  (n  =20)  South  Asian  (n  =20)  pb 
Mean*  r  pa  Mean*  r  pa 
Age  (years)  47.8  ±  1.0  0.45  0.048  46.3  ±  1.1  0.01  NS  NS 
BMI  (kg/m2)  26.4  ±  0.8  0.72  <0.001  26.3  ±  0.6  0.25  NS  NS 
%  body  fat  22.5  ±  1.7  0.49  0.028  26.8  +  1.3  0.31  NS  0.052 
WHR  0.91  ±  0.01  0.74  <0.001  0.92  +  0.01  0.25  NS  NS 
Visceral  fat  area*  (cm2)  113.5 
[87-  148] 
0.62  0.004  137.2 
[115  -  164] 
0.14  NS  NS 
Fasting  glucose  (mmol/I)  5.3  t  0.1  0.10  NS  5.4  0.1  -0.20  NS  NS 
2h  glucose  (mmol/l)  4.9  ±  0.2  -0.12  NS  5.9  0.4  -0.08  NS  0.022 
Fasting  insulin*  (µU  /ml)  4.9 
[3.7  -  6.5] 
0.37  NS  9.7 
[7.2  -  13.1] 
-0.17  NS  0.003 
2h  insulin*  (µU/ml)  10.3 
[6.9  -  15.6] 
0.15  NS  51.4 
[31.6-  83.7] 
-0.09  NS  <0.001 
ISI  (%/min)  3.4  ±  0.3  -0.53  0.016  2.4  +  0.2  0.03  NS  0.013 
Fasting  triglyceride* 
(mmol/I) 
1.46 
[1.2  -  1.8] 
0.13  NS  '  1.60 
[1.3  -  2.0] 
-0.08  NS  NS 
Fasting  NEFA*  (mmol/I)  0.29 
[0.24  -  0.37] 
0.04  NS  0.34 
[0.28-0.41] 
-0.19  NS  NS 
2h  NEFA*  (mmol/l)  0.06 
[0.04-0.10] 
0.01  NS  0.05 
[0.04-0.08] 
0.03  NS  NS 
Physical  activity  (1-5)  2.2  +  0.2  -0.33  NS  2.0  ±  0.2  -0.15  NS  NS 
Walking  score  (1-4)  3.0  ±  0.1  -0.08  NS  2.2  ±  0.2  0.04  NS  0.009 
Active  in  sport  (%)  25  0.02  NS  25  -0.03  NS  NS 
Ever  smoker  (%)  55  0.37  NS  10  -0.12  NS  0.002 
Arithmetic  means  and  SEM  are  given  except  where  the  variable  has  been  log  transformed  (*), 
where  geometric  means  and  95%  CIs  are  shown.  a:  significance  level  associated  with  r;  b:  p 
value  for  ethnic  difference  in  mean  values;  Exact  p  values  are  quoted  for  p<O.  10.  Ever  smoker 
=  past  or  current  smoker 
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Figure  14:  Relationship  between  insulin  sensitivity  index  and  intramyocellular  lipid 
content  in  40  European  and  South  Asian  men 
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Figure  15:  Relationship  between  insulin  sensitivity  index  and  BMI  in  40  European 
and  South  Asian  men 
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Body  mass  index  (kg/m2) When  water  was  used  as  the  internal  standard  instead  of  creatine,  the  results  were  similar 
but  associations  of  IMCL  content  with  ethnic  origin,  obesity,  insulin  sensitivity  and  lipids 
were  generally  weaker. 
7.1.2.  Relation  between  IMCL,  insulin  sensitivity,  obesity,  and  lipids 
The  relation  of  ISI  to  obesity,  plasma  lipids  and  IMCL  was  examined  in  each  ethnic  group 
separately.  All  analyses  were  adjusted  for  age,  and  standardised  regression  coefficients  are 
presented  (Table  16).  The  strongest  (age  adjusted)  associations  of  ISI  in  Europeans  were 
with:  generalised  obesity  [percent  fat  and  BMI],  central  obesity  [VFA,  WHR  and  waist 
girth],  and  IMCL.  There  was  no  significant  association  of  ISI  with  plasma  lipids  among 
Europeans.  Among  South  Asians  ISI  was  significantly  associated  with  plasma  fasting  and 
8h  triglyceride,  and  central  obesity  measured  anthropometrically  (WHR  and  waist  girth). 
However  ISI  in  South  Asians  was  not  significantly  associated  with  VFA,  IMCL,  BMI  or 
percent  fat.  These  results  were  unchanged  when  the  analyses  were  repeated  with  the 
exclusion  of  one  South  Asian  "outlier"  (figure  14). 
Table  16:  Age  adjusted  univariate  regressions  of  insulin  sensitivity  index  on 
measures  of  obesity,  plasma  lipids  and  IMCL  content  in  men  by  ethnic  group 
European  men  South  Asian  men 
ß  se  p  value  se  p  value 
VFA*  (cm2)  -0.79  0.25  0.005  -0.41  0.25  0.128 
WHR  -1.01 
0.44  0.034  -0.74  0.30  0.025 
Waist  girth  (cm)  -1.09  0.28  0.001  -0.41  0.20  0.063 
BMI  (kg/m2)  -1.03  0.25  0.001  -0.43  0.22  0.066 
percent  fat  -1.52  0.33  <0.001  -0.04  0.32  NS 
Fasting  TG*  (mmol/I)  0.22  0.29  NS  -0.72  0.17  <0.001 
8h  TG*  (mmol/I)  -0,12  0.32  NS  -0.67  0.17  0.001 
Fasting  NEFA*  (mmol/I)  -0.21  0.32  NS  -0.16  0.24  NS 
2h  NEFA*  (mmol/I)  -0.13  0.26  NS  -0.13  0.25  NS 
IMCL*  (mmol/kg  dry  wt)  -0.80 
0.39  0.058  0.02  0.17  NS 
*:  log  (natural)  transformed  values  of  these  variables  were  used;  TG  =  triglyceride;  Standardised 
regression  coefficient:  ß 
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with  strong  associations  with  central  obesity  (WHR,  waist  girth  and  VFA),  triglyceride 
level  (Oh  and  8h),  and  additionally  BMI  in  South  Asians.  In  Europeans  the  most 
significant  association  was  with  percent  fat,  but  not  with  central  obesity. 
In  multiple  regression  analyses  we  examined  whether  the  association  between  insulin 
sensitivity  and  central  obesity,  seen  in  both  European  and  South  Asian  men,  persisted  when 
adjusted  for  IMCL.  In  age-adjusted  analyses  in  Europeans  the  significant  association 
between  ISI  and  VFA,  and  ISI  and  percent  fat  persisted  even  after  adjustment  for  IMCL, 
in  contrast  to  the  association  between  ISI  and  WHR  which  was  made  non-significant  when 
adjusted  for  IMCL  (Table  17,  model  A).  Among  South  Asian  men  the  association  between 
ISI  and  WHR  remained  significant  when  adjusted  for  IMCL.  Among  European  men  the 
significant  association  between  IMCL  and  WHR,  and  IMCL  and  VFA  persisted  even  after 
adjusting  for  fasting  plasma  triglyceride  (Table  17,  model  B).  The  results  with  8h 
triglyceride  in  the  models  were  identical. 
The  significant  relationship  between  ISI  and  IMCL  in  Europeans  was  independent  of 
fasting  and  2h  glucose,  insulin  and  NEFA,  and  plasma  triglyceride.  However,  this 
association  was  no  longer  statistically  significant  when  adjustment  was  made  for 
generalised  obesity  [percent  fat:  ß=  -0.40,  p=0.199;  BMI:  ß=  0.03,  p=0.941]  or  for 
central  obesity  [VFA:  3=  -0.29,  p=0.493;  WHR:  ß=  -0.37,  p=0.494]. 
There  were  fewer  smokers  among  South  Asians  (Table  15).  Adjusting  for  smoking  did  not 
make  a  difference  to  the  relations  between  insulin  sensitivity,  central  obesity  and  IMCL. 
The  level  of  physical  activity  reported  were  low  in  both  groups,  and  adjusting  for  it  did  not 
alter  the  reported  results. 
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(ISI)  and  obesity,  and  of  (B)  adjusting  for  plasma  triglyceride  on  association  between 
IMCL  and  obesity,  in  men  by  ethnic  group 
European  South  Asian 
ßa  se  p  pa  se  p 
(A)  insulin  sensitivity  index  as  dependent  variable 
Slope  of  relationship  with  WHR 
age,  whr  -1.01  0.44  0.034  -0.74  0.30  0.025 
age,  whr,  IMCL*  -0.72  0.61  0.256  -0.80  0.32  0.022 
Slope  of  relationship  with  VFA 
age,  VFA*  -0.79  0.25  0.005  -0.41  0.25  0.128 
age,  VFA*,  IMCL*  -0.68  0.29  0.035  -0.42  0.26  0.129 
Slope  of  relationship  with  percent  body  fat 
age,  %fat  -1.52  0.33  <0.001  -0.04  0.19  0.909 
age,  %fat,  IMCL*  -1.38  0.34  0.001  -0.06  0.34  0.873 
(B)  IMCL  as  dependent  variable 
Slope  of  relationship  with  WHR 
age,  whr  0.38  0.10  0.001  0.25  0.23  0.299 
age,  whr,  plasma  fasting  TG*  0.36  0.11  0.006  0.32  0.26  0.242 
Slope  of  relationship  with  VFA 
age,  VFA*  0.19  0.07  0.019  0.11  0.18  0.543 
age,  VFA*,  plasma  fasting  TG*  0.23  0.10  0.043  0.09  0.19  0.636 
Slope  of  relationship  with  percent  body  fat 
age,  %fat  0.18  0.13  0.174  0.28  0.20  0.188 
age,  %fat,  plasma  fasting  TG*  0.11  0.14  0.441  0.17  0.24  0.484 
aß=  standardised  regression  coefficient;  *:  log  (natural  transformed)  values  used;  TG  = 
triglyceride 
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1.  South  Asian  men  compared  with  European  men  had  higher  mean  percent  fat  and  lower 
insulin  sensitivity. 
2.  Mean  intramyocellular  lipid  content  was  higher  in  South  Asian  men  than  in  European 
men. 
3.  In  Europeans  IMCL  was  strongly  correlated  with  percent  fat,  WHR,  visceral  fat  and 
insulin  sensitivity.  In  South  Asians  IMCL  was  not  significantly  related  to  insulin 
sensitivity  or  obesity,  and  the  strongest  associations  of  insulin  sensitivity  were  with 
plasma  triglyceride  (fasting  and  8h)  and  WHR. 
4.  In  Europeans  the  relation  between  IMCL  and  ISI  was  independent  of  plasma  glucose, 
insulin  or  lipid  levels,  but  not  independent  of  generalised  or  central  obesity. 
7.3.  Discussion  of  results 
Our  findings  in  Europeans  are  consistent  with  the  hypothesis  that  IMCL  content  modulates 
insulin  sensitivity.  We  found,  like  others208,  that  the  relation  in  Europeans  between  ISI  and 
IMCL  was  independent  of  fasting  and  2h  glucose,  insulin  and  NEFA,  and  triglyceride 
level.  However,  in  contrast  to  other  studies  where  insulin  sensitivity  was  correlated  with 
IMCL  independently  of  BMI  in  Europeans208  and  independently  of  BMI,  percent  fat  or 
waist/thigh  ratio  in  Pima  Indians202,  we  found  that  the  relation  between  ISI  and  IMCL  was 
not  independent  of  obesity  and  was  not  stronger  than  the  relation  between  ISI  and 
obesity209.  This  was  the  case  whether  we  used  creatine  or  water  as  the  internal  standard  in 
'H-NMR.  The  reason  for  these  differences  is  unclear,  but  it  is  unlikely  to  be  related  to 
data  acquisition  given  that  others  used  similar  localisation  techniques  and  have  reported 
similar  reproducibility208'209  Likely  possibilities  may  relate  to  differences  in  the  population 
sample,  and  the  larger  sample  size  of  our  study. 
Although  in  South  Asian  men  IMCL  content  was  higher  than  in  Europeans,  IMCL  was  not 
significantly  related  to  ISI  or  indices  of  obesity.  The  strongest  associations  of  ISI  were  with 
WHR  and  plasma  triglyceride  (fasting  and  8h)  in  South  Asians.  These  results  are  not 
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associations  of  central  obesity  and  raised  triglyceride  with  insulin  resistance  in  South 
Asians.  Phillips  et  a?  °°  have  shown  that  IMCL  measured  in  biopsy  specimens  of 
gastrocnemius  muscle  was  inversely  associated  with  glycogen  synthase  (an  insulin 
regulated  enzyme  that  is  rate  limiting  for  insulin  action  in  muscle),  but  not  with  insulin 
sensitivity  measured  by  the  short  insulin  tolerance  test.  However  in  our  study  we  found  an 
association  between  IMCL  and  ISI  in  Europeans  but  not  in  South  Asians.  Other 
physiological  mechanisms  may  mediate  impairment  of  insulin  sensitivity  in  South  Asians. 
For  instance  increased  lipolysis  of  IMCL  stores  (modulated  by  hormone-sensitive  lipase)  or 
increased  supply  of  triglyceride  from  plasma  could  cause  insulin  resistance.  The  strong 
correlation  between  plasma  triglyceride  and  ISI  observed  in  South  Asians  in  this  study  is 
consistent  with  this.  This  may  also  account  for  our  failure  to  detect  the  usual  association 
of  insulin  resistance  with  obesity  in  South  Asians  in  this  small  sample. 
We  would  expect  to  see  a  close  relationship  between  central  obesity  and  IMCL  content 
because  VLDL  triglyceride  is  likely  to  be  one  of  the  main  sources  of  triglyceride  in 
muscle,  and  the  main  substrate  for  hepatic  VLDL  triglyceride  production  is  NEFA  derived 
from  lipolysis  of  fat  stores  drained  by  the  portal  veina6,  as,  235  Because  lipolysis  of  lipid 
stores  in  skeletal  muscle  is  not  easily  suppressed  by  insulin,  the  NEFA  derived  from 
triglyceride  stores  would  compete  with  glucose  for  oxidative  metabolism  and  reduce 
insulin-mediated  glucose  uptake  via  the  glucose  fatty-acid  cycle. 
In  summary,  we  found  a  negative  correlation  between  IMCL  and  insulin  sensitivity  in 
Europeans  but  not  in  South  Asians.  To  establish  definitively  whether  insulin  resistance 
depends  upon  muscle  cell  triglyceride  stores  will  require  experimental  studies  of  the  effects 
of  dietary  and  pharmacological  interventions  that  alter  muscle  triglyceride  stores  on 
insulin-mediated  glucose  uptake.  This  could  open  up  possibilities  for  developing  new 
measures  to  prevent  and  control  insulin  resistance  and  NIDDM. 
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bio-electrical  impedance  analysis  to 
measure  percent  body  fat 
8.1.  Presentation  of  results 
8.1.1.  Validation  of  the  use  of  bio-electrical  impedance  (BIA) 
The  correlation  coefficients  of  the  relation  between  percent  fat  measured  by  DEXA  scan 
and  percent  fat  measured  by  BIA  in  each  of  the  4  sex  and  ethnic  groups  were  as  follows 
(Table  18)  : 
Table  18:  Product  moment  correlation  coefficients  (r)  between  %fat  by  DEXA  and 
BIA 
n  r  p  value 
South  Asian  men  26  0.77  <0.0001 
South  Asian  women  30  0.85  <0.0001 
European  men  31  0.86  <0.0001 
European  women  31  0.81  <0.0001 
The  relationship  between  BIA  and  DEXA  measurements  of  percent  fat  in  European  and 
South  Asian  men  and  women  is  shown  in  Figure  16  and  Figure  17  respectively. 
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Figure  16:  Relationship  between  measurement  of  %fat  by  DEXA  and  bio-electrical 
impedance  analysis  in  European  and  South  Asian  men 
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Figure  17:  Relationship  between  measurement  of  %fat  by  DEXA  and  bio-electrical 
impedance  analysis  in  European  and  South  Asian  women 
Validation  of  BIA  to  measure  %  body  fat  8-118 The  agreement  between  the  two  methods  (DEXA  and  BIA)  of  measuring  percent  fat  was 
calculated  using  the  method  of  Bland  and  Altman239.  The  results  of  this  calculation  which 
yielded  the  lower  and  upper  limits  of  agreement  between  the  two  methods  are  shown  in 
Table  19. 
Table  19:  Agreement  between  the  DEXA  and  BIA  measures  of  %fat 
Group  N  Mean  of 
differences 
sd  of 
differences 
Agreement: 
lower  limit 
Agreement: 
upper  limit 
All  South  Asians  56  2.43  2.99  -3.56  8.42 
All  Europeans  62  1.57  3.12  -4.67  7.81 
S.  Asian  men  26  1.90  3.18  -4.47  8.26 
S.  Asian  women  30  2.89  2.82  -2.75  8.53 
European  men  31  0.86  2.98  -5.11  6.82 
European  women  31  2.28  3.25  -4.23  8.79 
8.1.2.  Reproducibility  of  BIA 
Additionally  in  87  people  we  were  also  able  to  repeat  the  BIA  measurement  of  percent  fat 
during  the  visit  for  DEXA  scan.  There  was  very  strong  correlation  between  percent  fat 
measured  at  the  two  separate  visits  (Table  20). 
Table  20:  Product  moment  correlation  coefficients  (r)  between  %fat  at  two  separate 
visits  (measured  by  BIA) 
n  r  p  value 
South  Asian  men  22  0.91  <0.0001 
South  Asian  women  21  0.98  <0.0001 
European  men  23  0.96  <0.0001 
European  women  21  0.73  0.0002 
The  strong  correlation  between  the  two  visits  for  BIA-percent  fat  measurement  in 
European  and  South  Asian  men  and  women  is  shown  in  Figure  18  and  Figure  19 
respectively. 
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Figure  18:  Relationship  between  two  repeat  measurements  of  %fat  by  bio-electrical 
impedance  analysis  in  European  and  South  Asian  men 
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Figure  19:  Relationship  between  two  repeat  measurements  of  %fat  by  bio-electrical 
impedance  analysis  in  European  and  South  Asian  women 
Validation  of  BIA  to  measure  %  body  fat  8-120 To  assess  the  reproducibility  of  percent  fat  measurement  by  BIA,  the  coefficient  of 
variation  for  between-visits  was  calculated  for  each  group,  using  the  method  of  Bland24o 
The  coefficients  of  variation  for  two  repeat  measurements  of  percent  fat  by  BIA  in  87 
subjects  were  as  follows:  5.0%  in  South  Asian  men,  2.0%  in  South  Asian  women,  3.9%  in 
European  men  and  8.0%  in  European  women.  The  repeatability  coefficients  as  defined  by 
the  British  Standards  Institution  240,241  were  3.3  and  2.0  in  South  Asian  men  and  women 
respectively,  and  2.5  and  7.2  in  European  men  and  women  respectively.  The  reliability 
coefficient  represents  the  2x  sd  (of  differences),  the  value  below  which  the  difference 
between  two  measurements  will  lie  with  a  probability  of  0.9524' 
. 
8.2.  Summary  of  results 
We  have  shown  that  BIA  is  a  valid  and  reliable  (reproducible)  method  for  measuring 
percent  body  fat  in  both  South  Asians  and  Europeans.  We  have  validated  the  use  of  BIA 
against  DEXA  scan. 
8.3.  Discussion  of  results 
BIA  is  now  an  accepted  method  for  measuring  percent  body  fat.  Although  single 
frequency  BIA  has  been  validated  against  DEXA  for  use  in  people  of  European 
descent  ......  5,  its  validity  against  DEXA  scans  in  South  Asians  has  never  previously  been 
established. 
Since  the  design  and  conduct  of  the  current  study,  one  group  from  India  has  published 
results  for  the  validation  of  BIA  against  hydrodensitometry242.  They  found  that  BIA 
estimates  of  percent  fat  were  higher  than  those  from  hydrodensitometry,  which  they  argued 
could  be  attributable  to  the  use  of  inappropriate  regression  equations  derived  from  studies 
in  people  of  European  descent.  They  developed  their  own  predictive  equation  for  the 
derivation  of  fat-free  mass,  using  the  variables  of  height2/impedance  and  fat  free  mass  by 
under-water  weighing.  The  use  of  this  equation  in  BIA  gave  good  agreement  between  BIA 
and  hydrodensitometry  method.  We  were  unable  to  do  this  as  the  company  that 
Validation  of  BIA  to  measure  %  body  fat  8-121 manufactures  the  Bodystat  impedance  meters  was  unwilling  to  release  the  components  of 
the  equations  it  uses  in  computing  the  final  formula  for  percent  body  fat  or  for  impedance. 
Single  frequency  bio-electrical  impedance  analysis  can  be  used  as  an  epidemiological 
"tool"  to  measure  percent  fat  in  studies  of  South  Asians.  It  offers  a  cheap,  quick  and 
acceptable  method  to  measure  percent  fat,  which  can  be  performed  at  the  bedside. 
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Validation  of  BIA  to  measure  %  body  fat CHAPTER  9:  Relation  of  inflammation  with  risk  for  CHD 
During  the  course  of  this  study  evidence  started  to  emerge  for  a  possible  link  between 
markers  of  inflammation  (C-reactive  protein  level)  and  CHD.  Opportunistically  a 
collaboration  also  became  possible  (Appendix)  which  enabled  measurement  of  C-reactive 
protein  (CRP)  on  frozen  plasma  from  this  study.  Spare  aliquots  of  plasma  that  were  kept 
frozen  at  -70°C  from  the  visit  for  fat  tolerance  test  (n=113)  were  used  for  this 
measurement.  The  background  and  rationale  to  this  measurement  is  explained  below. 
9.1.  The  evidence  for  a  link  between  inflammation  and  CHD 
C-reactive  protein  (CRP)  is  an  acute  phase  reactant  which  is  a  measurable  marker  of 
inflammation  in  the  body.  There  is  a  growing  body  of  evidence  that  low  grade  chronic 
inflammation  may  be  associated  with  the  development  of  cardiovascular  disease241-246  A 
summary  of  published  studies  examining  the  association  between  CRP  and cardiovascular 
disease  has  recently  been  given  by  Lagrand  et  a1122.  Mild  elevations  of  CRP  concentrations 
even  when  within  the  clinically  'normal'  range  are  predictive  of  future  cardiovascular 
events.  This  association  holds  true  for  individuals  with  multiple  risk  factors247,  those  with 
stable  or  unstable  angina245,  and  in  men  with  favourable  coronary  risk  factor  profiles243 
More  recent  data  also  link  plasma  CRP  concentrations  to  the  risk  of  developing  peripheral 
arterial  disease248.  New  evidence  published  from  the  ARIC  study  (Atherosclerosis  Risk  in 
Communities)  has  also  linked  inflammation  to  the  development  of  diabetes  mellitus,  in  a 
population  free  of  diabetes  at  baseline  249 
Whether  inflammation  also  contributes  to  this  increased  CHD  risk  in  South  Asians  is  not 
known  as  no  studies  comparing  CRP  concentrations  in  South  Asians  and  other  groups  have 
been  published.  The  only  inflammatory  marker  to  have  been  studied  in  an  ethnic 
comparison  so  far  is  plasma  fibrinogen,  which  has  been  found  to  be  no  higher  in  South 
Asians  than  in  Europeans28'33.  It  is  certainly  plausible  that  inflammatory  markers  such  as 
CRP  might  be  elevated  in  South  Asians  compared  with  Europeans,  given  the  greater 
degree  of  total  fat  mass  in  South  Asians,  and  the  suggested  link  between  obesity  and  CRP 
level.  The  latter  is  thought  to  occur  through  increased  production  of  CRP  by  hepatocytes 
Inflammation  &  CHD  risk 
9-123 in  response  to  elevated  interleukin-6  cytokine,  which  in  turn  is  elevated  through  increased 
production  of  TNF-alpha250,  which  is  overproduced  by  adipocytes2s' 
Thus  we  measured  CRP  levels  with  the  following  aims:  to  test  (i)  whether  CRP 
concentrations  were  elevated  in  South  Asians  compared  with  Europeans,  (ii)  whether  CRP 
was  associated  with  insulin  sensitivity  measured  directly  by  the  short  insulin  test,  and 
indirectly  by  insulin  level,  and  (iii)  whether  there  was  an  association  between  CRP  level 
and  body  fat  distribution  and  lipid  levels  (fasting  and  postprandial)  in  the  two  ethnic 
groups. 
9.2.  Measurement  of  plasma  CRP 
C-reactive  protein  was  measured  using  a  sensitive  double  antibody  sandwich  ELISA  with 
rabbit  antihuman  C-reactive  protein  and  peroxidase  conjugated  rabbit  anti-human 
C-reactive  protein.  The  assay  was  linear  up  to  5mg/l  and  logarithmic  thereafter.  The 
interassay  and  intra-assay  coefficients  of  variation  were  less  than  10%  across  the  range  of 
measured  results252. 
9.3.  Presentation  of  results 
Among  women  median  CRP  level  was  higher  among  South  Asians  [1.35  mg/1, 
(interquartile  range  0.72,3.04)]  vs.  Europeans  [0.70  mg/1,  (0.41,1.70)],  p=0.050.  This 
was  despite  the  absence  of  any  smokers  among  South  Asian  women.  Although  the  median 
CRP  level  was  about  15%  higher  in  South  Asian  men  [1.07  mg/1,  (0.76,1.50)]  compared 
with  European  men  [0.92  mg/1,  (0.34,1.61)],  this  was  not  statistically  significantly 
different.  This  is  reflective  of  the  lack  of  power  to  examine  sub-group  differences  in  this 
study  with  relatively  small  numbers.  Only  3  people  had  CRP  level  greater  than  10  mg/1, 
the  cut  point  used  in  clinical  practice  to  identify  inflammation.  There  was  a  trend  towards 
a  significant  ethnic  difference  in  the  CRP  level  in  analysis  adjusted  for  age,  sex  and 
smoking  [ß=0.45,  se=0.25,  p=0.076]. 
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between  CRP  level  and  its  determinants  are  shown  in  Table  21.  CRP  concentrations  were 
generally  more  strongly  associated  with  central  obesity  in  South  Asians  but  with  both 
overall  obesity  and  central  obesity  in  Europeans.  Social  class  was  not  significantly 
associated  with  CRP  in  either  ethnic  group  in  this  study. 
Table  21:  Determinants  of  C  reactive  protein  concentration  among  Europeans  and 
South  Asians. 
Europeans  South  Asians 
ß  se  p  se  p 
Age  (years)a  0.35  0.18  0.053  0.21  0.12  0.087 
BMI  (kg/m2)  0.49  0.17  0.005  0.26  0.13  0.058 
Percent  fat  0.55  0.24  0.026  0.34  0.20  0.096 
Waist/hip  ratio  0.37  0.26  NS  0.60  0.15  <0.001 
Waist  girth  (cm)  0.49  0.21  0.027  0.44  0.13  0.002 
Visceral  fat  area*  (cm2)  0.51  0.20  0.013  0.41  0.14  0.004 
Exact  p  values  are  given  for  p<=0.1;  *:  log  (In)  transformed.  a  :  adjusted  only  for  sex  &  smoking 
Age,  sex  and  smoking  adjusted  standardised  regression  coefficients  are  given  for  log  (natural) 
C  reactive  protein  as  the  dependent  variable  (per  one  standard  deviation  increase  in 
explanatory  variable). 
The  association  of  CHD  risk  factors  with  CRP  concentration  as  the  independent  variable  is 
shown  in  Table  22.  In  multiple  regression  analyses  adjusted  for  age,  sex  and  smoking, 
CRP  level  was  significantly  associated  with  insulin  (Oh  and  2h)  and  triglyceride  (Oh  and 
8h)  in  both  ethnic  groups,  and  also  with  HDL-cholesterol  (negative)  and  Oh  glucose  in 
Europeans,  but  not  with  ISI  in  either  group.  After  additionally  adjusting  for  percent  fat, 
there  remained  an  independent  association  of  CRP  level  with  fasting  glucose  and  insulin 
and  HDL-cholesterol  in  Europeans,  and  with  triglyceride  level  in  South  Asians. 
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Europeans  and  South  Asians 
Europeans  South  Asians 
Dependent  variable  ß  se  p  ß  se  p 
ISI  (%/min)  a  -0.11  0.14  NS  -0.07  0.18  NS 
b  -0.04  0.15  NS  0.00  0.18  NS 
Fasting  insulin*  (µu/ml)  a  0.14  0.05  0.005  0.12  0.10  NS 
b  0.11  0.05  0.023  0.07  0.10  NS 
2h  insulin*  (µu/ml)  a  0.13  0.09  NS  0.33  0.15  0.029 
b  0.09  0.09  NS  0.26  0.14  0.085 
Fasting  glucose  (mmol/I)  a  0.10  0.04  0.018  0.03  0.08  NS 
b  0.09  0.04  0.017  0.02  0.09  NS 
2h  glucose  (mmol/1)  a  0.11  0.11  NS  0.38  0.25  NS 
b  0.10  0.11  NS  0.31  0.25  NS 
Fasting  triglyceride*  (mmol/I)  a  0.07  0.05  NS  0.19  0.08  0.025 
b  0.05  0.05  NS  0.16  0.08  0.054 
8h  triglyceride*  (mmol/i)  a  0.12  0.06  0.056  0.23  0.11  0.035 
b  0.11  0.07  NS  =  0.19  0.11  0.098 
Total  cholesterol  (mmol/l)  a  0.10  0.11  NS  0.15  0.14  NS 
b  0.13  0.12  NS  0.17  0.14  NS 
HDL-cholesterol*  (mmol/I)  a  -0.07  0.03  0.013  0.01  0.03  NS 
b  -0.06  0.03  0.044  0.02  0.04  NS 
log  (natural)  CRP  as  the  independent  variable  with  each  measured  cardiovascular  risk  factor  as 
the  dependent  variable  in  turn.  a=  adjusted  for  age,  sex  and  smoking;  b=  adjusted  for  age, 
sex,  smoking  and  percent  fat;  *=  log  (natural)  transformed  values  of  these  variables  were  used. 
To  account  for  potential  residual  confounding  when  adjusting  for  the  effect  of  smoking  we 
repeated  the  analyses  among  ever-smokers  and  never-smokers  separately.  In  analyses 
adjusted  for  age  and  sex,  among  ever-smokers  (n=41)  there  was  no  significant  ethnic 
difference  in  CRP  level  [P=0.06,  se=0.55,  p=0.913].  In  similar  analyses  among  never- 
smokers  (n=72)  South  Asians  had  higher  CRP  levels  than  Europeans  [1  for  ethnic 
difference  0.60,  se=0.28,  p=0.039].  With  additional  adjustment  for  triglyceride  level  (0 
and  8h)  and  BMI  the  ethnic  difference  persisted  [P=0.62,  se=0.26,  p=0.021].  The 
ethnic  difference  was  no  longer  statistically  significant  when  further  adjustment  was  made 
for  percent  fat  [ß=0.44,  se=0.27,  p=0.115]  or  for  VFA  [ß=0.42,  se=0.27,  p=0.121]. 
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In  this  study  healthy  South  Asian  women  and  all  never-smokers  (men  and  women 
combined)  had  higher  CRP  levels  than  Europeans.  Among  never-smokers  the  higher  CRP 
levels  in  South  Asians  vs.  Europeans  persisted  after  adjusting  for  age,  sex,  BMI  and 
triglyceride  level. 
It  is  interesting  that  we  found  a  significant  ethnic  difference  in  CRP  level  among  never- 
smokers  but  not  in  ever-smokers.  Our  finding  is  at  variance  with  that  of  one  group  who 
reported  that  the  association  between  CRP  level  and  increased  risk  for  CHD  death  in  men 
was  limited  to  smokers24',  and  that  lifetime  smoking  exposure  affects  the  association  of 
CRP  level  to  cardiovascular  disease  risk  factors253.  However,  our  finding  is  in  agreement 
with  recent  results  from  (i)  IRAS  (Insulin  Resistance  Atherosclerosis  Study)  where  in  1560 
participants  there  was  no  significant  relationship  between  smoking  status  and  CRP  level254, 
and  (ii)  the  Honolulu  Heart  Program  cohort,  where  baseline  CRP  level  was  significantly 
related  to  the  incidence  of  thromboembolic  stroke  in  Japanese  American  non-diabetic  never 
smokers,  but  not  in  current  or  past  smokers255.  We  speculate  that  our  finding  of  a 
significant  ethnic  difference  in  CRP  level  in  never  smokers  is  probably  because  most 
(89%)  of  the  South  Asians  in  this  study  were  never  smokers,  but  also  raises  the  possibility 
that  it  is  among  the  healthy  non-smokers  that  the  ethnic  difference  in  inflammatory  burden 
is  most  extreme.  A  high  proportion  of  South  Asians  at  high  risk  for  CHD  are  non- 
smokers. 
The  raised  CRP  concentrations  in  both  South  Asians  and  Europeans  were  strongly 
associated  with  obesity  (including  central  obesity),  raised  insulin  levels  and  raised 
triglyceride  concentration,  and  additionally  with  raised  glucose  levels  and  low  HDL- 
cholesterol  in  Europeans,  suggesting  an  association  of  CRP  level  with  features  of  the 
metabolic  syndrome.  However,  in  both  groups  there  was  no  direct  association  between 
CRP  and  insulin  sensitivity  index  measured  directly.  As  CRP  levels  are  related  to  insulin 
levels  and  to  obesity,  it  is  surprising  that  they  are  not  also  related  to  insulin  sensitivity 
index  measured  by  the  short  insulin  tolerance  test  in  the  current  study.  The  reasons  for 
differences  between  ISI  and  insulin  level  have  been  discussed  in  section  10.3.6.1. 
The  association  of  metabolic  disturbances  with  raised  C-reactive  protein  could  reflect  a 
higher  inflammatory  burden  associated  with  increased  atherosclerosis,  or  direct  metabolic 
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metabolic  effects  on  inflammation  and  acute  phase  response.  It  has  been  shown  that 
adipocytes  from  obese  humans  overproduce  tumour  necrosis  factor-alpha  (TNF-alpha) 
mRNA  and  protein25'  ,  and  TNF-alpha  is  a  potent  inducer  of  interleukin-6  (IL-6)  production 
by  various  cells250,  which  in  turn  causes  inflammation. 
A  previous  study  has  shown  a  correlation  between  plasma  fasting  triglyceride  concentration 
and  CRP  leve1257.  We  have  found  an  association  between  both  fasting  as  well  as  8h 
triglyceride  and  CRP  level  in  this  study,  suggesting  a  link  between  inflammation  and 
postprandial  fat  clearance.  This  may  be  a  direct  effect  of  cytokines  (IL-6  or  TNF-alpha) 
on  the  activity  of  lipoprotein  lipase218'259  (the  endothelial  enzyme  responsible  for  catabolism 
of  triglyceride-rich  lipoproteins),  or  alternatively  may  reflect  the  association  of  both  factors 
with  insulin  resistance.  CRP  levels  are  correlated  with  PAI-1  levels260,  which  are  also 
strongly  related  to  central  obesity,  insulin  resistance  and  lipid  disturbances.  It  has  been 
shown  that  PAI-1  synthesis  in  vitro  is  stimulated  by  raised  NEFA  levels26 
. 
If  this  applies 
to  CRP  also,  raised  (intracellular  or  extracellular)  NEFA  levels  could  underlie  the 
associations  of  CRP  with  triglyceride,  insulin  and  central  obesity.  The  association  of  CRP 
level  with  plasma  lipids  persisted  in  each  of  the  two  ethnic  groups  after  adjustment  for 
percent  body  fat,  but  the  ethnic  difference  in  CRP  level  was  no  longer  significant  when 
adjustment  was  made  for  percent  body  fat  or  for  VFA.  This  may  suggest  that  a  higher  fat 
mass  level,  in  association  with  greater  visceral  fat,  is  directly  responsible  for  an  increased 
inflammatory  burden  in  South  Asians. 
CRP  level  is  correlated  with  the  extent  of  coronary  disease  in  patients  undergoing 
angiography  and  predicts  the  progression  of  coronary  atherosclerosis262.  It  is  not  known 
whether  inflammation  (indexed  by  raised  CRP  level)  promotes  atherogenesis,  or  whether 
atheroma  itself  causes  raised  CRP  levels.  But,  whatever  the  mechanism,  if  our 
observations  are  confirmed  then  there  may  be  implications  for  preventive  strategies. 
Ridker  et  al  243  demonstrated  that  the  efficacy  of  aspirin  in  reducing  the  incidence  of 
myocardial  infarction  appears  to  be  directly  related  to  the  level  of  CRP.  If  elevated  levels 
of  CRP  account  for  some  of  the  excess  risk  of  CHD  in  South  Asians  compared  with  other 
groups  in  prospective  studies,  a  possible  next  step  might  be  to  evaluate  the  efficacy  of 
aspirin  therapy  in  reducing  the  high  CHD  risk  in  this  group. 
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10.1.  Main  findings  of  the  study 
This  study  has  shown  ethnic  differences  between  South  Asians  and  Europeans  in  body  fat 
distribution,  insulin  sensitivity,  intramyocellular  lipid  content,  lipid  metabolism  and 
inflammation,  and  the  inter-relationships  between  them.  Many  of  the  findings  have  been 
shown  for  the  first  time  in  South  Asians.  The  main  findings  from  different  parts  of  the 
study,  in  relation  to  the  hypotheses  we  had  on  an  a  priori  basis,  can  be  summarised  as 
following: 
"  South  Asians  had  more  total  body  fat  than  Europeans  at  a  given  level  of  BMI 
(significantly  so  in  women  in  this  study);  and  at  a  given  level  of  body  fat,  the 
distribution  of  this  fat  was  located  more  centrally  in  South  Asians  than  in  Europeans. 
In  addition  the  use  of  bio-electrical  impedance  analysis  as  a  field  method  for 
quantifying  total  percent  body  fat  in  South  Asians  was  validated  against  DEXA  scan 
measurement,  and  its  reproducibility  established.  This  provides  a  basis  for  using  this 
quick,  safe  and  cheap  method  in  future  studies.  There  are  also  implications  for  public 
health  -  criteria  for  "ideal  weight"  that  are  based  on  weight-for-height  in  European 
populations  may  be  inappropriate  for  South  Asian  populations  where  for  any  given 
BMI  average  percent  body  fat  is  higher  than  in  Europeans. 
"  As  the  level  of  central  obesity  increased,  levels  of  insulin  resistance  (as  measured  by 
insulin  concentration)  increased  more  steeply  in  South  Asians  than  in  Europeans.  Thus 
we  found  that  the  slopes  of  the  regression  lines  for  the  association  between  fasting  or 
2h  insulin  and  central  obesity  were  significantly  steeper  in  South  Asians  than  in 
Europeans.  This  is  in  keeping  with  our  original  hypothesis  that  the  tendency  to  insulin 
resistance  in  South  Asians  increases  at  higher  levels  of  central  adiposity.  Thus  lean 
individuals  of  either  ethnic  group  are  insulin  sensitive,  but  as  central  obesity  increases 
South  Asians  become  more  insulin  resistant  than  Europeans.  However  the  slopes  of 
the  regression  lines  for  the  association  between  insulin  sensitivity  (as  measured  by  the 
short  insulin  tolerance  test)  and  obesity  (both  generalised  and  central  obesity)  were  not 
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in  the  two  methods  of  measuring  insulin  resistance,  and  is  discussed  further  below 
(section  10.3.6.1). 
"  The  hypothesis  was  not  confirmed  that  visceral  obesity  would  account  for  the  lower 
insulin  sensitivity  in  South  Asians  compared  with  Europeans.  Visceral  obesity  had  a 
strong  and  independent  association  with  insulin  sensitivity  in  both  Europeans  and  South 
Asians,  but  it  failed  to  explain  the  ethnic  difference  in  insulin  sensitivity.  We  found 
that  the  proportion  of  the  ethnic  difference  in  insulin  sensitivity  index  that  was 
accounted  for  by  adjusting  for  visceral  fat  area  alone  was  27%,  adjusting  for  visceral 
fat  area  as  well  as  percent  body  fat  was  34%,  and  adjusting  for  obesity  (visceral  fat 
area  and  percent  fat)  as  well  as  fasting  and  postprandial  triglyceride  concentration  was 
42%.  No  more  than  40  %  of  the  ethnic  difference  in  each  of  fasting  and  2h  insulin  was 
accounted  for  by  central  obesity  or  obesity  plus  triglyceride  concentration.  We 
suggested  that  lipid  disturbances  (in  the  fasting  or  postprandial  state)  may  be  the 
primary  defect  underlying  the  higher  insulin  resistance  in  this  group. 
0  The  hypothesis  that  South  Asians  would  have  higher  postprandial  triglyceride 
concentration  than  Europeans  was  not  substantiated  at  the  single  postprandial  time 
point  of  8h  at  which  triglyceride  level  was  measured  in  this  study.  We  did  however 
establish  that  an  elevated  postprandial  triglyceride  level  is  associated  with  component 
features  of  the  insulin  resistance  syndrome  in  all  groups. 
"  South  Asian  men  had  greater  intramyocellular  lipid  content  than  European  men.  In 
Europeans  there  was  a  strong  association  between  insulin  sensitivity,  central  obesity 
and  intramyocellular  lipid  content,  but  not  in  South  Asians.  Thus  the  findings  in 
Europeans  were  consistent  with  the  hypothesis  that  the  relation  between  insulin- 
mediated  glucose  uptake  and  central  obesity  is  mediated  through  triglyceride  stores  in 
skeletal  muscle.  However  this  was  not  demonstrated  in  South  Asians.  As  this 
technique  is  new  and  has  never  been  validated  in  South  Asians,  there  remain 
uncertainties  about  its  use  in  South  Asians. 
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C-reactive  protein  concentration  was  found  to  be  higher  in  South  Asians  than  Europeans, 
particularly  in  women  and  all  non-smokers,  and  it  was  associated  with  features  of  the 
insulin  resistance  syndrome  and  with  central  obesity  and  percent  fat,  as  well  as  triglyceride 
concentration  in  both  the  fasting  and  postprandial  state.  From  this  we  hypothesise  that 
inflammation  may  mediate  the  greater  insulin  resistance  seen  in  South  Asians,  and  also 
may  mediate  the  relation  between  insulin  resistance  and  CHD  in  South  Asians.  This 
hypothesis  would  need  to  be  tested  in  further  studies. 
Other  hypotheses  relate  to  measurement  issues. 
Firstly  we  hypothesise  that  measurement  of  insulin  concentration  is  more  effective  in 
studying  ethnic  differences  in  insulin  resistance  than  the  use  of  the  short  insulin  tolerance 
test  as  used  in  this  study.  We  have  found  that  measurement  of  insulin  resistance  by  the 
fasting  and  2h  insulin  concentration  showed  much  greater  ethnic  differences  than 
measurement  of  insulin  sensitivity  by  the  short  insulin  tolerance  test.  Additionally  with 
insulin  concentration  as  the  dependent  variable  the  slopes  of  the  relationship  with  central 
obesity  were  significantly  steeper  in  South  Asians  than  in  Europeans,  but  this  was  not  the 
case  when  the  insulin  sensitivity  index  was  the  dependent  variable.  This  subject  is 
discussed  in  greater  detail  below  (section  10.3.6.1). 
Secondly  we  hypothesise  that  in  epidemiological  studies,  including  those  of  a  metabolic 
nature,  use  of  anthropometric  measures  to  quantify  central  obesity  is  adequate,  and  no 
added  advantage  is  gained  by  measuring  visceral  fat  area  directly  by  CT  scan.  This  is 
based  on  the  following.  In  this  small  study  of  subjects  frequency  matched  on  BMI  we 
found  no  ethnic  difference  in  the  waist/hip  ratio  or  waist  circumference  in  either  men  or  in 
women,  but  visceral  fat  area  was  higher  among  South  Asians  compared  with  Europeans, 
and  significantly  so  in  women.  However  we  found  that  there  was  high  correlation  between 
both  waist/hip  ratio  and  waist  girth  with  visceral  fat  area  (see  section  6.1.2  for  results). 
We  also  found  that  whatever  associations  were  found  for  CT-derived  visceral  fat  area  with 
variables  of  interest  such  as  insulin  resistance  (insulin  sensitivity  index  or  insulin 
concentration),  intramyocellular  lipid  content,  triglyceride  concentration  or  C-reactive 
protein  concentration,  were  also  of  similar  magnitude  and  direction  for  anthropometrically 
derived  measures  of  central  obesity  (waist  girth  or  waist/hip  ratio).  Thus  the  use  of  a 
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degree  of  radiation  exposure  is  not  justified  on  the  basis  of  this  study. 
Although  hypotheses  have  been  generated  and  some  a  priori  hypotheses  have  been 
substantiated  or  rejected  by  this  study,  they  need  to  be  seen  in  the  light  of  the  many 
limitations  of  the  study.  These  limitations  relate  particularly  to  methodological  issues 
including  the  study  design  itself,  the  methods  employed  in  the  study  and  the  lack  of  pilot 
studies,  and  these  are  discussed  below. 
10.3.  Methodological  issues 
10.3.1.  Study  design 
A  cross-sectional  design  was  chosen  as  we  wanted  to  generate  hypotheses  about  the 
relation  between  obesity,  body  fat  pattern,  insulin  sensitivity,  postprandial  lipids  and 
intramyocellular  lipid  in  relation  to  ethnicity  in  a  preliminary  study.  This  is  the  first  study 
to  examine  these  relationships  in  detail.  We  chose  to  study  an  age  group  of  people  (40  to 
55  years)  who  were  young  enough  to  have  not  developed  chronic  illnesses  such  as  diabetes 
and  coronary  heart  disease.  To  avoid  the  influence  of  exogenous  oestrogens  on  insulin 
resistance  and  lipid  metabolism  in  women,  we  only  included  women  who  were  not  taking 
any  hormonal  preparations.  The  majority  of  the  women  included  were  premenopausal 
(section  6.1.1) 
. 
This  study  suffers  with  the  usual  limitations  of  cross-sectional  studies.  One  of  these  is  that 
the  status of  an  individual  with  respect  to  the  presence  or  absence  of  both  exposure  and 
disease  is  assessed  at  the  same  point  in  time.  Thus  it  is  difficult  to  distinguish  the  causal 
pathways,  and  to  know  the  temporal  sequence  of  events  (such  as  which  is  the  "chicken" 
and  which  is  the  "egg"  in  a  sequence  of  events).  However,  associations  can  still  be 
defined,  and  particularly  if  the  associations  are  strong  and  independent  of  other  effects, 
interpretation  can  be  made  based  on  biological  plausibility.  Thus  given  the  current  results 
(chapter  6)  it  is  possible  to  say  in  this  study  that  the  findings  are  consistent  with  the  idea 
that  primary  defect  in  South  Asians  is  something  to  do  with  lipid  metabolism. 
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disease  by  furnishing  a  "snapshot"  of  the  health  experience  of  the  study  population  at  a 
specified  time.  This  is  a  limitation  in  that  what  may  be  the  situation  at  one  time  point 
might  be  different  at  another  time  point.  However,  as  our  aim  was  to  compare  the  ethnic 
differences  in  characteristics  such  as  response  to  a  fat  meal  and  to  a  bolus  of  insulin 
injection,  this  is  a  valid  study  design.  Case  control  studies  also  suffer  from  the  same  draw- 
backs.  Prospective  studies  in  the  metabolic  field  are  difficult  to  design  and  perform 
because  of  the  dynamic  nature  of  the  metabolic  variables,  and  are  often  not  feasible. 
We  have  found  ethnic  differences  in  obesity,  body  fat  pattern,  insulin  sensitivity,  lipid 
levels  and  intramyocellular  lipid  content  in  this  cross-sectional  study.  Although  it  is 
difficult  to  tease  out  the  temporal  sequence  of  events,  hypotheses  can  be  generated,  which 
can  be  tested  in  future,  better  designed  studies.  Some  suggestions  for  these  are  given  in 
chapter  11. 
10.3.2.  Subject  recruitment 
The  selection  of  participants  in  this  study  was  through  inviting  randomly  eligible  healthy 
people  registered  with  general  practitioners.  A  total  of  1638  invitations  were  sent  out  and 
351  people  responded  (22%).  Of  these,  210  were  eligible  for  participating,  thus 
representing  13%  of  those  invited.  We  actually  only  invited  143  of  those  eligible,  because 
mainly  of  frequency  matching  on  BMI,  and  because  a  larger  number  were  not  needed 
according  to  our  sample  size  calculations.  Thus  9%  of  the  original  invitees  attended  for 
the  first  screening  visit.  A  response  rate  of  22%  and  a  participation  rate  of  9%  is  very 
small,  but  is  understandable  given  the  very  involved  and  invasive  nature  of  a  study  with 
multiple  visits,  which  was  clearly  explained  in  detail  as  part  of  the  original  invitation. 
Most  studies  of  a  metabolic  nature  often  recruit  volunteers  through  advertisements  in  the 
media  because  of  the  expected  low  response  rate  from  healthy  subjects  registered  with 
family  practitioners.  We  chose  not  to  do  that  to  make  an  attempt  to  draw  our  study  sample 
from  randomly  eligible  people  who  represented  a  cross-section  of  the  population  residing 
in  the  geographical  area  of  the  study. 
We  might  speculate  that  the  motivation  for  participating  in  the  study  might  have  been 
because  of  family  history  of  diabetes  or  CHD.  We  did  find  a  high  prevalence  of  family 
history  for  CHD  that  was  not  different  in  the  two  groups.  We  also  found  a  high 
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than  in  Europeans  (though  this  did  not  reach  statistical  significance).  Although  not 
formally  recorded,  it  was  indicated  to  the  registrant  by  some  participants  that  their 
motivation  to  participate  was  that  they  might  get  a  "full  check  up"  and  might  get  advice  for 
healthy  living,  and  find  out  if  "anything  was  wrong  with  them".  Some  also  said  they  just 
wanted  to  help  with  medical  research  because  it  is  "very  worthwhile". 
We  do  not  have  detailed  information  available  about  the  non-responders,  except  that  they 
were  healthy  according  to  their  doctor's  records.  To  assess  seriously  if  there  were 
differences  between  the  participants  and  non  participants,  one  could  send  out 
questionnaires  asking  about  family  history,  for  example,  or  for  reasons  for  participating  or 
not.  However  it  was  not  felt  necessary  to  do  that  in  the  current  metabolic  study.  Response 
rate  could  have  been  increased  by  following  up  the  first  invitation  letter  with  a  second  one, 
or  with  a  phone  call  or  a  visit.  However,  given  the  invasive  and  involved  nature  of  the 
study,  it  was  not  considered  ethical  to  "pressurise"  people  to  take  part.  Selecting 
participants  in  this  manner,  particularly  for  a  metabolic  study,  does  not  invalidate  the 
findings,  but  may  limit  their  generalisability.  Since  our  aim  was  to  compare  the  results  for 
the  two  ethnic  groups,  this  is  particularly  the  case. 
Three  of  the  four  general  practices  whose  lists  were  used  for  the  initial  mailshots  had 
previously  been  involved  in  research  studies  in  collaboration  with  the  London  School  of 
Hygiene  and  Tropical  Medicine.  These  practices  may  be  above  average  in  Southall  and 
Greenford  with  respect  to  the  services  they  offer  patients  and  their  organisational 
efficiency.  This  may  in  turn  be  reflected  in  the  readiness  of  the  responders  to  participate 
in  such  a  study.  Again,  these  factors  do  not  undermine  the  validity  of  the  results  but  may 
affect  their  generalisability. 
10.3.3.  Adverse  events 
The  main  adverse  event  was  that  of  a  chemical  phlebitis  following  the  injection  of  50% 
dextrose  solution  to  terminate  the  SITT  as  mentioned  in  section  5.5.4.  The  precaution  of 
giving  the  injection  slowly  and  of  using  plenty  of  saline  flush,  combined  with  raising  the 
arm  after  the  flush  minimised  such  incidents  in  anyone  who  complained  of  an  "aching"  or 
"burning"  sensation  in  the  receiving  arm. 
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Of  the  143  people  who  were  screened  there  were  11  not  eligible  to  proceed  and  12  people 
withdrew,  leaving  a  total  of  120  people  who  proceeded  with  the  rest  of  the  study  (see 
section  5.5.6).  Among  those  who  withdrew  the  reasons  given  were  mainly  practical  ones 
(section  5.5.6)  except  for  2  people  who  felt  the  tests  were  too  invasive.  This  actually  left 
us  with  our  target  number  of  120  people  for  the  study.  Because  of  the  multiple  visits 
involved  and  the  implication  for  taking  time  off  work,  not  all  120  people  could  complete 
all  the  stages  of  the  study.  A  summary  of  the  number  of  people  completing  each  of  the 
stages  of  the  study  is  given  in  section  5.5.6.1.  For  a  study  of  this  nature  the  compliance 
with  attendance  was  actually  quite  good  and  acceptable. 
10.3.5.  Time  lag  between  visits 
We  tried  to  get  participants  through  all  stages  of  the  study  in  batches,  so  there  was  a 
minimal  time  delay  between  visits.  So  rather  than  complete  the  screening  stage  for  all 
participants,  before  starting  on  other  visits  and  so  on,  we  took  a  batch  of  people  through 
the  first  stage,  on  to  the  next  and  so  on,  while  a  new  batch  of  people  was  starting  on  the 
first  stage.  For  many  participants  this  meant  attending  for  the  second  visit  within  3  to  4 
weeks  of  the  screening  visit,  on  to  the  3`d  visit  within  another  4  weeks  and  so  on.  The 
clinical  data  collection  was  completed  within  a  total  of  8  months  for  all  participants,  for  all 
stages  of  the  study,  except  for  the  sub  study  involving  NMR-spectroscopy  in  40  men.  This 
was  completed  within  15  months  from  starting. 
The  time  lag  between  different  stages  of  the  study  may  introduce  behavioural  changes  for 
instance  which  might  affect  the  results  of  the  study.  For  example  some  participants  might 
increase  the  amount  of  exercise  taken  regularly,  or  improve  their  diet.  Or  changes  may 
occur  with  the  passing  of  time  involuntarily.  We  did  not  measure  any  of  these  factors.  In 
a  study  of  this  nature  it  was  impossible  to  complete  the  many  stages  of  the  study  any 
sooner  than  already  accomplished. 
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A  description  of  the  reasons  for  choice  of  the  particular  tests  that  were  used  in  this  study 
has  already  been  given  in  section  5.10.  However  based  on  the  results  of  the  study,  certain 
points  arise  regarding  the  choice  of  methods. 
10.3.6.1.  Measurement  of  insulin  resistance 
The  method  employed  for  obtaining  a  direct  measure  of  insulin  sensitivity  in  this  study  was 
the  short  insulin  tolerance  test.  However  it  was  apparent  that  measurement  of  fasting  and 
2h  insulin  concentration  showed  much  larger  ethnic  differences,  with  elevated  levels 
among  South  Asians  relative  to  Europeans,  than  did  measurement  of  the  insulin  sensitivity 
index.  We  also  found  that  the  ethnic  differences  in  insulin  level  were  present  among  both 
men  and  women,  while  those  for  ISI  were  only  significant  in  men. 
Furthermore  the  data  failed  to  show  a  significant  ethnic  difference  in  the  slope  of  the 
relationship  between  ISI  (as  measured  by  the  short  insulin  tolerance  test)  and  measures  of 
central  obesity.  There  was,  however,  a  significant  ethnic  difference  in  the  slope  of  the 
relationship  between  both  fasting  and  2h  insulin  as  the  dependent  variable,  with  measures 
of  central  obesity  as  the  independent  variables. 
This  raises  two  issues.  The  first  relates  to  the  fact  that  ISI  and  insulin  level  are  measuring 
two  different  things.  In  the  short  insulin  test  we  measure  the  glucose  disposal  rate  in 
response  to  a  bolus  of  insulin,  while  in  the  measurement  of  2h  insulin  level  we  measure  the 
body's  response  to  an  oral  glucose  load.  The  SITT  gives  an  overall  assessment  of  whole 
body  sensitivity  to  insulin,  but  does  not  allow  direct  quantitative  measurement  of  insulin 
mediated  glucose  metabolism.  The  SITT  also  does  not  distinguish  between  hepatic  and 
peripheral  insulin  sensitivity.  It  is  possible  that  the  SITT  measures  mainly  the  effect  of 
suppression  of  hepatic  glucose  production  following  a  bolus  of  exogenous  insulin. 
The  second  issue  relates  to  the  fact  that  there  is  a  possibility  that  the  defect  in  insulin- 
mediated  glucose  disposal  in  South  Asians  may  be  more  evident  after  a  glucose  load  than 
in  the  fasting  state.  It  has  been  observed  that  ethnic  differences  in  the  2h  insulin  level  are 
much  greater  than  the  differences  in  fasting  insulin.  This  could  be  extrapolated  to  imply 
that  the  insulin  resistance  in  South  Asians  is  a  specific  defect  in  the  delayed  response  to 
insulin.  It  would  be  of  interest  to  perform  studies  of  an  ethnic  comparison  of  the  time- 
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might  be  shifted  to  the  right  in  South  Asians. 
Furthermore  the  use  of  the  short  insulin  tolerance  test  has  never  previously  been  validated 
specifically  in  South  Asians.  A  pilot  study  validating  the  SITT  against  the  "gold  standard" 
of  an  euglycaemic  clamp  would  have  added  to  this  study,  but  was  not  undertaken  due 
mainly  to  the  following  reasons:  time  constraints,  the  fact  that  the  SITT  had  been  used  in  a 
study  of  an  ethnic  comparison  of  first  degree  relatives  of  Europeans  and  South  Asians  with 
diabetes53,  the  fact  that  this  was  an  already  invasive  study  and  further  tests  were  not 
feasible  and  also  because  the  ISI  calculated  from  the  SITT  allows  relative  ranking  of 
individuals  with  respect  to  insulin  sensitivity,  which  was  our  main  aim  in  this  study. 
This  study  did  not  find  any  advantage  of  the  short  insulin  tolerance  test  over  the 
measurement  of  insulin  resistance  by  a  fasting  and  post-challenge  insulin  concentration  in 
studying  the  relationship  of  insulin  resistance  with  obesity,  metabolic  measures  and  ethnic 
origin. 
10.3.6.2.  Fat  tolerance  test  and  postprandial  triglyceride 
As  discussed  in  section  6.3.4,  for  this  epidemiological  study,  rather  than  undertake  a  full 
fat  tolerance  test  with  hourly  blood  samples,  we  took  a  single  post-load  sample  at  8h,  plus 
a  6h  measurement  in  35  people.  It  is  possible  that  we  have  underestimated  the  ethnic 
difference  in  postprandial  triglyceride  level  by  relying  on  a  single  measurement  at  8h  in 
most  participants.  If  so,  then  it  is  possible  that  we  have  also  underestimated  the  extent  to 
which  differences  in  postprandial  triglyceride  levels  could  account  for  the  ethnic  difference 
in  insulin  sensitivity. 
With  hindsight,  a  more  detailed  fat  tolerance  test,  with  measurements  at  perhaps  4,6  and  8 
hours  would  have  allowed  a  much  more  comprehensive  assessment  of  the  role  of 
postprandial  triglyceride,  as  the  area  under  the  triglyceride  curve  could  possibly  give  more 
information  than  just  a  single  measurement.  If  the  finding  of  Patsch263  in  an  European 
population  suggesting  that  a  single  time  point  at  6  or  8  hours  was  as  discriminatory 
between  cases  of  CHD  and  controls  is  to  be  extrapolated  to  a  South  Asian  population,  and 
a  study  of  an  ethnic  comparison,  as  in  this  study,  a  pilot  study  should  have  been 
undertaken  first.  This  would  have  helped  to  determine  the  optimal  time  point(s)  for 
measurement  of  total  triglyceride  concentration  in  the  fat  tolerance  test  which  would  have 
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a  significant  ethnic  difference  in  the  6h  triglyceride  concentration  in  those  men  who  had  it 
measured,  but  by  8  hours  postprandially  the  triglyceride  concentration  was  returning 
towards  fasting  values  and  was  no  longer  significantly  different  between  ethnic  groups.  A 
pilot  study  of  triglyceride  concentrations  at  different  time  points  of  a  full  (unmodified)  fat 
tolerance  test  in  each  of  the  four  ethnic  and  sex  groups  would  have  enabled  us  to  avoid  the 
problem  we  experienced  of  having  missed  the  optimal  time  point  for  maximal  ethnic 
differences.  This  should  be  considered  before  future  fat  tolerance  test  studies  are 
undertaken. 
We  only  measured  total  postprandial  triglyceride  level.  It  would  have  been  more 
informative  to  have  the  measurement  of  apoB-48  and  apoB-100,  as  well  as  retinyl  palmitate 
in  chylomicron  and  non-chylomicron  plasma  fractions,  as  discussed  in  section  6.3.4. 
Future  studies  should  attempt  to  undertake  these  more  detailed  measurements. 
10.4.  Discussion  of  results 
The  results  have  been  specifically  discussed  in  sections  6.3,7.3,8.3  and  9.4. 
10.5.  Relevance  of  the  findings  of  this  study  to  overall  strategies  to 
reduce  CH  D  risk  in  South  Asians 
We  have  found  an  adverse  risk  factor  profile  of  factors  associated  with  CHD  risk  in  South 
Asians  compared  with  Europeans  in  this  study.  These  risk  factors  included:  (i)  greater 
levels  of  obesity,  generalised  and  central,  in  South  Asians  as  shown  by  the  greater  amount 
of  total  percent  fat  and  visceral  fat  in  South  Asians;  (ii)  higher  degree  of  insulin  resistance 
in  South  Asians  as  shown  by  the  lower  insulin  sensitivity  index  in  South  Asians  (significant 
in  men  only),  and  higher  levels  of  fasting  and  2h  insulin  in  South  Asian  men  and women; 
(iii)  a  steeper  rise  in  insulin  concentration  in  South  Asians  (than  in  Europeans)  with 
increasing  levels  of  central  adiposity,  and  (iv)  a  trend  towards  higher  postprandial 
triglyceride  level  in  South  Asian  men  (significant  at  6h,  but  not  at  8h  postprandially). 
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physical  activity  was  limited,  and  based  on  self-report  in  response  to  a  questionnaire.  This 
showed  that  levels  of  physical  activity  were  low  in  both  groups,  but  even  lower  in  South 
Asians,  and  especially  so  among  South  Asian  women.  Attempts  to  reduce  the  absolute  risk 
for  CHD  include  lifestyle  interventions  such  as  modifications  to  diet  and  physical  activity, 
as  well  as  therapeutic  interventions  such  as  to  lower  lipids.  The  relevance  of  these 
strategies  to  South  Asians  is  discussed  in  the  following  sections. 
10.5.1.  Physical  activity 
The  increased  obesity  in  South  Asians  may  be  due  to  genetic  reasons,  or  to  lifestyle  and 
environmental  factors  including  lack  of  exercise.  But  whatever  the  reason,  prevention  of 
diabetes  and  CHD  in  South  Asians  may  require  control  of  obesity  and  regular  exercise  to 
be  maintained  throughout  life. 
10.5.1.1.  Effect  of  physical  activity  on  risk  for  diabetes  and  CHD 
The  effect  of  physical  activity  on  the  development  of  diabetes  in  people  with  impaired 
glucose  tolerance  (with  50  %  from  minorities  including  people  of  Asian  origin)  is  being 
tested  in  the  United  States  as  part  of  a  multicentre  (27  centres)  randomised  controlled  trial, 
the  Diabetes  Prevention  Program  (DPP)264.3000  participants  are  being  randomised  to 
either  a  standard  advice  package  and  placebo  (as  control  group),  or  an  intensive  lifestyle 
intervention  comprising  weight-loss  diet  and  exercise  or  to  metformin.  There  was  to  be  an 
additional  treatment  group,  with  troglitazone,  a  thiazolidinedione  recently  licensed  for  use 
in  insulin  resistant  states  in  the  U.  S.  However  this  has  now  been  discontinued  because  of 
the  hepato-toxicity  of  the  drug.  The  main  outcome  measure  during  follow-up  is  the 
development  of  NIDDM.  This  study  will  yield  important  information  on  the  relative 
effectiveness  of  the  three  interventions. 
The  Southall  Intervention  Study  [Gail  Davey,  manuscript  submitted  to  Medicine  and 
Science  in  Sports  and  Exercise]  is  the  first  to  demonstrate  a  significant  increase  in  insulin 
sensitivity  in  the  twenty-four  hours  following  exercise  in  South  Asians  (and  Europeans). 
The  results  of  this  study  suggested  that  exercise  may  increase  insulin  sensitivity, 
independent  of  its  effect  on  body  weight  or  lipid  profile 
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10-140 promotion  material  has  moved  from  encouraging  vigorous  exercise  for  twenty  minutes 
three  times  per  week265  to  advocating  daily  or  more  than  daily  activity  of  lower  intensity266 
These  changes  reflect  the  trend  towards  increasing  energy  expenditure  rather  than  fitness  in 
interventions  against  coronary  heart  disease.  The  Southall  Intervention  Study  adds  support 
to  this  pattern  of  increased  frequency  of  activity  for  improving  insulin  resistance.  Lehman 
et  a1267  conducted  a  trial  of  exercise  training  over  3  months  in  16  patients  with  NIDDM, 
with  13  NIDDM  patients  as  controls.  They  found  that  in  those  who  took  regular  physical 
exercise  there  was  a  significant  amelioration  of  cardiovascular  risk  profile;  in  particular 
total  percent  fat,  WHR  and  triglycerides  decreased,  while  HDL-cholesterol  levels 
increased  independently  of  changes  in  body  weight  and  glycaemic  control. 
10.5.1.2.  Effect  of  physical  activity  on  abdominal  obesity 
That  exercise  training  can  be  beneficial  in  South  Asians  is  highlighted  by  the  fact  that  the 
effect  of  training  is  to  reduce  both  percent  body  fat  as  well  as  visceral  fat.  Despres  et  a1268 
have  shown  that  when  aerobic  exercise  is  used  to  induce  weight  loss,  men  generally  lose 
more  fat  than  women.  In  men  the  loss  of  adipose  tissue  is  more  central.  Although 
resistance  to  fat  loss  is  noted  in  women,  those  with  a  "male"  distribution  of  adipose  tissue 
greatly  benefit  from  aerobic  exercise  training.  They  showed  further  that  obese 
premenopausal  women  who  participated  in  an  exercise  training  programme  lost  a  greater 
amount  of  fat  (measured  by  CT)  from  the  abdominal  area  than  from  the  mid-thigh  area  269 
Another  group  showed  that  of  60-70  year  old  men  and  women  who  participated  in  a  9-12 
month  exercise  programme,  men  lost  more  weight  than  women,  but  in  both  groups  the 
largest  absolute  and  relative  changes  occurred  in  the  truncal  area,  indicating  a  preferential 
loss  of  fat  from  the  central  regions  of  the  body270.  This  preferential  loss  of  visceral  adipose 
tissue  with  exercise  in  women  has  also  been  shown  by  others  271 
. 
However  one  group  showed  that  decrease  in  subcutaneous  fat  mass,  but  not  visceral  fat 
mass  was  proportional  to  the  amount  of  aerobic  exercise  training  in  women272.  They 
argued  that  the  change  in  visceral  fat  mass  appears  to  be  related  to  a  deficit  in  caloric 
balance  either  by  dietary  restriction  (decrease  in  caloric  intake)  or  by  increased  caloric 
expenditure.  Ross273  reviewed  the  studies  of  effects  of  diet  and  exercise  induced  weight 
loss  on  visceral  adipose  tissue  in  men  and  women.  He  concluded  that  for  every  kg  of  diet- 
induced  weight  loss,  the  corresponding  reduction  in  visceral  fat  was  about  3-4  cm2,  and 
that  there  appears  to  be  a  resistance  to  visceral  fat  area  reduction  in  obese  women  but  not 
Overall  discussion  10-141 in  men.  He  suggested  that  data  on  the  separate  effects  of  diet  and  exercise  induced  weight 
loss  on  visceral  fat  from  well  controlled  studies  are  required to  advance  current  knowledge 
with  respect  to  the  effects  of  diet  and  exercise  on  the  adipose  tissue  depot  that  conveys  the 
greatest  health  risk.  Such  studies  are  not  only  needed  for  the  general  population,  but  also 
for  people  from  the  Indian  sub-continent,  whose  risk  for  visceral  obesity,  insulin 
resistance,  diabetes  and  CHD  remains  high. 
10.5.1.3.  Effect  of  physical  activity  on  postprandial  lipids 
It  is  now  known  that  exercise  can  also  have  a  beneficial  effect  on  postprandial  lipaemia. 
Zhang  et  a!  274  studied  21  recreationally  trained  men  and  found  that  exercising  before  a  fat 
meal,  at  60  %  of  maximal  02  consumption  for  1  hour,  had  a  beneficial  effect  on 
postprandial  triglyceride  response  and  HDL  metabolism.  Another  group275  studied 
postprandial  triglyceride  and  apoB-100  level  in  54  men  and  women  who  were  sedentary, 
recreational  exercisers  or  endurance  trained.  They  found  that  both  recreational  and 
competitive  aerobic  training  were  associated  with  a  lower  triglyceride  response  and 
apoB-100  level  after  a  fatty  meal.  Further,  Hardman  et  aP76  have  studied  changes  in 
postprandial  lipaemia  in  endurance  trained  people  during  a  short  interruption  to  training. 
They  found  that  postprandial  lipaemia  increased  with  detraining,  and  concluded  that 
frequent  exercise  is  needed  to  maintain  a  low  level  of  postprandial  lipaemia  and 
insulinaemia  in  trained  individuals. 
Thus  there  is  evidence  that  physical  activity  is  beneficial  both  for  increasing  insulin 
sensitivity,  and  for  reducing  a  postprandial  lipaemic  response.  Although  there  are 
numerous  such  studies  in  Europeans,  further  such  studies  need  to  be  performed  in  South 
Asians.  However,  it  seems  plausible  that  physical  activity  will  be  equally,  if  not  more, 
beneficial  in  South  Asians. 
10.5.1.4.  Public  health  implications  of  physical  activity 
But  how  can  this  public  health  message  about  the  necessity  and  beneficial  effect  of  exercise 
be  highlighted  to  the  public,  especially  the  South  Asian  population  in  the  U.  K.?  In  the 
United  Kingdom,  the  Health  Education  Authority  are  currently  encouraging  exercise 
among  people  in  a  national  campaign  called  "Active  for  Life".  The  second  phase  of  the 
campaign  over  1997-98,  had  as  its  target  people  over  the  age  of  50  years  and  people  from 
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and  local  media  to  promote  regular  moderate  physical  activity.  It  has  also  undertaken 
training  for  general  practitioners  and  community  nurses,  and  offered  support  including 
small  grants  to  health  professionals.  The  message  being  conveyed  encourages  modest  but 
frequent  physical  activity  such  as  cycling,  dancing,  walking  and  gardening.  These  have 
been  put  across  as  activities  that  do  not  require  special  preparation  or  facilities,  but  can 
contribute  to  health  if  pursued  frequently.  Another  part  of  the  campaign  involves  general 
practitioners  in  "exercise  prescription"  (free  or  at  reduced  rates)  schemes  in  conjunction 
with  local  leisure  centres.  However,  the  aims  of  the  campaign  are  broad:  improving  health 
by  increasing  physical  activity,  which  makes  evaluation  difficult.  While  one  could 
evaluate  whether  activity  has  increased  by  using,  for  instance,  actometers,  no  such 
evaluation  efforts  have  been  made.  Thus  what  proportion  of  South  Asians,  particularly 
women  have  taken  the  "message  on-board"  is  currently  unknown. 
10.5.2.  Diet 
In  the  current  study  there  were  more  vegetarians  among  South  Asians  than  among 
Europeans.  Detailed  information  on  diet  was  not  collected  in  this  study.  However  we 
have  information  about  diet  in  this  group  of  people  from  a  previous,  larger  study,  the 
Southall  Study36.  Recording  of  7-day  weighed  dietary  intakes  in  173  South  Asian  and 
European  men  showed  that  overall  the  South  Asian  diet  was  more  favourable:  in  South 
Asian  men  (compared  with  European  men)  mean  energy  intake  was  lower,  carbohydrate 
intake  was  higher,  polyunsaturated  fat  intake  was  higher,  and  dietary  fibre  intake  was 
higher.  Elevated  serum  2h-insulin  concentrations  were  positively  associated  with 
carbohydrate  intake,  but  not  with  saturated  fatty  acid  intake.  The  authors  concluded  that 
the  high  coronary  risk  in  South  Asians  is  not  explained  by  any  unfavourable  characteristic 
of  South  Asian  diets. 
Leaf27'278  has  estimated  that  the  average  diet  of  our  ancestors  consisted  of  fat  as  about  20% 
of  total  food  energy,  with  7  to  8%  saturated  fat,  and  a  n-6  to  n-3  fatty  acid  ratio  of  about  4 
to  3.  However,  since  the  Industrial  Revolution  the  saturated  fat  content  has  risen 
dramatically,  and  the  n-6  to  n-3  fatty  acid  ratio  has  changed  to  about  15  to  1.  He  argues 
that  n-3  class  of  polyunsaturated  fatty  acids  (PUFA)  are  beneficial  for  coronary 
protection  2",  2'9.  The  Diet  and  Reinfarction  trial  (DART)  was  the  first  large  trial  to  report 
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reduction  in  total  mortality  in  the  first  two  years  after  myocardial  infarction280. 
It  has  been  suggested  that  low  intake  of  polyunsaturated  fatty  acids  of  the  n-3  series  (alpha 
linolenic  acid)  may  contribute  to  the  high  coronary  risk  in  South  Asians281-283.  This  may  be 
one  factor  in  causing  high  rates  of  CHD  in  Gujarati  Hindus,  but  cannot  account  for  the 
high  risk  in  Bengalis12  whose  diet  is  high  in  n-3  fatty  acids  from  fish284.  Also,  some  groups 
from  South  Asia  already  have  low  average  plasma  cholesterol  and  low  saturated  fat  intake, 
but  still  have  very  high  CHD  mortality,  such  as  among  Gujarati  Hindu  women  living  in 
North-West  London3s,  zgs 
10.5.2.1.  Effects  of  dietary  change  on  plasma  lipids 
Previous  dietary  advice  consisted  of  lowering  total  fat  intake  by  low  fat  diets.  However 
such  low  fat  diets  were  achieved  by  having  a  higher  proportion  of  carbohydrates. 
Carbohydrates,  however,  not  only  decreased  LDL-cholesterol,  but  also  lowered 
HDL-cholesterol286.287.  First  suggested  in  the  1970's38,  it  is  now  well  accepted  that 
HDL-cholesterol  is  cardioprotective.  Thus  recommendations  to  decrease  fat  and  increase 
carbohydrate  intake  have  come  under  scrutiny288.  In  a  recent  commentary  Katan287 
discusses  the  evidence  for  whether  there  are  "good  and  bad  carbohydrates  for 
HDL-cholesterol",  based  mainly  on  a  recent  report  by  Frost  and  colleagues289  suggesting 
that  the  glycaemic  index  of  the  diet  is  a  stronger  predictor  than  dietary  fat  intake,  of  serum 
HDL-cholesterol  concentration.  Katan  concludes  that  as  yet  the  effects  of  low-glycaemic 
index  foods  on  blood  lipids  remain  unproven287. 
10.5.2.2.  Effects  of  diet  on  CHD  risk 
It  is  known  that  lowering  saturated  fat  intake  by  substituting  it  with  polyunsaturated  fatty 
acids  of  the  n-6  series  (linoleic  acid;  such  as  in  vegetable  oils)  has  adverse  effects  or  fails 
to  improve  clinical  prognosis.  It  is  only  when  n-6  fatty  acids  are  decreased  and  n-3  fatty 
acids  are  increased  that  there  is  clinical  benefit  and  risk  reduction  for  CHD. 
Ravnskov290  has  reviewed  the  existing  literature  on  the  influence  of  diet  on  cardiovascular 
disease.  He  examined  the  results  of  all  available  ecological,  cross-sectional,  case-control, 
cohort  and  intervention  studies  (including  randomised  trials)  of  the  effect  of  fat  reduction 
alone  on  cardiovascular  disease.  He  reported  that  the  findings  from  these  numerous 
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results.  He  thus  concluded  that  the  hypothesis  that  dietary  saturated  fatty  acids  are  harmful 
while  polyunsaturated  fatty  acids  are  protective  for  CHD  is  questionable.  However  he 
presents  one  extreme  view.  Most  epidemiological  evidence  now  points  in  favour  of 
advocating  a  "Mediterranean"  diet,  high  in  n-3  polyunsaturated  fatty  acids,  mono- 
unsaturates,  fibre,  fish  and  fresh  vegetables. 
The  results  of  the  recent  Lyon  Diet  Heart  Study  provide  support  for  a  cardio-protective 
role  of  the  Mediterranean  type  diet27'291.  An  initial  report  of  this  randomised  secondary 
prevention  trial292  at  27  months  of  follow  up  had  shown  a  striking  70%  reduction  in 
all-cause  mortality  due  to  a  reduction  in  CHD  mortality  and  non-fatal  CHD  sequelae. 
Thus  the  trial  was  terminated  by  the  Ethics  committee  at  27  months  rather  than  the  planned 
5  years.  Recently  published  results  of  the  final  4  year  follow  up  of  this  cohort  further 
show  that  the  initial  remarkably  beneficial  effects  of  the  experimental  dietary  programme 
persisted  compared  with  the  control  group  consuming  the  usual  Western  type  diet.  The 
heartening  thing  about  this  diet,  versus  low  fat  diets,  seems  to  be  that there  was  continued 
good  adherence  to  the  experimental  diet  for  up  to  4  years,  despite  the  fact  that  the  study 
was  officially  terminated  at  a  mean  follow  up  of  27  months.  The  Mediterranean  type  diet 
consisted  of  about  30%  total  fat,  with  only  8%  saturated  fat.  Participants  were  instructed 
to  consume  more  bread,  root  and  green  vegetables,  more  fish  and  less  meat,  fruit  at  least 
once  daily,  canola-based  margarine  (made  from  rapeseed  oil,  and  rich  in  n-3  PUFA)  and 
olive  oil  as  a  fat  source.  The  authors  concluded  that  a  cardio-protective  diet  should  be  part 
of  a  comprehensive  programme  to  reduce  CHD  morbidity  and  mortality. 
If  these  results  can  be  confirmed  by  others,  there  are  implications  for  preventive  strategies. 
It  has  been  argued  whether  18:  3[n-3]  PUFA  (alpha  linolenic  acid)  derived  from  vegetable 
oils  such  as  soya  oil  and  rapeseed  oil  could  have  similar  cardio-protective  effects  as 
93  20:  5[n-3]  PUFA  (eicosapentaenoic  acid)  derived  from  oily  fish2.  It  would  be  useful  to 
test  specifically  in  secondary  prevention  trials  the  effect  of  substituting  oils  containing 
18:  3[n-3]  PUFA  for  other  sources  of  dietary  fat.  The  rationale  for  this  is  that  it  is  easier  to 
substitute  vegetable  oils  rich  in  18:  3[n-3]  PUFA  for  other  sources  of  dietary  fat  than  to 
increase  consumption  of  oily  fish  on  a  mass  scale. 
Based  on  the  currently  available  evidence  no  specific  recommendations  regarding  the  South 
Asian  diet  can  be  made.  However,  it  would  do  well  for  all  people,  South  Asian  or 
European  to  reduce  their  total  daily  fat  intake.  It  also  stands  to  reason  that  a 
Overall  discussion 
10-145 Mediterranean  type  diet  would  be  beneficial  to  both  Europeans  and  South  Asians.  The 
Panel  on  Dietary  Reference  Values  of  the  Committee  on  Medical  Aspects  of  Food  Policy29' 
recommended  that  the  average  intake  of  saturated  fatty  acids  should  be  reduced  to  10%  of 
total  energy.  Based  on  the  Keys  equation295  it  has  been  estimated  by  McKeigue  and 
Sevak27  that  among  South  Asians  achieving  the  above  goal  could  reduce  the  average 
cholesterol  to  about  5.0  mrnol/l.  Some  would  extrapolate  this  to  predict  that  in  so  doing 
effective  control  of  CHD  as  a  leading  cause  of  death  could  be  achieved. 
10.5.3.  Lipid  abnormalities 
10.5.3.1.  Underlying  defect  might  be  related  to  lipid  metabolism 
It  is  intriguing  that  while  there  was  a  trend  towards  higher  postprandial  triglyceride  level 
coupled  with  a  higher  intramyocellular  lipid  content  in  South  Asian  men,  yet  postprandial 
triglyceride  failed  to  account  for  the  lower  insulin  sensitivity,  and  the  intramyocellular  lipid 
content  was  not  related  to  insulin  sensitivity  in  South  Asians  in  this  study.  However 
postprandial  triglyceride  was  strongly  related  to  the  insulin  resistance  syndrome,  and 
together  with  body  fat  distribution,  accounted  for  almost  50%  of  the  ethnic  difference  in 
insulin  sensitivity. 
This  raises  the  possibility  that  there  is  some  basic  derangement  in  lipid  metabolism  or 
storage  in  South  Asians,  which  with  better  measurement  technique(s)  could  yield  more 
detailed  information.  For  instance,  we  have  only  been  able  to  measure  the  level  of 
triglyceride  in  this  study  in  plasma  and  in  skeletal  muscle.  It  would  be  informative  to  be 
able  to  measure  the  flux  of  lipids  between  different  body  compartments  such  as  plasma  and 
muscle.  It  would  also  be  informative  and  of  interest  to  measure  the  fate  of  triglyceride 
after  a  fat  load;  thus  studies  of  intramyocellular  lipid  by  NMR  spectroscopy  before  and 
after  a  fat  load  would  be  helpful.  Techniques  for  study  of  uptake  of  NEFA  in  cells  are 
becoming  available296.  Such  techniques  as  positron  emission  tomography  (PET)  can  be 
used  to  measure  the  uptake  of  NEFA  into  muscle  cells.  Using  this  technique  a  recent 
study296  showed  that  subjects  with  impaired  glucose  tolerance  (compared  with 
normoglycaemic  controls)  had  similar  myocardial  but  lowered  femoral  muscle  NEFA 
uptake.  Such  studies  performed  in  South  Asians  would  be  valuable  to  try  and  tease  out  the 
mechanisms  involved  in  their  high  rates  of  insulin  resistance. 
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of  insulin  resistance  and  diabetes  mellitus  is  not  new.  Randle  et  a1182  proposed  a  glucose- 
fatty  acid  cycle  in  1963.  The  pros  and  cons  of  this  cycle  have  been  discussed  in  section 
3.1.1.  McGarry  raised  this  possibility  in  his  classical  paper  in  1992297  entitled  "What  if 
Minkowski  had  been  ageusic?  An  alternative  angle  on  diabetes".  Boden155  has  reviewed 
the  evidence  for  a  central  role  of  NEFA  in  the  pathogenesis  of  insulin  resistance  and 
Type  II  diabetes. 
Genetic  studies  in  rat  models  are  also  beginning  to  support  this  hypothesis.  Aitman  et  al298 
reported  earlier  this  year  that  Cd36  (Fat)  is  an  insulin  resistance  gene  causing  defective 
fatty  acid  and  glucose  metabolism  in  the  spontaneously  hypertensive  rat.  Cd36  has  been 
identified  as  a  fatty  acid  receptor/transporter.  Aitman  et  al  found  that  the  protein  product 
of  Cd36  is  absent  in  the  rat  adipocyte  plasma  membrane,  while  overexpression  of  Cd36  in 
transgenic  mice  reduces  blood  triglycerides  and  fatty  acids.  This  suggests  that  a  deficiency 
of  Cd36  (i.  e.  a  defect  in  a  fatty  acid  transport  gene)  underlies  insulin  resistance,  defective 
fatty  acid  metabolism  and  hypertriglyceridaemia  in  the  rat  model.  By  extrapolation,  Cd36 
may  play  an  important  part  in  the  pathogenesis  of  human  insulin  resistance  syndromes. 
However,  since  the  publication  of  Aitman's  report,  there  has  been  a  further  report  (in  July 
1999)  by  a  Japanese  group299  showing  that  the  Cd36  mutation  is  absent  in  the  original 
spontaneously  hypertensive  rat  strains,  maintained  since  their  development  in  Japan.  This 
throws  into  question  the  aetiological  relevance  of  the  Cd36  mutation  to  insulin  resistance  in 
this  rat  model.  However,  further  study  of  this  rat  line,  as  well  as  others  and  studies  of  the 
human  genome  project  should  shed  further  light  into  the  genetic  origins  of  insulin 
resistance. 
10.5.3.2.  Management  of  lipid  abnormalities 
Evidence  from  several  large  randomised  clinical  trials  has  shown  coronary  benefit  of 
reducing  LDL  cholesterol,  and  evidence  is  also  emerging  for  a  beneficial  effect  of 
lowering  elevated  triglyceride  levels.  Among  South  Asians  the  predominant  lipid 
disturbances  are  related  to  the  insulin  resistance  syndrome  and  include  high  triglyceride 
level  and  low  HDL-cholesterol,  as  well  as  increased  concentrations  of  small  dense  LDL 
particles.  When  these  lipid  abnormalities  occur  together  the  atherogenic  lipoprotein 
phenotype  (ALP)  is  said  to  exist.  The  role  of  lipid  lowering  drugs  specifically  in  South 
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triglycerides  and  the  ALP,  or  LDL  cholesterol. 
10.5.3.3.  Lowering  plasma  triglyceride  levels 
The  data  available  so  far  suggest  that  treatment  to  lower  plasma  triglyceride  levels  may 
reduce  cardiovascular  events.  In  the  Helsinki  Heart  Study  (HHS)  treatment  with  the 
fibrate  gemfibrozil  produced  a  34%  reduction  in  incident  coronary  events  with  a  35% 
reduction  in  plasma  triglyceride  levels,  a  9%  increase  in  HDL-cholesterol  levels  and  an 
11%  reduction  in  plasma  LDL  concentration  300.  However  the  beneficial  effect  of 
gemfibrozil  was  mostly  confined  to  overweight  subjects  (with  BMI  greater  than  26  kg/m2). 
This  may  not  be  directly  relevant  to  those  South  Asians  who  have  the  lipid  abnormalities 
despite  average/below  average  BMI.  The  formal  published  results  of  the  Bezafibrate 
Infarction  Prevention  (BIP)  secondary  prevention  trial  are  still  awaited,  in  which  subjects 
with  CHD  were  randomised  to  either  bezafibrate  or  placebo.  However  a  preliminary 
report  was  presented  at  the  European  Society  of  Cardiology  meeting  in  Vienna  in  1998. 
This  showed  a  non-significant  9%  reduction  in  CHD  (combined  endpoint  of  nonfatal 
myocardial  infarction,  fatal  myocardial  infarction,  or  sudden  death).  Total  mortality  was 
also  unaffected  by  bezafibrate,  and  only  a  small  sub-group  with  high  baseline  plasma 
triglyceride  levels  profited  from  treatment. 
Results  of  a  large  scale  trial  to  address  the  issue  of  these  lipid  abnormalities  in  the 
secondary  prevention  of  CHD  have  just  been  published  (August  1999).  The  Veterans 
Affairs  HDL-cholesterol  Intervention  Trial  (VA-HIT)  Study301  of  2531  men  with  previous 
CHD,  with  HDL-cholesterol  levels  of  1.0  mmol/1  or  less  and  LDL  cholesterol  levels  of  3.6 
mmol/1  or  less  showed,  at  one year,  a  relative  risk  reduction  of  22%  (95%  CI  7  to  35%) 
for  CHD  (non-fatal  myocardial  infarction  or  coronary  death)  in  those  treated  with  a  fibrate 
(gemfibrozil)  compared  with  those  on  placebo.  The  effect  of  treatment  with  gemfibrozil 
was  to  increase  HDL-cholesterol  (6%),  lower  the  mean  triglyceride  level  (31  %)  and  lower 
the  total  cholesterol  level  (4  %).  LDL  cholesterol  levels  did  not  differ  between  the 
treatment  groups.  It  was  concluded  that  the  rate  of  coronary  events  is  reduced  by  raising 
HDL-cholesterol  levels  and  lowering  triglyceride  levels,  without  lowering  LDL  cholesterol 
levels.  This  may  be  of  relevance  to  South  Asians.  If  these  findings  apply  to  South  Asians, 
they  may  also  benefit  from  reversing  of  these  lipid  abnormalities.  Trials  of  fibrates  in 
South  Asians  would  merit  consideration. 
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fasting  triglyceride  levels  but  elevated  postprandial  triglyceride  levels  will  benefit  from 
drug  therapy  targeted  at  lowering  of  postprandial  triglyceride  levels.  Further  more  detailed 
studies  are  needed  to  first  establish  whether  this  is  the  case  in  South  Asians,  and  then 
randomised  trials  will  need  to  be  conducted  to  gather  the  evidence  for  any  beneficial  effect 
on  CHD  risk. 
10.5.3.4.  Lipid  lowering  with  statins 
10.5.3.4.1.  Evidence  for  coronary  benefit  of  statin  therapy 
Statins  are  hydroxymethylglutaryl  coenzyme  A  (HMG-CoA)  reductase  inhibitors  that  form 
an  important  group  of  lipid-lowering  drugs  for  prevention  of  CHD.  Compelling  evidence 
for  their  role  in  cardioprotection  has  been  shown  in  large  trials  of  secondary  prevention 
such  as  the  Scandinavian  Simvastatin  Survival  Study  (4S)302,  the  Cholesterol  and  Recurrent 
Events  Trial  (CARE)303  and  the  Long-term  Intervention  with  Pravastatin  in  Ischaemic 
Disease  (LIPID)  study304.  These  studies  showed  reduction  in  relative  risk  for  CHD  of 
34%,  24%  and  24%  respectively.  Evidence  for  a  cardioprotective  role  has  also  come  from 
trials  of  primary  prevention  such  as  the  West  of  Scotland  Coronary  Prevention  Study 
(WOSCOPS)305  and  the  Air  Force/Texas  Coronary  Atherosclerosis  Prevention  Study 
(AFCAPS/TexCAPS)306  study  in  the  United  States.  These  studies  showed  a  relative  risk 
reduction  of  CHD  of  31  %  and  37  %  respectively.  The  initial  reports  of  these  trials  have 
largely  been  in  people  with  average  to  high  lipid  levels  and  with  no  history  of  diabetes. 
However,  little  information  has  been  available  on  the  role  of  statins  in  people  with  diabetes 
or  glucose  intolerance  until  recently. 
The  role  of  pravastatin  has  been  investigated  in  a  subgroup  analysis  of  patients  with 
diabetes  and  glucose  intolerance  with  average  cholesterol  levels  in  the  CARE  trial  (of 
secondary  prevention  in  myocardial  infarction  survivors)307.  The  trial  included  586 
patients  with  clinical  diagnosis  of  diabetes,  and  342  patients  from  3553  non-diabetic 
patients  had  impaired  fasting  glucose  at  entry.  The  analysis  showed  that  patients  with 
diabetes  and  impaired  fasting  glucose  were  at  high  risk  of  recurrent  coronary  events  that 
could  be  substantially  reduced  by  pravastatin  therapy  (in  the  diabetic  group:  absolute  risk 
reduction  of  8.1%,  and  relative  risk  reduction  of  25%;  in  the  impaired  fasting  glucose 
group:  50%  reduced  recurrence  rates  for  non-fatal  MI  in  treatment  group).  Similar  results 
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patients  in  the  4S  study308.  The  authors  concluded  that  cholesterol  lowering  with 
simvastatin  improves  the  prognosis  of  diabetic  patients  with  CHD.  They  argued  that  the 
absolute  clinical  benefit  achieved  may  be  greater  in  diabetic  than  in  non-diabetic  patients 
with  CHD  because  diabetic  patients  have  a  higher  absolute  risk  of  recurrent  CHD  events. 
It  is  also  been  shown  by  Haffner  et  al3o9in  a7  year  follow-up  study  of  2432  subjects  that 
diabetic  patients  without  prior  myocardial  infarction  had  as  high  a  risk  of  myocardial 
infarction  (20.2  %)  as  non-diabetic  patients  with  previous  myocardial  infarction  (18.8%). 
They  argued  that  CHD  risk  factors  in  diabetic  subjects  should  be  treated  as  aggressively  as 
in  non-diabetic  patients  with  a  prior  history  of  CHD.  Since  much  of  the  risk  for 
macrovascular  disease  (such  as  CHD)  is  associated  with  impaired  glucose  tolerance,  before 
the  onset  of  clinically  detectable  diabetes,  it  can  be  extrapolated  that  people  with  impaired 
glucose  tolerance  will  have  risk  for  CHD  of  similar  proportions.  This  is  important  in  the 
context  of  the  high  prevalence  of  insulin  resistance  and  glucose  intolerance,  as  well  as 
diabetes,  in  people  of  South  Asian  descent. 
10.5.3.4.2.  Relation  between  baseline  cholesterol  level  and  benefit  from  statin  therapy 
Evidence  is  now  accumulating  that  statins  are  beneficial  regardless  of  the  baseline 
cholesterol  level.  Results  of  the  CARE  study3o3  showed  benefit  of  statins  in  those  with 
average  cholesterol  levels  (total  cholesterol  below  6.2  mmol/l  and  LDL  cholesterol 
between  3  to  4.5  mmol/1).  A  further  analysis  of  results  from  CARE  trial  showed  that  the 
LDL  concentration  achieved  during  follow-up  was  a  significant  predictor  of  the  coronary 
event  rate  down  to  an  LDL  concentration  of  3.2  mmol/1310  However,  the  extent  of  LDL 
reduction  (absolute  or  percentage  reduction)  had  no  significant  relationship  to  coronary 
events.  Results  of  the  LIPID  study304  also  showed  benefit  of  statins  in  subjects  with  a 
broad  range  of  initial  cholesterol  levels  (total  cholesterol  of  4  to  7  mmol/1).  Benefit  of 
statin  therapy  was  also  shown  by  MacMahon  et  a131  in  the  LIPID  Carotid  Atherosclerosis 
Sub-study  of  the  LIPID  trial  among  522  patients  with  a  history  of  ischaemic  heart  disease. 
Thickening  of  the  carotid  arteries  increased  in  those  given  placebo,  but  decreased  in  those 
given  pravastatin.  The  statin  prevented  substantial  carotid  wall  thickening  in  patients  with 
cholesterol  levels  that  were  high  or  average  as  well  as  below  average  (4  to  7  mmol/1). 
These  studies  suggest  that  there  might  be  benefit  in  lowering  cholesterol  even  in 
normocholesterolaemic  individuals  at  high  risk  for  CHD 
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the  beneficial  effects  of  cholesterol  lowering,  especially  in  people  with  average  or  below 
average  cholesterol  levels.  It  seems  likely  that  plaque  stabilisation  or  improvement  in 
endothelial  function  will  play  a  part.  Further  studies  will  help  to  clarify  this. 
10.5.3.4.3.  Non  lipid  lowering  effects  of  statins 
In  fact  evidence  is  now  emerging  that  statins  may  also  exert  their  effect  independently  of 
their  lipid-lowering  effects.  Ridker  et  a1313  have  shown  this  recently  in  a  trial  of  secondary 
prevention  of  472  survivors  of  myocardial  infarction.  They  found  that  C-reactive  protein 
concentrations  (CRP  -a  marker  for  inflammation)  fell  by  a  mean  of  17%  in  patients 
receiving  pravastatin  but  rose  by  4%  in  those  treated  with  standard  therapy  plus  placebo. 
The  changes  in  CRP  did  not  correlate  with  changes  in  lipid  values,  so  for  example,  CRP 
values  rose  in  patients  who  lowered  their  LDL-cholesterol  by  diet  and  exercise. 
10.5.3.4.4.  Should  statins  be  used  in  South  Asians? 
South  Asians  have  higher  prevalence  of  insulin  resistance  and  diabetes  associated  with  high 
risk  for  CHD  in  the  face  of  cholesterol  levels  in  the  normal  or  below  normal  range.  Thus 
a  case  can  be  made  for  consideration  of  statin  therapy  in  the  prevention  (primary  and 
secondary)  of  CHD  in  South  Asians.  This  is  based  on  the  evidence  available  for  coronary 
benefit  of  statin  therapy  in  those  with  glucose  intolerance  and  diabetes,  coupled  with  the 
evidence  that  statins  are  beneficial  regardless  of  initial  cholesterol  levels. 
At  present  risk  for  CHD  is  commonly  calculated  as  a  probability  (%)  of  developing  CHD 
(non-fatal  myocardial  infarction  or  coronary  death)  over  10  years;  that  is,  the  number  of 
people  per  100  expected  to  have  a  major  CHD  event  in  the  next  10  years.  This  calculation 
is  based  on  the  risk  equation  from  the  Framingham  study.  However,  this  equation  has  not 
been  validated  for  use  in  ethnic  minorities.  For  example,  raised  serum  triglycerides  or 
evidence  of  impaired  glucose  tolerance  or  insulin  resistance  are  not  currently  part  of  the 
risk  calculation. 
To  test  if  there  is  specific  coronary  benefit  in  South  Asians  one  possibility  is  to  consider 
trials  of  statins  in  South  Asians  with  evidence  of  insulin  resistance.  The  selection  of  a 
group  of  people  suitable  for  randomisation  would  have  to  be  carefully  performed  as  there 
will  be  some  in  whom  it  will  be  unethical  not  to  treat  with  a  statin,  while  there  will  also  be 
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ethical  to  perform  a  trial  of  secondary  prevention,  where  perhaps  everyone  with  a  previous 
myocardial  infarction  should  be  on  a  statin,  but  it  may  be  ethical  to  perform  a  trial  of 
primary  prevention. 
Of  course  there  will  be  cost  implications  for  use  of  statins  in  primary  prevention  in  South 
Asians.  In  general  as  the  CHD  risk  profile  becomes  less  favourable  the  cost-effectiveness 
increases.  Thus  the  number  of  subjects  who  would  need  to  be  treated  in  order  to  prevent 
an  adverse  event  decreases  dramatically.  However,  specific  studies  of  cost-effectiveness 
will  need  to  performed. 
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research 
From  the  results  of  this  study  we  can  conclude  as  follows:  South  Asians  have  more  total 
body  fat  than  Europeans  at  a  given  level  of  BMI,  and  it  is  more  centrally  distributed, 
especially  in  the  women  in  this  study.  South  Asians  have  lower  insulin  sensitivity  than 
Europeans,  especially  so  in  men.  Insulin  concentration  rises  significantly  more  steeply  in 
South  Asians  compared  with  Europeans  as  the  level  of  central  obesity  increases.  There  is 
a  trend  towards  a  higher  postprandial  triglyceride  response  in  South  Asian  men,  and 
elevated  postprandial  triglyceride  level  is  associated  with  component  features  of  the  insulin 
resistance  syndrome  in  all  groups.  South  Asian  men  also  have  greater  intramyocellular 
lipid  content  than  European  men.  In  Europeans  there  is  a  strong  association  between 
insulin  sensitivity,  central  obesity  and  intramyocellular  lipid  content,  but  not  in  South 
Asians.  Although  visceral  obesity  has  a  strong  and  independent  association  with  insulin 
sensitivity  in  both  Europeans  and  South  Asians,  it  fails  to  account  for  the  lower  insulin 
sensitivity  in  South  Asians  compared  with  Europeans.  Lastly,  there  is  a  trend  towards 
higher  CRP  concentrations  in  South  Asians,  and  CRP  concentration  is  associated  with 
features  of  the  insulin  resistance  syndrome. 
We  have  suggested  that  postprandial  lipid  metabolism  may  be  important  in  South  Asians, 
and  that  lipid  disturbances  (in  the  fasting  or  postprandial  state)  may  be  the  primary  defect 
underlying  the  higher  insulin  resistance  in  this  group.  However  it  has  not  been  possible  in 
this  study  to  determine  what  specific  lipid  disturbance  may  be  more  important  in  South 
Asians.  The  possible  defects  in  lipid  metabolism  in  South  Asians  could  include  one  or 
more  of  the  following:  (i)  increased  VLDL-triglyceride  production  or  failure  to  shut  down 
postprandial  triglyceride  production,  (ii)  reduced  triglyceride  clearance,  or  (iii)  increased 
triglyceride  storage  in  skeletal  muscle. 
Although  we  have  learnt  in  more  detail  about  the  relationships  between  body  fat 
distribution,  insulin  sensitivity  and  lipid  disturbances  (in  plasma  as  well  as  in  skeletal 
muscle)  from  this  cross-sectional  study,  there  remain  large  gaps  in  our  understanding  of 
the  reasons  for  the  excess  risk  for  CHD  and  diabetes  in  South  Asians.  Some  specific 
suggestions  for  further  research  arising  from  the  current  study  are  as  follows. 
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Several  novel  techniques,  not  previously  used  in  South  Asians,  were  employed  in  this 
study.  Their  strengths  and  weaknesses  have  been  discussed  before,  but  specific 
recommendations  are  summarised  below. 
Specific  validation  of  the  short  insulin  tolerance  test  (SITT)  against  the  euglycaemic  insulin 
clamp  should  be  performed  in  South  Asians.  While  the  validity  and  reproducibility  of  the 
SITT  have  been  established  in  European  subjects,  South  Asians  have  not  been  included  in 
such  studies.  It  is  possible  that  in  South  Asians  measurement  of  insulin  concentration 
following  an  oral  glucose  load  is  a  more  valid  measurement  to  use  than  the  SITT.  Until 
this  specific  validation  has  been  performed  the  use  of  the  SITT  is  not  recommended  in 
studies  of  South  Asians  as  it  is  not  clear  that  ethnic  differences  in  insulin  resistance  are 
"captured"  by  the  SITT. 
Pilot  studies  should  be  performed  with  the  full  (unmodified)  fat  tolerance  test  to  determine 
the  optimal  time  point(s)  for  measurement  of  total  triglyceride  concentration  that  would 
discriminate  best  between  Europeans  and  South  Asians.  To  determine  which  component  of 
lipid  metabolism  is  specifically  defective  more  detailed  studies  than  measuring  total 
triglyceride  concentration  should  also  be  performed.  This  includes  measuring  exogenous 
(dietary  derived;  apoB-48)  and  endogenous  (hepatic  derived,  apoB-100)  triglyceride 
concentration  in  different  plasma  fractions  (plasma  chylomicron  and  non-chylomicron 
fractions).  Measurement  of  a  single  8h  postprandial  total  triglyceride  concentration  proved 
to  be  inadequate  in  this  study,  and  is  not  recommended  for  future  studies. 
Reproducibility  and  validity  of  nuclear  magnetic  resonance  spectroscopy  to  measure  IMCL 
content  should  also  be  performed  specifically  in  South  Asians.  To  date  all  such  studies 
have  been  limited  to  European  descent  populations.  The  results  of  the  current  study 
showing  higher  IMCL  content  in  South  Asian  men,  but  failure  to  find  any  association 
between  IMCL  and  insulin  resistance  or  obesity  measures  raise  questions  about  the  use  of 
the  technique  in  this  ethnic  group. 
Measurement  of  central  obesity  by  anthropometric  measures  of  waist/hip  ratio  or  waist 
girth  was  adequate.  No  additional  benefit  was  found  in  measuring  visceral  fat  area  directly 
by  CT  scan  for  studying  the  associations  between  central  obesity  and  various  metabolic 
measurements.  This  study  has  validated  bio-electrical  impedance  analysis  against  DEXA 
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that  future  studies  should  include  measurement  of  percent  body  fat,  measured  by  this  non- 
invasive  technique. 
11.2.  Further  experimental  studies 
Suggestions  for  specific  experimental  studies  that  build  on  the  research  findings  from  the 
current  study  are  as  follows. 
Measuring  plasma  triglyceride  concentration  alone  yields  limited  information.  Studies  of 
triglyceride  flux  (in  the  fasting  state  and  postprandially)  between  plasma  and  the  muscle 
compartment  will  add  to  our  understanding  of  ethnic  differences  in  synthesis  and  clearance 
of  lipids.  The  availability  of  a  non-invasive  method,  the  nuclear  magnetic  resonance 
spectroscopy,  has  now  opened  up  the  possibility  for  performing  such  studies.  Examples  of 
such  studies  include  examining  what  happens  when  one  manipulates  intramyocellular  lipid 
stores  by  short-term  experimental  interventions  such  as  running  a  marathon  or  consuming  a 
fatty-meal.  Studies  can  also  be  designed  to  measure  changes  in  muscle  triglyceride  content 
before  and  after  administration  of  drugs  that  modulate  (increase  or  decrease)  plasma 
triglyceride  concentration.  Such  changes  should  also  be  measured  before  and  after 
administration  of  drugs  that  modulate  insulin  sensitivity.  It  would  be  of  interest  to  study 
whether  insulin  sensitising  drugs  affect  insulin  resistance  at  the  level  of  skeletal  muscle, 
and  whether  there  are  any  ethnic  differences  in  such  effects. 
11.3.  Suggestions  for  other  studies  to  take  forward  the  current 
area  of  research 
11.3.1.  The  use  of  electron  beam  computerised  tomography  (EBCT) 
In  the  past  there  has  been  almost  exclusive  focus  on  clinical  cardiovascular  events  as  an 
outcome  in  epidemiological  studies.  As  such  we  have  little  information  on  the  distribution 
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EBCT,  a  rapid,  non-invasive  method  of  detecting  and  quantifying  calcification  in  the 
coronary  arteries,  provides  us  for  the  first  time  with  a  research  tool  that  can  define  early 
(pre-symptomatic)  atheromatous  change  in  the  coronary  arteries.  This  opens  up  exciting 
possibilities  in  the  current  area  of  research.  Specific  suggestions  for  studies  using  EBCT 
are  as  follows. 
To  study  postprandial  lipid  metabolism  in  both  ethnic  groups  in  subjects  with  and  without 
evidence  of  coronary  calcification  on  EBCT.  This  will  help  to  determine  whether 
postprandial  triglyceride  concentration  is  associated  with  the  presence  of  coronary 
calcification,  and whether  ethnic  origin  is  associated  with  calcified  coronary  atheroma.  To 
date  there  is  scant  information  on  the  relative  importance  of  early  atheroma  development 
and  later  stages  such  as  arterial  occlusion  in  the  pathogenesis  of  cardiovascular  events.  It 
is  of  scientific  interest  to  find  out  whether  elevated  postprandial  triglyceride  concentration 
relates  only  to  late  stages  of  atheroma  formation  manifested  by  arterial  occlusion,  or 
whether  it  is  also  associated  with  early  calcification  (and  atheroma)  development. 
A  further  separate  suggestion  is  for  a  case-control  study  of  the  association,  in  South  Asians 
and  Europeans,  between  CRP  concentration  and  coronary  calcification  on  EBCT.  CRP 
concentration  would  be  measured  in  those  with  and  without  evidence  of  coronary 
calcification.  This  would  help  to  clarify  whether  inflammatory  markers  such  as  CRP 
concentration  are  elevated  in  association  with  development  of  coronary  calcification,  or 
predate  its  development.  This  would  be  an  important  contribution  as  it  is  not  known 
whether  inflammation  is  a  phenomenon  arising  as  a  result  of  development  of 
atherosclerosis,  or  is  causal  in  the  development  of  atherosclerosis. 
11.3.2.  Prospective  studies 
Our  finding  of  a  trend  towards  elevated  C-reactive  protein  concentration  in  South  Asians 
should  be  confirmed  in  larger  studies.  The  ideal  setting  for  this  would  be  a  prospective 
study  of  stored  sera  from  the  Southall  Study29,  where  records  were  flagged  at  the  ONS 
(Office  of  National  Statistics)  and  mortality  data  are  available  from  death  certificates  for 
each  person  enrolled  in  that  study  in  1988-1990.  Association  between  baseline  CRP 
concentration  and  CHD  mortality  at  10  years  of  follow-up  can  be  studied  prospectively.  If 
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the  first  such  data  in  this  group. 
Another  separate  suggestion  relates  to  the  use  of  the  stored  sera  in  a  prospective  study 
design.  While  the  stored  sera  were  thawed  for  analysis  of  CRP  concentration,  it  would  be 
opportune  to  measure  antibodies  to  Chlamydia  pneumoniae  and  Helicobacter  pylori  in  the 
stored  sera,  to  test  if  the  excess  CHD  incidence  in  South  Asians  can  be  accounted  for  by  an 
ethnic  difference  in  the  prevalence  of  chronic  infections  (section  1.6).  Additionally  the 
extent  to  which  Lp(a)  could  account  for  the  ethnic  differences  in  CHD  mortality  has  not 
been  examined.  Lp(a)  should  also  be  measured  on  the  frozen  sera.  At  the  same  time  there 
would  be  the  opportunity  to  measure  serum  homocysteine,  raised  levels  of  which  have 
been  shown  to  be  associated  with  increased  cardiovascular  disease  risk. 
11.3.3.  Randomised  clinical  trials 
If  in  larger,  prospective  studies,  elevated  levels  of  CRP  are  confirmed  in  South  Asians,  and 
an  association  is  found  with  CHD  mortality  as  has  been  reported  in  European  populations, 
and  if  elevated  levels  of  C-reactive  protein  are  shown  to  account  for  some  of  the  excess 
risk  of  CHD  in  South  Asians  compared  with  other  groups,  a  recommended  next  step  would 
be  to  evaluate  the  efficacy  of  aspirin  therapy  in  reducing  the  high  CHD  risk  in  South 
Asians.  The  hypothesis  would  be  that  aspirin  therapy  would  reduce  CHD  mortality 
through  reductions  in  CRP  concentrations. 
A  case  for  possible  randomised  trials  of  fibrate  therapy  or  statin  therapy,  or  both,  in  South 
Asians  has  already  been  discussed  in  sections  10.5.3.3  and  10.5.3.4.4. 
11.3.4.  Studies  of  the  vascular  endothelium 
The  present  study  has  raised  the  possibility  that  there  is  a  trend  towards  higher  postprandial 
lipid  concentration  in  South  Asians  (which  would  have  been  better  measured  with  a  more 
detailed  fat  tolerance  test  as  discussed  before).  New  evidence  is  emerging  in  studies  of 
people  of  European  descent  that  postprandial  lipaemia  can  affect  endothelial  function  (as 
discussed  in  section  2.3.1.1).  One  recent  study314  of  44  men  showed  that  endothelial 
function  was  impaired  in  healthy  South  Asians  compared  with  Europeans,  and  the  defect 
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fasting  triglyceride  level  (which  was  not  significantly  different  in  the  two  groups).  Non- 
invasive  techniques  such  as  brachial  artery  ultrasound  can  be  easily  undertaken  in  South 
Asians  to  assess  the  effects  on  the  vascular  endothelium  of  postprandial  lipaemia. 
The  reasons  for  the  excess  risk  of  diabetes  and  CHD  in  South  Asians  are  still  not 
understood.  From  the  results  of  this  study,  in  general  we  have  demonstrated  that  insulin 
resistance  is  closely  related  to  plasma  lipid  levels,  but  not  simply  to  excess  of  central 
obesity  or  excess  of  intramyocellular  lipid  stores.  To  understand  this  further  we  need 
focused  studies  of  lipid  metabolism  and  its  effects  on  insulin  resistance  and  atheroma. 
There  are  very  few  research  groups  addressing  the  issue  in  South  Asians  of  metabolic  and 
physiological  disturbances  associated  with  insulin  resistance,  diabetes  and  CHD.  The 
results  from  the  current  study,  albeit  with  its  limitations,  as  well  as  the  suggestions  made 
for  further  research,  should  help  us  to  understand  this  more  clearly. 
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Many  departments  and  people  enabled  this  study  to  be  performed  and  completed.  Those 
who  collaborated  or  helped  were  as  follows: 
Funding  for  this  study  came  from  the  Wellcome  Trust,  as  part  of  a  clinical  training  fellowship 
in  Clinical  Epidemiology  for  the  registrant,  Nita  Forouhi. 
Supervision  was  provided  by  Dr  Paul  McKeigue.  The  idea  for  the  study  was  originally 
conceived  by  him.  He  was  available  for  discussion  regarding  any  problems.  He  also  read 
the  first  draft  of  the  dissertation  and  gave  his  comments  for  improvement. 
This  study  was  performed  in  the  department  of  cardiology  at  Ealing  Hospital,  Uxbridge  Road, 
Southall,  Middx,  UB1  3HWI,  and  was  facilitated  by  Dr  Jaspal  Kooner.  He  also  kindly 
arranged  for  Miss  Mary  Rowley,  research  nurse,  to  assist  up  to  two  mornings  a  week  with 
clinical  data  collection.  CT  scans  were  kindly  performed  with  the  agreement  of  Dr  Bill 
Svennson  at  Ealing  Hospital.  Mr  Paul  Eathorne  and  Mr  Tim  Rabbitte  performed  all  the 
scans. 
DEXA  scans  were  performed  by  Mr  Uday  Bhonsle  at  the  Medical  Physics  Department  of  the 
Northwick  Park  Hospital,  Watford  Road,  Harrow,  Middlesex.  He  provided  the  final  percent 
fat  data  to  the  registrant. 
Magnetic  resonance  spectroscopy  was  undertaken  at  the  Robert  Steiner  MRiI  Unit, 
Hammersmith  Hospital,  Du  Cane  Road,  London,  with  the  collaboration  of  Dr  Jimmy  Bell. 
Louise  Thomas,  Gabby  Jenkinson  and  S  Mierisova  performed  the  scans  and  analysed  the 
computer  output  for  the  scans. 
The  laboratory  analyses  were  undertaken  at  the  Wynn  Division  of  Medicine,  Wellington 
Road,  London,  NW1.  The  lab  work  was  mainly  performed  by  Mandeep  Sidhu,  Melik 
Worthington  and  Tony  Proudler  under  the  supervision  of  Dr  Ian  Godsland  and  Dr  David 
Crook.  The  chylomicron  separation  protocol  was  developed  by  Dr  David  Crook. 
The  analysis  of  C-reactive  protein  was  very  kindly  performed  by  Dr.  Naveed  Sattar  of  the 
department  of  Pathological  Biochemistry  at  the  Glasgow  Royal  Infirmary. 
The  following  general  practioners  assisted  with  subject  recruitment.  Dr  Chatrath  and  Dr 
Choudhury,  Drs  Thomas,  Gill  and  Patel,  Drs  Jenkins  and  Heavey,  and  Dr  Irene  Ross. 
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178 Dr  Saiqa  Mullick  attended  during  clinical  data  sessions.  She  helped  with  clinical  data 
collection. 
Mrs  Jan  Bibi  Mazar,  research  assistant,  helped  with  data  entry  and  in  booking  appointments 
for  the  study  participants.  Mrs  Sheelagh  Kerr  set  up  the  FoxPro  database  for  data  entry. 
Mrs  Christine  Brandon-Jones  gave  advice  regarding  preparing  small  labels  for  subject 
identification,  and  helped  with  teaching  the  registrant  how  to  use  the  File  Maker  Pro 
database. 
Mr  Stephen  Sharp,  medical  statistics  unit  at  the  London  School  of  Hygiene  &  Tropical 
Medicine,  helped  with  writing  a  programme  to  calculate  the  insulin  sensitivity  index,  and  with 
generating  the  graphs  for  the  mean  glucose  values  against  time.  Mr  Ian  White,  also  of  the 
same  unit,  helped  with  the  original  sample  size  calculations  for  the  study. 
Dr  Janendrappa,  a  visiting  clinical  fellow  from  Bangalore,  India,  attended  some  clinical 
sessions  during  his  short  stay  in  London.  During  these  he  helped  with  preparing  sample 
collection  tubes. 
Lucozade  for  the  study  was  donated  by  Smith  Kline  Beecham. 
The  responsibility  for  the  study  rested  with  the  registrant.  She  attended  every  single  clinical 
session  and  did  all  the  data  collection  personally.  She  also  prepared  the  fat  meal  for  the  fat 
tolerance  test.  All  the  insulin  tolerance  tests  were  personally  performed  by  her.  She 
managed  all  the  day  to  day  running  of  the  project,  from  grant  proposal  stage,  through  to 
completion  of  the  study.  The  ordering  of  equipment  and  managing  of  the  budget,  secretarial 
work  and  all  management  and  administrative  issues  were  dealt  with  by  her.  The  registrant 
performed  all  the  statistical  analyses  and  wrote  the  papers  for  publication.  This  dissertation 
has  been  written  by  the  registrant. 
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